Poly aromatic sodium channel blockers

ABSTRACT

Polyaromatic sodium channel blockers represented by the formula: 
     
       
         
         
             
             
         
       
     
     are provided where the structural variables are defined herein. The invention also includes a variety of compositions, combinations and methods of treatment using these inventive sodium channel blockers.

This application is a Divisional application of U.S. application Ser.No. 13/353,018, filed on Jan. 18, 2012, which is a Continuation of U.S.patent application Ser. No. 12/393,252, filed on Feb. 26, 2009, now U.S.Pat. No. 8,124,607, which claims priority to U.S. provisionalapplication Ser. No. 61/031,466, filed on Feb. 26, 2008, eachincorporated herein by reference.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to sodium channel blockers. The presentinvention also includes a variety of methods of treatment using theseinventive sodium channel blockers.

2. Description of the Background

The mucosal surfaces at the interface between the environment and thebody have evolved a number of “innate defense”, i.e., protectivemechanisms. A principal form of such innate defense is to cleanse thesesurfaces with liquid. Typically, the quantity of the liquid layer on amucosal surface reflects the balance between epithelial liquidsecretion, often reflecting anion (Cl⁻ and/or HCO₃ ⁻) secretion coupledwith water (and a cation counter-ion), and epithelial liquid absorption,often reflecting Na⁺ absorption, coupled with water and counter anion(Cl⁻ and/or HCO₃ ⁻). Many diseases of mucosal surfaces are caused by toolittle protective liquid on those mucosal surfaces created by animbalance between secretion (too little) and absorption (relatively toomuch). The defective salt transport processes that characterize thesemucosal dysfunctions reside in the epithelial layer of the mucosalsurface.

One approach to replenish the protective liquid layer on mucosalsurfaces is to “re-balance” the system by blocking Na⁺ channel andliquid absorption. The epithelial protein that mediates therate-limiting step of Na⁺ and liquid absorption is the epithelial Na⁺channel (ENaC). ENaC is positioned on the apical surface of theepithelium, i.e. the mucosal surface-environmental interface. Therefore,to inhibit ENaC mediated Na⁺ and liquid absorption, an ENaC blocker ofthe amiloride class (which blocks from the extracellular domain of ENaC)must be delivered to the mucosal surface and, importantly, be maintainedat this site, to achieve therapeutic utility. The present inventiondescribes diseases characterized by too little liquid on mucosalsurfaces and “topical” sodium channel blockers designed to exhibit theincreased potency, reduced mucosal absorption, and slow dissociation(“unbinding” or detachment) from ENaC required for therapy of thesediseases.

Chronic obstructive pulmonary diseases are characterized by dehydrationof airway surfaces and the retention of mucous secretions in the lungs.Examples of such diseases include cystic fibrosis, chronic bronchitis,and primary or secondary ciliary dyskinesia. Such diseases affectapproximately 15 million patients in the United States, and are thesixth leading cause of death. Other airway or pulmonary diseasescharacterized by the accumulation of retained mucous secretions includesinusitis (an inflammation of the paranasal sinuses associated withupper respiratory infection) and pneumonia.

Chronic bronchitis (CB), including the most common lethal genetic formof chronic bronchitis, cystic fibrosis (CF), are diseases that reflectthe body's failure to clear mucus normally from the lungs, whichultimately produces chronic airways infection. In the normal lung, theprimary defense against chronic intrapulmonary airways infection(chronic bronchitis) is mediated by the continuous clearance of mucusfrom bronchial airway surfaces. This function in health effectivelyremoves from the lung potentially noxious toxins and pathogens. Recentdata indicate that the initiating problem, i.e., the “basic defect,” inboth CB and CF is the failure to clear mucus from airway surfaces. Thefailure to clear mucus reflects an imbalance between the amount ofliquid and mucin on airway surfaces. This “airway surface liquid” (ASL)is primarily composed of salt and water in proportions similar to plasma(i.e., isotonic). Mucin macromolecules organize into a well defined“mucus layer” which normally traps inhaled bacteria and is transportedout of the lung via the actions of cilia which beat in a watery, lowviscosity solution termed the “periciliary liquid” (PCL). In the diseasestate, there is an imbalance in the quantities of mucus as ASL on airwaysurfaces. This results in a relative reduction in ASL which leads tomucus concentration, reduction in the lubricant activity of the PCL, anda failure to clear mucus via ciliary activity to the mouth. Thereduction in mechanical clearance of mucus from the lung leads tochronic bacterial colonization of mucus adherent to airway surfaces. Itis the chronic retention of bacteria, the failure of local antimicrobialsubstances to kill mucus-entrapped bacteria on a chronic basis, and theconsequent chronic inflammatory responses of the body to this type ofsurface infection, that lead to the syndromes of CB and CF.

The current afflicted population in the U.S. is 12,000,000 patients withthe acquired (primarily from cigarette smoke exposure) form of chronicbronchitis and approximately 30,000 patients with the genetic form,cystic fibrosis. Approximately equal numbers of both populations arepresent in Europe. In Asia, there is little CF but the incidence of CBis high and, like the rest of the world, is increasing.

There is currently a large, unmet medical need for products thatspecifically treat CB and CF at the level of the basic defect that causethese diseases. The current therapies for chronic bronchitis and cysticfibrosis focus on treating the symptoms and/or the late effects of thesediseases. Thus, for chronic bronchitis, β-agonists, inhaled steroids,anti-cholinergic agents, and oral theophyllines and phosphodiesteraseinhibitors are all in development. However, none of these drugs treateffectively the fundamental problem of the failure to clear mucus fromthe lung. Similarly, in cystic fibrosis, the same spectrum ofpharmacologic agents is used. These strategies have been complemented bymore recent strategies designed to clear the CF lung of the DNA(“Pulmozyme”; Genentech) that has been deposited in the lung byneutrophils that have futilely attempted to kill the bacteria that growin adherent mucus masses and through the use of inhaled antibiotics(“TOBI”) designed to augment the lungs' own killing mechanisms to ridthe adherent mucus plaques of bacteria. A general principle of the bodyis that if the initiating lesion is not treated, in this case mucusretention/obstruction, bacterial infections became chronic andincreasingly refractory to antimicrobial therapy. Thus, a major unmettherapeutic need for both CB and CF lung diseases is an effective meansof re-hydrating airway mucus (i.e., restoring/expanding the volume ofthe ASL) and promoting its clearance, with bacteria, from the lung.

R. C. Boucher, in U.S. Pat. No. 6,264,975, describes the use ofpyrazinoylguanidine sodium channel blockers for hydrating mucosalsurfaces. These compounds, typified by the well-known diureticsamiloride, benzamil, and phenamil, are effective. However, thesecompounds suffer from the significant disadvantage that they are (1)relatively impotent, which is important because the mass of drug thatcan be inhaled by the lung is limited; (2) rapidly absorbed, whichlimits the half-life of the drug on the mucosal surface; and (3) arefreely dissociable from ENaC. The sum of these disadvantages embodied inthese well known diuretics produces compounds with insufficient potencyand/or effective half-life on mucosal surfaces to have therapeuticbenefit for hydrating mucosal surfaces.

R. C. Boucher, in U.S. Pat. No. 6,926,911, suggests the use of therelatively impotent sodium channel blockers such as amiloride, withosmolytes for the treatment of airway diseases. This combination givesno practical advantage over either treatment alone and is clinically notuseful, see Donaldson et al, N Eng J. Med., 2006; 353:241-250. Amiloridewas found to block the water permeability of airways and negate thepotential benefit of concurrent use of hypertonic saline and amiloride.

U.S. Pat. No. 5,817,028 to Anderson describes a method for theprovocation of air passage narrowing (for evaluating susceptibility toasthma) and/or the induction of sputum in subjects via the inhalation ofmannitol. It is suggested that the same technique can be used to inducesputum and promote mucociliary clearance. Substances suggested includesodium chloride, potassium chloride, mannitol and dextrose.

Clearly, what is needed are drugs that are more effective at restoringthe clearance of mucus from the lungs of patients with CB/CF. The valueof these new therapies will be reflected in improvements in the qualityand duration of life for both the CF and the CB populations.

Other mucosal surfaces in and on the body exhibit subtle differences inthe normal physiology of the protective surface liquids on theirsurfaces but the pathophysiology of disease reflects a common theme,i.e., too little protective surface liquid. For example, in xerostomia(dry mouth) the oral cavity is depleted of liquid due to a failure ofthe parotid sublingual and submandibular glands to secrete liquiddespite continued Na⁺ (ENaC) transport mediated liquid absorption fromthe oral cavity. Similarly, keratoconjunctivitis sira (dry eye) iscaused by failure of lacrimal glands to secrete liquid in the face ofcontinued Na⁺ dependent liquid absorption on conjunctional surfaces. Inrhinosinusitis, there is an imbalance, as in CB, between mucin secretionand relative ASL depletion. Finally, in the gastrointestinal tract,failure to secrete C1-(and liquid) in the proximal small intestine,combined with increased Na⁺ (and liquid) absorption in the terminalileum leads to the distal intestinal obstruction syndrome (DIOS). Inolder patients excessive Na⁺ (and volume) absorption in the descendingcolon produces constipation and diverticulitis.

Fifty million Americans and hundreds of millions of others around theworld suffer from high blood pressure and the subsequent sequalaeleading to congestive heart failure and increasing mortality. It is theWestern World's leading killer and there is a need there for newmedicines to treat these diseases. Thus, in addition, some of the novelsodium channel blockers of this invention can be designed to target thekidney and as such they may be used as diuretics for the treatment ofhypertension, congestive heart failure (CHF) and other cardiovasculardiseases. These new agents may be used alone or in combination withbeta-blockers, ACE inhibitors, HMGCoA reductase inhibitors, calciumchannel blockers and other cardiovascular agents.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide compounds that aremore potent and/or absorbed less rapidly from mucosal surfaces, and/orare less reversible as compared to known compounds.

It is another aspect of the present invention to provide compounds thatare more potent and/or absorbed less rapidly and/or exhibit lessreversibility, as compared to compounds such as amiloride, benzamil, andphenamil. Therefore, the compounds will give a prolonged pharmacodynamichalf-life on mucosal surfaces as compared to known compounds.

It is another object of the present invention to provide compounds whichare (1) absorbed less rapidly from mucosal surfaces, especially airwaysurfaces, as compared to known compounds and; (2) when absorbed frommucosal surfaces after administration to the mucosal surfaces, areconverted in vivo into metabolic derivatives thereof which have reducedefficacy in blocking sodium channels as compared to the administeredparent compound. It is another object of the present invention toprovide compounds that are more potent and/or absorbed less rapidlyand/or exhibit less reversibility, as compared to compounds such asamiloride, benzamil, and phenamil. Therefore, such compounds will give aprolonged pharmacodynamic half-life on mucosal surfaces as compared toprevious compounds.

It is another object of the present invention to provide compounds thattarget the kidney for use in the treatment of cardiovascular disease.

It is another object of the present invention to provide methods oftreatment that take advantage of the pharmacological properties of thecompounds described above.

In particular, it is an object of the present invention to providemethods of treatment which rely on rehydration of mucosal surfaces.

In particular, it is an object of the present invention to providemethods of treating cardiovascular disease.

The objects of the present invention may be accomplished with a class ofpyrazinoylguanidine represented by a compound of formula (I)

and includes racemates, enantiomers, diastereomers, tautomers,polymorphs, pseudopolymorphs and pharmaceutically acceptable salts,thereof, wherein:

X is hydrogen, halogen, trifluoromethyl, lower alkyl, unsubstituted orsubstituted phenyl, lower alkyl-thio, phenyl-lower alkyl-thio, loweralkyl-sulfonyl, or phenyl-lower alkyl-sulfonyl;

Y is hydrogen, hydroxyl, mercapto, lower alkoxy, lower alkyl-thio,halogen, lower alkyl, unsubstituted or substituted mononuclear aryl, or—N(R²)₂;

R¹ is hydrogen or lower alkyl;

each R² is, independently, —R⁷, —(CH₂)_(m)—OR⁸, —(CH₂)_(m)—NR⁷R¹⁰,—(CH₂)_(n)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —(CH₂CH₂O)_(m)—R⁸,—(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰, —(CH₂)_(n)—C(═O)NR⁷R¹⁰,—(CH₂)_(n)—(Z)_(g)—R⁷, —(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—(CH₂)_(n)—CO₂R⁷, or

R³ and R⁴ are each, independently, hydrogen, lower alkyl, hydroxyl-loweralkyl, phenyl, (phenyl)-lower alkyl, (halophenyl)-lower alkyl,((lower-alkyl)phenyl)-lower-alkyl, ((lower-alkoxy)phenyl))-lower alkyl,(naphthyl)-lower alkyl, or (pyridyl)-lower alkyl, or a group representedby formula A or formula B, with the proviso that at least one of R³ andR⁴ is a group represented by the formula A or formula B;

—(C(R^(L))₂)_(o)-x-(C(R^(L))₂)_(p)A¹  formula A:

—(C(R^(L))₂)_(o)-x-(C(R^(L))₂)_(p)A²  formula B:

A¹ is a C₇-C₁₅-membered aromatic carbocycle substituted with at leastone R⁵ and the remaining substituents are R⁶;

A² is a seven to fifteen-membered aromatic heterocycle substituted withat least one R⁵ and the remaining substituents are R⁶ wherein saidaromatic heterocycle comprises 1-4 heteroatoms selected from the groupconsisting of O, N, and S;

each R^(L) is, independently, —R⁷, —(CH₂)_(n)—OR⁸, —O—(CH₂)_(m)—OR⁸,—(CH₂)_(n)—NR⁷R¹⁰, —O—(CH₂)_(m)—NR⁷R¹⁰,—(CH₂)_(n)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—O—(CH₂)_(m)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —(CH₂CH₂O)_(m)—R⁸,—O—(CH₂CH₂O)_(m)—R⁸, —(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰,—O—(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰, —(CH₂)_(n)—C(═O)NR⁷R¹⁰,—O—(CH₂)_(m)—C(═O)NR⁷R¹⁰, —(CH₂)_(n)—(Z)_(g)—R⁷,—O—(CH₂)_(m)—(Z)_(g)—R⁷, —(CH₂)_(n)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—O—(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —(CH₂)_(n)—CO₂R⁷,—O—(CH₂)_(m)—CO₂R⁷, —OSO₃H, —O-glucuronide, —O-glucose,

each o is, independently, an integer from 0 to 10;

each p is, independently, an integer from 0 to 10;

with the proviso that the sum of o and p in each contiguous chain is

from 1 to 10;

each x is, independently, O, NR¹⁰, C(═O), CHOH, C(═N—R¹⁰), CHNR⁷R¹⁰, ora single bond;

each R⁵ is, independently, OH, —(CH₂)_(m)—OR⁸, —O—(CH₂)_(m)—OR⁸,—(CH₂)_(n)—NR⁷R¹⁰, —O—(CH₂)_(m)—NR⁷R¹⁰,—(CH₂)_(n)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—O—(CH₂)_(m)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —(CH₂CH₂O)_(m)—R⁸,—O—(CH₂CH₂O)_(m)—R⁸, —(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰,—O—(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰, —(CH₂)_(n)—C(═O)NR⁷R¹⁰,—O—(CH₂)_(m)—C(═O)NR⁷R¹⁰, —(CH₂)_(n)—(Z)_(g)—R⁷,—O—(CH₂)_(m)—(Z)_(g)—R⁷, —(CH₂)_(n)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—O—(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —(CH₂)_(n)—CO₂R⁷,—O—(CH₂)_(m)—CO₂R⁷, —OSO₃H, —O-glucuronide, —O-glucose,

—(CH₂)_(n)—CO₂R¹³, -Het-(CH₂)_(m)—CO₂R¹³, —(CH₂)_(n)—(Z)_(g)—CO₂R¹³,-Het-(CH₂)_(m)—(Z)_(g)—CO₂R¹³,—(CH₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CO₂R¹³,-Het-(CH₂)_(m)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CO₂R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—CO₂R¹³, -Het-(CH₂)_(m)—(CHOR⁸)_(m)—CO₂R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)(Z)_(g)—CO₂R¹³,-Het-(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CO₂R¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)—CO₂R¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)—CO₂R¹³,—(CH₂)_(n)—(Z)_(g)(CHOR⁸)_(m)—(Z)_(g)—CO₂R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—CO₂R¹³,—(CH₂)_(n)—CONH—C(═NR¹³)—NR¹³R¹³, -Het-(CH₂)_(n)—CO—NH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—CONH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—CONH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CONH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CONH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—CONH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(CHOR⁸)_(m)—CONH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CONH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CONH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—CONH—C(═NR¹³)—NR¹³R¹³,Het-(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—CONH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—CONR⁷—CONR¹³R¹³, -Het-(CH₂)_(n)—CONR⁷—CONR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—CONR⁷—CONR¹³R¹³, —(CH₂)_(n)—(Z)_(g)—CONR⁷—CONR¹³R¹³,—(CH₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CONR⁷—CONR¹³R¹³,-Het-(CH₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CONR⁷—CONR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—CONR⁷—CONR¹³R¹³,Het-(CH₂)_(n)—(CHOR⁸)_(m)—CONR⁷—CONR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷—CONR¹³R¹³,-Het-(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CNR⁷—CONR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONR⁷—CONR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONR⁷—CONR¹³R¹³,—(CH₂)_(n)—(Z)_(g)(CHOR⁸)_(m)—(Z)_(g)—CONR⁷—CONR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)(CHOR⁸)_(m)—(Z)_(g)—CONR⁷—CONR¹³R¹³,—(CH₂)_(n)—CONR⁷SO₂NR¹³R¹³, -Het-(CH₂)_(m)—CONR⁷SO₂NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—CONR⁷SO₂NR¹³R¹³,-Het-(CH₂)_(m)—(Z)_(g)—CONR⁷SO₂NR¹³R¹³,—(CH₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CONR⁷SO₂NR¹³R¹³,-Het-(CH₂)_(m)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(m)—CONR⁷SO₂NR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—CONR⁷SO₂NR¹³R¹³,-Het-(CH₂)_(m)—(CHOR⁸)_(rn)—CONR⁷SO₂NR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷SO₂NR¹³R¹³,-Het-(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷SO₂NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONR⁷SO₂NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONR⁷SO₂NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷SO₂NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷SO₂NR¹³R¹³,—(CH₂)_(n)—SO₂NR¹³R¹³, -Het-(CH₂)_(m)—SO₂NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—SO₂NR¹³R¹³, -Het-(CH₂)_(n)—(Z)_(g)—SO₂NR¹³R¹³,—(CH₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—SO₂NR¹³R¹³,-Het-(CH₂)_(m)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(m)—SO₂NR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—SO₂NR¹³R¹³,-Het-(CH₂)_(m)—(CHOR⁸)_(m)—SO₂NR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—SO₂NR¹³R¹³,-Het-(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—SO₂NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)SO₂NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)SO₂NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—SO₂NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—SO₂NR¹³R¹³,—(CH₂)_(n)—CONR¹³R¹³, -Het-(CH₂)_(m)—CONR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—CONR¹³R¹³, -Het-(CH₂)_(m)—(Z)_(g)—CONR¹³R¹³,—(CH₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CONR¹³R¹³,-Het-(CH₂)_(m)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CONR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—CONR¹³R¹³, -Het-(CH₂)_(m)—(CHOR⁸)_(m)—CONR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CONR¹³R¹³,-Het-(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CONR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—CONR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—CONR¹³R¹³,—(CH₂)_(n)—CONR⁷COR¹³, -Het-(CH₂)_(m)—CONR⁷COR¹³,—(CH₂)_(n)—(Z)_(g)—CONR⁷COR¹³, -Het-(CH₂)_(m)—(Z)_(g)—CONR⁷COR¹³,—(CH₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CONR⁷COR¹³,-Het-(CH₂)_(m)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CONR⁷COR¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—CONR⁷COR¹³,-Het-(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷COR¹³,—(CH₂)_(m)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷COR¹³,-Het-(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷COR¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONR⁷COR¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONR⁷COR¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷COR¹³,—(CH₂)_(n)—CONR⁷CO₂R¹³, —(CH₂)_(n)—(Z)_(g)—CONR⁷CO₂R¹³,-Het-(CH₂)_(m)—(Z)_(g)—CONR⁷CO₂R¹³,—(CH₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CONR⁷CO₂R¹³,-Het-(CH₂)_(m)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CONR⁷CO₂R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—CONR⁷CO₂R¹³,-Het-(CH₂)_(m)—(CHOR⁸)_(m)—CONR⁷CO₂R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷CO₂R¹³,-Het-(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷CO₂R¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONR⁷CO₂R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONR⁷CO₂R¹³,—(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷CO₂R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷CO₂R¹³,—(CH₂)_(n)—NH—C(═NR¹³)—NR¹³R¹³, -Het-(CH₂)_(m)—NH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—NH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(m)—(Z)_(g)—NH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—NH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(m)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—NH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—NH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(m)—(CHOR⁸)_(m)—NH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—NH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—NH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)NH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)NH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—NH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—NH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—C(═NR¹³)—NR¹³R¹³, Het-(CH₂)_(m)—C(═NH)—NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—C(═NH)—NR¹³R¹³, Het-(CH₂)_(m)—(Z)_(g)—C(═NH)—NR¹³R¹³,—(CH₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—C(═NR¹³)—NR¹³R¹³,Het-(CH₂)_(m)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(m)—(CHOR⁸)_(m)—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)—C(═NHC(═NR¹³)—NR¹³R¹³,Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—NR¹²R¹², —O—(CH₂)_(m)—NR¹²R¹², —O—(CH₂)_(n)—NR¹²R¹²,—O—(CH₂)_(m)(Z)_(g)R¹², —(CH₂)_(n)NR¹¹R¹¹, —O—(CH₂)_(m)NR¹¹R¹¹,—(CH₂)_(n)—N^(⊕)—(R¹¹)₃, —(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)—NR¹⁰R¹⁰,—O—(CH₂)_(m)—(Z)_(g)—(CH₂)_(m)—NR¹⁰R¹⁰, —(CH₂CH₂O)_(m)—CH₂CH₂NR¹²R¹²,—O—(CH₂CH₂O)_(m)—CH₂CH₂NR¹²R¹², —(CH₂)_(n)—(C═O)NR¹²R¹²,—O—(CH₂)_(m)—(C═O)NR¹²R¹², —O—(CH₂)_(m)—(CHOR⁸)_(m)CH₂NR¹⁰—(Z)_(g)—R¹⁰,—(CH₂)_(n)—(CHOR⁸)_(m)CH₂—NR¹⁰—(Z)_(g)—R¹⁰,—(CH₂)_(n)NR¹⁰—O(CH₂)_(m)(CHOR⁸)_(n)CH₂NR¹⁰—(Z)_(g)—R¹⁰,—O(CH₂)_(m)—NR¹⁰—(CH₂)_(m)—(CHOR⁸)_(n)CH₂NR¹⁰—(Z)_(g)—R¹⁰,-(Het)-(CH₂)_(m)—OR⁸, -(Het)-(CH₂)_(m)—NR⁷R¹⁰,-(Het)-(CH₂)_(m)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, -(Het)-(CH₂CH₂O)_(m)—R⁸,-(Het)-(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰, -(Het)-(CH₂)_(m)—C(═O)NR⁷R¹⁰,-(Het)-(CH₂)_(m)—(Z)_(g)—R⁷,-(Het)-(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,-(Het)-(CH₂)_(m)—CO₂R⁷, -(Het)-(CH₂)_(m)—NR¹²R¹²,-(Het)-(CH₂)_(n)—NR¹²R¹², -(Het)-(CH₂)_(m)—(Z)_(g)R¹²,-(Het)-(CH₂)_(m)NR¹¹R¹¹, -(Het)-(CH₂)_(m)—N^(⊕)—(R¹¹)₃,-(Het)-(CH₂)_(m)—(Z)_(g)—(CH₂)_(m)—NR¹⁰R¹⁰,-(Het)-(CH₂CH₂O)_(m)—CH₂CH₂NR¹²R¹², -(Het)-(CH₂)_(m)—(C═O)NR¹²R¹²,-(Het)-(CH₂)_(m)—(CHOR⁸)_(m)CH₂NR¹⁰—(Z)_(g)—R¹⁰,-(Het)-(CH₂)_(m)—NR¹⁰—(CH₂)_(m)—(CHOR⁸)_(n)CH₂NR¹⁰—(Z)_(g)—R¹⁰,—(CH₂)_(n)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—O—(CH₂)_(m)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—(CH₂)_(n)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—O—(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, Link-(CH₂)_(n)—CAP,Link-(CH₂)_(n)(CHOR⁸)(CHOR⁸)_(n)—CAP, Link-(CH₂CH₂O)_(m)—CH₂—CAP,Link-(CH₂CH₂O)_(m)—CH₂CH₂—CAP, Link-(CH₂)_(n)(Z)_(g)—CAP,Link-(CH₂)_(n)(Z)_(g)—(CH₂)_(m)—CAP,Link-(CH₂)_(n)—NR¹³—CH₂(CHOR⁸)(CHOR⁸)_(n)—CAP,Link-(CH₂)_(n)—(CHOR⁸)_(m)CH₂—NR¹³—(Z)_(g)—CAP,Link-(CH₂)_(n)NR¹³—(CH₂)_(m)(CHOR⁸)_(n)CH₂NR¹³—(Z)_(g)—CAP,-Link-(CH₂)_(m)—(Z)_(g)—(CH₂)_(m)—CAP, Link-NH—C(═O)—NH—(CH₂)_(m)—CAP,Link-(CH₂)_(m)—C(═O)NR¹³—(CH₂)_(m)—C(═O)NR¹⁰R¹⁰,Link-(CH₂)_(m)—C(═O)NR¹³—(CH₂)_(m)—CAP, Link-(CH₂)_(m)—C(═O)NR¹¹R¹¹,Link-(CH₂)_(m)C(═O)NR¹²R¹²,Link-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)—(Z)_(g)—CAP,Link-(Z)_(g)—(CH₂)_(m)-Het-(CH₂)_(m)—CAP, Link —(CH₂)_(n)—CR¹¹R¹¹—CAP,Link —(CH₂)_(n)(CHOR⁸)(CHOR⁸)_(n)—CR¹¹R¹¹—CAP, Link—(CH₂CH₂O)_(m)—CH₂—CR¹¹R¹¹—CAP, Link —(CH₂CH₂O)_(m)—CH₂CH₂—CR¹¹R¹¹—CAP,Link —(CH₂)_(n)—(Z)_(g)—CR¹¹R¹¹—CAP,Link-(CH₂)_(n)(Z)_(g)—(CH₂)_(m)—CR¹¹R¹¹—CAP, Link—(CH₂)_(n)—NR¹³—CH₂(CHOR⁸)(CHOR⁸)_(n)—CR¹¹R¹¹—CAP, Link—(CH₂)_(n)—(CHOR⁸)_(m)CH₂—NR¹³—(Z)_(g)—CR¹¹R¹¹—CAP, Link—(CH₂)_(n)NR¹³—(CH₂)_(m)(CHOR⁸)_(n)CH₂NR¹³—(Z)_(g)—CR¹¹R¹¹—CAP, Link—(CH₂)_(m)—(Z)_(g)—(CH₂)_(m)—CR¹¹R¹¹—CAP, LinkNH—C(═O)—NH—(CH₂)_(m)—CR¹¹R¹¹—CAP, Link—(CH₂)_(m)—C(═O)NR¹³—(CH₂)_(m)—CR¹¹R¹¹—CAP, Link—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)—(Z)_(g)—CR¹¹R¹¹—CAP, or Link—(Z)_(g)—(CH₂)_(m)-Het-(CH₂)_(m)—CR¹¹R¹¹—CAP;

each R⁶ is, independently, R⁵, —R⁷, —OR¹¹, —N(R⁷)₂, —(CH₂)_(m)—OR⁸,—O—(CH₂)_(m)—OR⁸, —(CH₂)_(n)—NR⁷R¹⁰, —O—(CH₂)_(m)—NR⁷R¹⁰,—(CH₂)_(n)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—O—(CH₂)_(m)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —(CH₂CH₂O)_(m)—R⁸,—O—(CH₂CH₂O)_(m)—R⁸, —(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰,—O—(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰, —(CH₂)_(n)—C(—O)NR⁷R¹⁰,—O—(CH₂)_(m)—C(═O)NR⁷R¹⁰, —(CH₂)_(n)—(Z)_(g)—R⁷,—O—(CH₂)_(m)—(Z)_(g)—R⁷, —(CH₂)_(n)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—O—(CH₂)_(m)—NR¹⁹—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —(CH₂)_(n)—CO₂R⁷,—O—(CH₂)_(m)—CO₂R⁷, —OSO₃H, —O-glucuronide, —O-glucose,

wherein when two R⁶ are —OR¹¹ and are located adjacent to each other onthe aromatic carbocycle or aromatic heterocycle, the two OR¹¹ may form amethylenedioxy group;

each R⁷ is, independently, hydrogen, lower alkyl, phenyl, substitutedphenyl or —CH₂(CHOR⁸)_(m)—CH₂OR⁸;

each R⁸ is, independently, hydrogen, lower alkyl, —C(═O)—R¹¹,glucuronide, 2-tetrahydropyranyl, or

each R⁹ is, independently, —CO₂R⁷, —CON(R⁷)₂, —SO₂CH₃, —C(═O)R⁷,—CO₂R¹³, —CON(R¹³)₂, —SO₂CH₂R¹³, or —C(═O)R¹³;

each R¹⁰ is, independently, —H, —SO₂CH₃, —CO₂R⁷, —C(═O)NR⁷R⁹, —C(═O)R⁷,or —CH₂—(CHOH)_(n)—CH₂OH;

each Z is, independently, —(CHOH)—, —C(═O)—, —(CHNR⁷R¹⁰)—, —(C═NR¹⁰)—,—NR¹⁰—, —(CH₂)_(n)—, —(CHNR¹³R¹³)—, —(C═NR¹³)—, or —NR¹³—;

each R¹¹ is, independently, hydrogen, lower alkyl, phenyl lower alkyl orsubstituted phenyl lower alkyl;

each R¹² is, independently, —SO₂CH₃, —CO₂R⁷, —C(═O)NR⁷R⁹, —C(═O)R⁷,—CH₂(CHOH)_(n)—CH₂OH, —CO₂R¹³, —C(═O)NR¹³R¹³, or —C(═O)R¹³;

each R¹³ is, independently, R⁷, R¹⁰, —(CH₂)_(m)—NR⁷R¹⁰,—(CH₂)_(m)—NR⁷R⁷, —(CH₂)_(m)—NR¹¹R¹¹, —(CH₂)_(m)—(NR¹¹R¹¹R¹¹)⁺,—(CH₂)_(m)—(CHOR⁸),(CH₂)_(m)NR¹¹R¹¹,—(CH₂)_(m)—(CHOR⁸)_(m)—(CH₂)_(m)NR⁷R¹⁰, —(CH₂)_(m)—NR¹⁹R¹⁰,—(CH₂)_(m)—(CHOR⁸)_(m)—(CH₂)_(m)—(NR¹¹R¹¹R¹¹)⁺,—(CH₂)_(m)—(CHOR⁸)_(m)—(CH₂)_(m)NR⁷R⁷,

with the proviso that in the moiety —NR¹³R¹³, the two R¹³ along with thenitrogen to which they are attached may, optionally, form a ringselected from:

each V is, independently, —(CH₂)_(m)—NR⁷R¹⁰, —(CH₂)_(m)—NR⁷R⁷,—(CH₂)_(m)—(NR¹¹R¹¹R¹¹)⁺, —(CH₂)_(n)—(CHOR⁸)_(m)—(CH₂)_(m)NR⁷R¹⁰,—(CH₂)_(n)—NR¹⁰R¹⁰—(CH₂)_(n)—(CHOR⁸)_(m)—(CH₂)_(m)NR⁷R⁷,—(CH₂)_(n)—(CHOR⁸)_(m)—(CH₂)_(m)—(NR¹¹R¹¹R¹¹)⁺ with the proviso thatwhen V is attached directly to a nitrogen atom, then V can also be,independently, R⁷, R¹⁰, or (R¹¹)₂;

each R¹⁴ is, independently, H, R¹², —(CH₂)_(n)—SO₂CH₃,—(CH₂)_(n)—CO₂R¹³, —(CH₂)_(n)—C(═O)NR¹³R¹³, —(CH₂)_(n)—C(═O)R¹³,—(CH₂)_(n)—(CHOH)_(n)—CH₂OH, —NH—(CH₂)_(n)—SO₂CH₃,NH—(CH₂)_(n)—C(═O)R¹¹, NH—C(═O)—NH—C(═O)R¹¹, —C(═O)NR¹³R¹³, —OR¹¹,—NH—(CH₂)_(n)—R¹⁰, —Br, —Cl, —F, —I, SO₂NHR¹¹, —NHR¹³,—NH—C(═O)—NR¹³R¹³, —(CH₂)_(n)—NHR¹³, or —NH—(CH₂)_(n)—C(═O)—R¹³;

each g is, independently, an integer from 1 to 6;

each m is, independently, an integer from 1 to 7;

each n is, independently, an integer from 0 to 7;

each -Het- is, independently, —N(R⁷)—), —N(R¹⁰)—, —S—, —SO—, —SO₂—; —O—,—SO₂NH—, —NHSO₂—, —NR⁷CO—, —CONR⁷—, —N(R¹³)—, —SO₂NR¹³—, —NR¹³CO—, or—CONR¹³—;

each Link is, independently, —O—, —(CH₂)_(n)—, —O(CH₂)_(m)—,—NR¹³—C(═O)—NR¹³—, —NR¹³—C(═O)—(CH₂)_(m)—, —C(═O)NR¹³—(CH₂)_(m) ⁻,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(n)—, —S—, —SO—, —SO₂—, —SO₂NR⁷—, —SO₂NR¹⁰—, or-Het-;

each CAP is, independently, thiazolidinedione, oxazolidinedione,-heteroaryl-C(═O)N R¹³R¹³, heteroaryl-W, —CN, —O—C(═S)NR¹³R¹³,—(Z)_(g)R¹³, —CR¹⁰((Z)_(g)R¹³)((Z)_(g)R¹³), —C(═O)OAr, —C(═O)NR¹³Ar,imidazoline, tetrazole, tetrazole amide, —SO₂NHR¹³,—SO₂NH—C(R¹³R¹³)—(Z)_(g)—R¹³, a cyclic sugar or oligosaccharide, acyclic amino sugar, oligosaccharide,—CR¹⁰(—(CH₂)_(m)—R⁹)(—(CH₂)_(m)—R⁹), —N(—(CH₂)_(m)—R⁹)(—(CH₂)_(m)—R⁹),—NR¹³(—(CH₂)_(m)—CO₂R¹³),

each Ar is, independently, phenyl, substituted phenyl, wherein thesubstituents of the substituted phenyl are 1-3 substituentsindependently selected from the group consisting of OH, OCH₃, NR¹³R¹³,Cl, F, and CH₃, or heteroaryl; and

each W is, independently, thiazolidinedione, oxazolidinedione,heteroaryl-C(═O)N R¹³R¹³, —CN, —O—C(═S)NR¹³R¹³, —(Z)_(g)R¹³,—CR¹⁰((Z)_(g)R¹³)((Z)_(g)R¹³), —C(═O)OAr, —C(═O)N R¹³Ar, imidazoline,tetrazole, tetrazole amide, —SO₂NHR¹³, —SO₂NH—C(R¹³R¹³)—(Z)_(g)—R¹³, acyclic sugar or oligosaccharide, a cyclic amino sugar, oligosaccharide,

with the proviso that when any —CHOR⁸— or —CH₂OR⁸ groups are located1,2- or 1,3- with respect to each other, the R⁸ groups may, optionally,be taken together to form a cyclic mono- or di-substituted 1,3-dioxaneor 1,3-dioxolane.

The present also provides pharmaceutical compositions which comprise acompound described herein.

The present invention also provides a method of promoting hydration ofmucosal surfaces, comprising:

administering an effective amount of a compound described herein to amucosal surface of a subject.

The present invention also provides a method of restoring mucosaldefense, comprising:

topically administering an effective amount of compound described hereinto a mucosal surface of a subject in need thereof.

The present invention also provides a method of blocking ENaC,comprising:

contacting sodium channels with an effective amount of a compoundrepresented by described herein.

The present invention also provides a method of promoting mucusclearance in mucosal surfaces, comprising:

administering an effective amount of a compound represented describedherein to a mucosal surface of a subject.

The present invention also provides a method of treating chronicbronchitis, comprising:

administering an effective amount of a compound described herein to asubject in need thereof.

The present invention also provides a method of treating cysticfibrosis, comprising:

administering an effective amount of compound described herein to asubject in need thereof.

The present invention also provides a method of treating rhinosinusitis,comprising:

administering an effective amount of a compound described herein to asubject in need thereof.

The present invention also provides a method of treating nasaldehydration, comprising:

administering an effective amount of a compound described herein to thenasal passages of a subject in need thereof.

In a specific embodiment, the nasal dehydration is brought on byadministering dry oxygen to the subject.

The present invention also provides a method of treating sinusitis,comprising:

administering an effective amount of a compound described herein to asubject in need thereof.

The present invention also provides a method of treating pneumonia,comprising:

administering an effective amount of a compound described herein to asubject in need thereof.

The present invention also provides a method of treatingventilator-induced pneumonia, comprising:

administering an effective compound described herein to a subject bymeans of a ventilator.

The present invention also provides a method of treating asthma,comprising:

administering an effective amount of a compound described herein to asubject in need thereof.

The present invention also provides a method of treating primary ciliarydyskinesia, comprising:

administering an effective amount of a compound described herein to asubject in need thereof.

The present invention also provides a method of treating otitis media,comprising:

administering an effective amount of a compound described herein to asubject in need thereof.

The present invention also provides a method of inducing sputum fordiagnostic purposes, comprising:

administering an effective amount of compound described herein to asubject in need thereof.

The present invention also provides a method of treating chronicobstructive pulmonary disease, comprising:

administering an effective amount of a compound described herein to asubject in need thereof.

The present invention also provides a method of treating emphysema,comprising:

administering an effective amount of a compound described herein to asubject in need thereof.

The present invention also provides a method of treating dry eye,comprising:

administering an effective amount of a compound described herein to theeye of the subject in need thereof.

The present invention also provides a method of promoting ocularhydration, comprising:

administering an effective amount of a compound described herein to theeye of the subject.

The present invention also provides a method of promoting cornealhydration, comprising:

administering an effective amount of a compound described herein to theeye of the subject.

The present invention also provides a method of treating Sjögren'sdisease, comprising:

administering an effective amount of compound described herein to asubject in need thereof.

The present invention also provides a method of treating vaginaldryness, comprising:

administering an effective amount of a compound described herein to thevaginal tract of a subject in need thereof.

The present invention also provides a method of treating dry skin,comprising:

administering an effective amount of a compound described herein to theskin of a subject in need thereof.

The present invention also provides a method of treating dry mouth(xerostomia), comprising:

administering an effective amount of compound described herein to themouth of the subject in need thereof.

The present invention also provides a method of treating distalintestinal obstruction syndrome, comprising:

administering an effective amount of compound described herein to asubject in need thereof.

The present invention also provides a method of treating esophagitis,comprising:

administering an effective amount of a compound described herein to asubject in need thereof.

The present invention also provides a method of treating bronchiectasis,comprising:

administering an effective amount of a compound described herein to asubject in need thereof.

The present invention also provides a method of treating constipation,comprising:

administering an effective amount of a compound described herein to asubject in need thereof. In one embodiment of this method, the compoundis administered either orally or via a suppository or enema.

The present invention also provides a method of treating chronicdiverticulitis comprising:

administering an effective amount of a compound described herein to asubject in need thereof.

The present invention also provides a method of treating hypertension,comprising administering the compound described herein to a subject inneed thereof.

The present invention also provides a method of reducing blood pressure,comprising administering the compound described herein to a subject inneed thereof.

The present invention also provides a method of treating edema,comprising administering the compound described herein to a subject inneed thereof.

The present invention also provides a method of promoting diuresis,comprising administering the compound described herein to a subject inneed thereof.

The present invention also provides a method of promoting natriuresis,comprising administering the compound described herein to a subject inneed thereof.

The present invention also provides a method of promoting saluresis,comprising administering the compound described herein to a subject inneed thereof.

It is an object of the present invention to provide treatmentscomprising the use of osmolytes together with sodium channel blockers offormula (I) that are more potent, more specific, and/or absorbed lessrapidly from mucosal surfaces, and/or are less reversible as compared tocompounds such as amiloride, benzamil, and phenamil

It is another aspect of the present invention to provide treatmentsusing sodium channel blockers of formula (I) that are more potent and/orabsorbed less rapidly and/or exhibit less reversibility, as compared tocompounds such as amiloride, benzamil, and phenamil when administeredwith an osmotic enhancer. Therefore, such sodium channel blockers whenused in conjunction with osmolytes will give a prolonged pharmacodynamichalf-life on mucosal surfaces as compared to either compound used alone.

It is another object of the present invention to provide treatmentsusing sodium channel blockers of formula (I) and osmolytes togetherwhich are absorbed less rapidly from mucosal surfaces, especially airwaysurfaces, as compared to compounds such as amiloride, benzamil, andphenamil

It is another object of the invention to provide compositions whichcontain sodium channel blockers of formula (I) and osmolytes.

The objects of the invention may be accomplished with a method oftreating a disease ameliorated by increased mucociliary clearance andmucosal hydration comprising administering an effective amount of acompound of formula (I) as defined herein and an osmolyte to a subjectto a subject in need of increased mucociliary clearance and mucosalhydration.

The objects of the invention may also be accomplished with a method ofinducing sputum for diagnostic purposes, comprising administering aneffective amount of a compound of formula (I) as defined herein and anosmolyte to a subject in need thereof.

The objects of the invention may also be accomplished with a method oftreating anthrax, comprising administering an effective amount of acompound of formula (I) as defined herein and an osmolyte to a subjectin need thereof.

The objects of the invention may also be accomplished with a method ofprophylactic, post-exposure prophylactic, preventive or therapeutictherapeutic treatment against diseases or conditions caused bypathogens, particularly pathogens which may be used in bioterrorism,comprising administering an effective amount of a compound of formula(I) to a subject in need thereof.

The objects of the invention may also be accomplished with acomposition, comprising a compound of formula (I) as defined herein andan osmotically active compound.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is based on the discovery that the compounds offormula (I) are more potent and/or, absorbed less rapidly from mucosalsurfaces, especially airway surfaces, and/or less reversible frominteractions with ENaC as compared to compounds such as amiloride,benzamil, and phenamil. Therefore, the compounds of formula (I) have alonger half-life on mucosal surfaces as compared to these compounds.

The present invention is also based on the discovery that certaincompounds embraced by formula (I) are converted in vivo into metabolicderivatives thereof that have reduced efficacy in blocking sodiumchannels as compared to the parent administered compound, after they areabsorbed from mucosal surfaces after administration. This importantproperty means that the compounds will have a lower tendency to causeundesired side-effects by blocking sodium channels located at untargetedlocations in the body of the recipient, e.g., in the kidneys.

The present invention is also based on the discovery that certaincompounds embraced by formula (1) target the kidney and thus may be usedas cardiovascular agents.

In the compounds represented by formula (I), X may be hydrogen, halogen,trifluoromethyl, lower alkyl, lower cycloalkyl, unsubstituted orsubstituted phenyl, lower alkyl-thio, phenyl-lower alkyl-thio, loweralkyl-sulfonyl, or phenyl-lower alkyl-sulfonyl. Halogen is preferred.

Examples of halogen include fluorine, chlorine, bromine, and iodine.Chlorine and bromine are the preferred halogens. Chlorine isparticularly preferred. This description is applicable to the term“halogen” as used throughout the present disclosure.

As used herein, the term “lower alkyl” means an alkyl group having lessthan 8 carbon atoms. This range includes all specific values of carbonatoms and subranges there between, such as 1, 2, 3, 4, 5, 6, and 7carbon atoms. The term “alkyl” embraces all types of such groups, e.g.,linear, branched, and cyclic alkyl groups. This description isapplicable to the term “lower alkyl” as used throughout the presentdisclosure. Examples of suitable lower alkyl groups include methyl,ethyl, propyl, cyclopropyl, butyl, isobutyl, etc.

Substituents for the phenyl group include halogens. Particularlypreferred halogen substituents are chlorine and bromine.

Y may be hydrogen, hydroxyl, mercapto, lower alkoxy, lower alkyl-thio,halogen, lower alkyl, lower cycloalkyl, mononuclear aryl, or —N(R²)₂.The alkyl moiety of the lower alkoxy groups is the same as describedabove. Examples of mononuclear aryl include phenyl groups. The phenylgroup may be unsubstituted or substituted as described above. Thepreferred identity of Y is —N(R²)₂. Particularly preferred are suchcompounds where each R² is hydrogen.

R¹ may be hydrogen or lower alkyl. Hydrogen is preferred for R¹.

Each R² may be, independently, —R⁷, —(CH₂)_(m)—OR⁸, —(CH₂)_(m)—NR⁷R¹⁰,—(CH₂)_(n)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —(CH₂CH₂O)_(m)—R⁸,—(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰, —(CH₂)_(n)—C(═O)NR⁷R¹⁰,—(CH₂)_(n)—(Z)_(g)—R⁷, —(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—(CH₂)_(n)—CO₂R⁷, or

Hydrogen and lower alkyl, particularly C₁-C₃ alkyl, are preferred forR². Hydrogen is particularly preferred.

R³ and R⁴ may be, independently, hydrogen, lower alkyl, hydroxyl-loweralkyl, phenyl, (phenyl)-lower alkyl, (halophenyl)-lower alkyl,((lower-alkyl)phenyl)-lower-alkyl), (lower-alkoxyphenyl)-lower alkyl,(naphthyl)-lower alkyl, (pyridyl)-lower alkyl or a group represented by—(C(R^(L))₂)_(o)-x-(C(R^(L))₂)_(p)A¹ or—(C(R¹)₂)_(o)-x-(C(R^(L))₂)_(p)A², provided that at least one of R³ andR⁴ is a group represented by —(C(R^(L))₂)_(o)-x-(C(R^(L))₂)_(p)A¹ or—(C(R^(L))₂)_(o)-x-(C(R^(L))₂)_(p)A².

Preferred compounds are those where one of R³ and R⁴ is hydrogen and theother is represented by —(C(R^(L))₂)_(o)-x-(C(R^(L))₂)_(p)A¹ or—(C(R^(L))₂)_(o)-x-(C(R^(L))₂)_(p)A². In a particularly preferred aspectone of R³ and R⁴ is hydrogen and the other of R³ or R⁴ is represented by—(C(R^(L))₂)_(o)-x-(C(R^(L))₂)_(p)A¹. In another particularly preferredaspect one of R³ and R⁴ is hydrogen and the other of R³ or R⁴ isrepresented by —(C(R^(L))₂)_(o)-x-(C(R^(L))₂)_(p)A².

A moiety —(C(R^(L))₂)_(o)-x-(C(R^(L))₂)_(p)— defines an alkylene groupbonded to the group A¹ or A². The variables o and p may each,independently, be an integer from 0 to 10, subject to the proviso thatthe sum of o and p in the chain is from 1 to 10. Thus, o and p may eachbe 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. Preferably, the sum of o and pis from 2 to 6. In a particularly preferred embodiment, the sum of o andp is 4.

The linking group in the alkylene chain, x, may be, independently, O,NR¹⁰, C(═O), CHOH, C(═N—R¹⁰), CHNR⁷R¹⁰, or a single bond;

Therefore, when x is a single bond, the alkylene chain bonded to thering is represented by the formula —(C(R^(L))₂)_(o+p)—, in which the sumo+p is from 1 to 10.

Each R^(L) may be, independently, —R⁷, —(CH₂)_(n)—OR⁸, —O—(CH₂)_(m)—OR⁸,—(CH₂)_(n)—NR⁷R¹⁰, —O—(CH₂)_(m)—NR⁷R¹⁰,—(CH₂)_(n)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—O—(CH₂)_(m)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —(CH₂CH₂O)_(m)—R⁸,—O—(CH₂CH₂O)_(m)—R⁸, —(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰,—O—(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰, —(CH₂)_(n)—C(═O)NR⁷R¹⁰,—O—(CH₂)_(m)—C(═O)NR⁷R¹⁰, —(CH₂)_(n)—(Z)_(g)—R⁷,—O—(CH₂)_(m)—(Z)_(g)—R⁷, —(CH₂)_(n)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—O—(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —(CH₂)_(n)—CO₂R⁷,—O—(CH₂)_(m)—CO₂R⁷, —OSO₃H, —O-glucuronide, —O-glucose,

The term —O-glucuronide, unless otherwise specified, means a grouprepresented by

wherein the

O means the glycosidic linkage can be above or below the plane of thering.

The term —O-glucose, unless otherwise specified, means a grouprepresented by

wherein the

O means the glycosidic linkage can be above or below the plane of thering.

The preferred R^(L) groups include —H, —OH, —N(R⁷)₂, especially whereeach R⁷ is hydrogen.

In the alkylene chain in —(C(R^(L))₂)_(o)-x-(C(R^(L))₂)_(p)A¹ or—(C(R^(L))₂)_(o)-x-(C(R^(L))₂)_(p)A², it is preferred that when oneR^(L) group bonded to a carbon atoms is other than hydrogen, then theother R^(L) bonded to that carbon atom is hydrogen, i.e., the formula—CHR^(L)—. It is also preferred that at most two R^(L) groups in analkylene chain are other than hydrogen, wherein the other R^(L) groupsin the chain are hydrogens. Even more preferably, only one R^(L) groupin an alkylene chain is other than hydrogen, wherein the other R^(L)groups in the chain are hydrogens. In these embodiments, it ispreferable that x is a single bond.

In another particular embodiment of the invention, all of the R^(L)groups in the alkylene chain are hydrogen. In these embodiments, thealkylene chain is represented by the formula —(CH₂)_(o)-x-(CH₂)_(p)—.

A¹ is a C₇-C₁₅-membered aromatic carbocycle substituted with at leastone R⁵ and the remaining substituents are R⁶. The term aromatic is wellknown term of chemical art and designates conjugated systems of 4n′+2electrons that are within a ring system, that is with 6, 10, 14, etc.π-electrons wherein, according to the rule of Huckel, n′ is 1, 2, 3,etc. The 4n′+2 electrons may be in any size ring including those withpartial saturation so long as the electrons are conjugated. Forinstance, but not by way of limitation, 5H-cyclohepta-1,3,5-triene,benzene, naphthalene, 1,2,3,4-tetrahydronaphthalene etc. would all beconsidered aromatic.

The C₇-C₁₅ aromatic carbocycle may be monocyclic, bicyclic, or tricyclicand may include partially saturated rings. Non-limiting examples ofthese aromatic carbocycles comprise 5H-cyclohepta-1,3,5-triene,naphthalene, phenanthrene, azulene, anthracene,1,2,3,4-tetrahydronapthalene, 1,2-dihydronaphthalene, indene,5H-dibenzo[a,d]cycloheptene, etc.

The C₇-C₁₅ aromatic carbocycle may be attached to the—(C(R^(L))₂)_(o))-x-(C(R^(L))₂)_(p)— moiety through any ring carbon atomas appropriate, unless otherwise specified. Therefore, when partiallysaturated bicyclic aromatic is 1,2-dihydronapthalene, it may be1,2-dihydronapthalen-1-yl, 1,2-dihydronapthalen-3-yl,1,2-dihydronapthalen-5-yl, etc. In a preferred embodiment A¹ is indenyl,napthalenyl, 1,2-dihydronapthalenyl, 1,2,3,4-tetrahydronapthalenyl,anthracenyl, fluorenyl, phenanthrenyl, azulenyl,cyclohepta-1,3,5-trienyl or 5H-dibenzo[a,d]cycloheptenyl. In anotherpreferred embodiment, A¹ is napthalen-1-yl. In another preferredembodiment, A¹ is napthalen-2-yl.

In another preferred embodiment, A¹ is

wherein each Q is, independently, C—H, C—R⁵, or C—R⁶, with the provisothat at least one Q is C—R⁵. Therefore, Q may be 1, 2, 3, 4, 5, or 6C—H. Therefore, Q may be 1, 2, 3, 4, 5, or 6 C—R⁶. In a particularlypreferred embodiment, each R⁶ is H.

In another preferred embodiment, A¹ is

wherein each Q is, independently, C—H, C—R⁵, C—R⁶, with the proviso thatat least one Q is C—R⁵. Therefore, Q may be 1, 2, 3, 4, 5, or 6 C—H.Therefore, Q may be 1, 2, 3, 4, 5, or 6 C—R⁶. In a particularlypreferred embodiment, each R⁶ is H.

In a particularly preferred embodiment, A¹ is

In another particularly preferred embodiment, A¹ is

A² is a seven to fifteen-membered aromatic heterocycle substituted withat least one R⁵ and the remaining substituents are R⁶ wherein thearomatic heterocycle comprises 1-4 heteroatoms selected from the groupconsisting of O, N, and S.

The seven to fifteen-membered aromatic heterocycle may be monocyclic,bicyclic, or tricyclic and may include partially saturated rings. Nonlimiting examples of these aromatic heterocycles include 1H-azepine,benzo[b]furan, benzo[b]thiophene, isobenzofuran, isobenzothiophene,2,3-dihydrobenzo[b]furan, benzo[b]thiophene,2,3-dihydrobenzo[b]thiophene, indolizine, indole, isoindole benzoxazole,benzimidazole, indazole, benzisoxazole, benzisothizole, benzopyrazole,benzoxadiazole, benzothiadiazole, benzotriazole, purine, quinoline,1,2,3,4-tetrahydroquinoline, 3,4-dihydro-2H-chromene,3,4-dihydro-2H-thiochromene, isoquinoline, cinnoline, quinolizine,phthalazine, quinoxaline, quinazoline, naphthiridine, pteridine,benzopyrane, pyrrolopyridine, pyrrolopyrazine, imidazopyrdine,pyrrolopyrazine, thienopyrazine, furopyrazine, isothiazolopyrazine,thiazolopyrazine, isoxazolopyrazine, oxazolopyrazine, pyrazolopyrazine,imidazopyrazine, pyrrolopyrimidine, thienopyrimidine, furopyrimidine,isothiazolopyrimidine, thiazolopyrimidine, isoxazolopyrimidine,oxazolopyrimidine, pyrazolopyrimidine, imidazopyrimidine,pyrrolopyridazine, thienopyridazine, furopyridazine,isothiazolopyridazine, thiazolopyridazine, oxazolopyridazine,thiadiazolopyrazine, oxadiazolopyrimidine, thiadiazolopyrimidine,oxadiazolopyridazine, thiazolopyridazine, imidazooxazole,imidazothiazole, imidazoimidazole, isoxazolotriazine,isothiazolotriazine, oxazolotriazine, thiazolotriazine, carbazole,acridine, phenazine, phenothiazine, phenooxazine, and5H-dibenz[b,f]azepine, 10,11-dihydro-5H-dibenz[b,f]azepine, etc.

The seven to fifteen-membered aromatic heterocycle may be attached tothe —(C(R^(L))₂)_(o)-x-(C(R^(L))₂)_(p)— moiety through any ring carbonatom or ring nitrogen atom so long as a quanternary nitrogen atom is notformed by the attachment. Therefore, when partially saturated aromaticheterocycle is 1H-azepine, it may be 1H-azepin-1-yl, 1H-azepin-2-yl,1H-azepin-3-yl, etc. Preferred aromatic heterocycles are indolizinyl,indolyl, isoindolyl, indolinyl, benzo[b]furanyl,2,3-dihydrobenzo[b]furanyl, benzo[b]thiophenyl,2,3-dihydrobenzo[b]thiophenyl, indazolyl, benzimidazolyl, benzthiazolyl,purinyl, quinolinyl, 1,2,3,4-tetrahydroquinolinyl,3,4-dihydro-2H-chromenyl, 3,4-dihydro-2H-thiochromenyl, isoquinolinyl,cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl,1,8-naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl,phenothiazinyl, phenoxazinyl, dibenzofuranyl, dibenzothiophenyl,1H-azepinyl, 5H-dibenz[b,f]azepinyl, are10,11-dihydro-5H-dibenz[b,f]azepinyl.

In another preferred embodiment, A² is

wherein each Q is, independently, C—H, C—R⁵, C—R⁶, or a nitrogen atom,with the proviso that at least one Q is nitrogen and one Q is C—R⁵, andat most three Q in a ring are nitrogen atoms. Therefore, in any onering, each Q may be 1, 2, or 3 nitrogen atoms. In a preferredembodiment, only one Q in each ring is nitrogen. In another preferredembodiment, only a single Q is nitrogen. Optionally, 1, 2, 3, 4, or 5 Qmay be C—R⁶. Optionally, Q may be 1, 2, 3, 4, or 5 C—H. In aparticularly preferred embodiment, each R⁶ is H.

In another preferred embodiment, A² is

wherein each Q is, independently, C—H, C—R⁵, C—R⁶, or a nitrogen atom,with the proviso that at least one Q is nitrogen and one Q is C—R⁵, andat most three Q in a ring are nitrogen atoms. Therefore, in any onering, each Q may be 1, 2, or 3 nitrogen atoms. In a preferredembodiment, only one Q in each ring is nitrogen. In another preferredembodiment, only a single Q is nitrogen. Optionally, Q may be 1, 2, 3,4, or 5 C—H. Optionally, 1, 2, 3, 4, or 5 Q may be C—R⁶. In aparticularly preferred embodiment, each R⁶ is H.

Each R⁵ is, independently, OH, —(CH₂)_(m)—OR⁸, —O—(CH₂)_(m)—OR⁸,—(CH₂)_(n)—NR⁷R¹⁰, —O—(CH₂)_(m)—NR⁷R¹⁰,—(CH₂)_(n)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—O—(CH₂)_(m)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —(CH₂CH₂O)_(m)—R⁸,—O—(CH₂CH₂O)_(m)—R⁸, —(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰,—O—(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰, —(CH₂)_(n)—C(═O)NR⁷R¹⁰,—O—(CH₂)_(m)—C(═O)NR⁷R¹⁰, —(CH₂)_(n)—(Z)_(g)—R⁷,—O—(CH₂)_(m)—(Z)_(g)—R⁷, —(CH₂)_(n)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—O—(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —(CH₂)_(n)—CO₂R⁷,—O—(CH₂)_(m)—CO₂R⁷, —OSO₃H, —O-glucuronide, —O-glucose,

—(CH₂)_(n)—CO₂R¹³, -Het-(CH₂)_(m)—CO₂R¹³, —(CH₂)_(n)—(Z)_(g)—CO₂R¹³,-Het-(CH₂)_(m)—(Z)_(g)—CO₂R¹³,—(CH₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CO₂R¹³,-Het-(CH₂)_(m)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CO₂R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—CO₂R¹³, -Het-(CH₂)_(m)—(CHOR⁸)_(m)—CO₂R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)(Z)_(g)—CO₂R¹³,-Het-(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CO₂R¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)—CO₂R¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)—CO₂R¹³,—(CH₂)_(n)—(Z)_(g)(CHOR⁸)_(m)—(Z)_(g)—CO₂R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—CO₂R¹³,—(CH₂)_(n)—CONH—C(═NR¹³)—NR¹³R¹³, -Het-(CH₂)_(n)—CO—NH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—CONH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—CONH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CONH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CONH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—CONH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(CHOR⁸)_(m)—CONH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CONH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CONH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—CONH—C(═NR¹³)—NR¹³R¹³,Het-(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—CONH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—CONR⁷—CONR¹³R¹³, -Het-(CH₂)_(n)—CONR⁷—CONR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—CONR⁷—CONR¹³R¹³, —(CH₂)_(n)—(Z)_(g)—CONR⁷—CONR¹³R¹³,—(CH₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CONR⁷—CONR¹³R¹³,-Het-(CH₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CONR⁷—CONR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—CONR⁷—CONR¹³R¹³,Het-(CH₂)_(n)—(CHOR⁸)_(n)—CONR⁷—CONR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷—CONR¹³R¹³,-Het-(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CNR⁷—CONR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(n)—CONR⁷—CONR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONR⁷—CONR¹³R¹³,—(CH₂)_(n)(Z)_(g)(CHOR⁸)_(m)—(Z)_(g)—CONR⁷—CONR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)(CHOR⁸)_(m)—(Z)_(g)—CONR⁷—CONR¹³R¹³,—(CH₂)_(n)—CONR⁷SO₂NR¹³R¹³, -Het-(CH₂)_(m)—CONR⁷SO₂NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—CONR⁷SO₂NR¹³R¹³,-Het-(CH₂)_(m)—(Z)_(g)—CONR⁷SO₂NR¹³R¹³,—(CH₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CONR⁷SO₂NR¹³R¹³,-Het-(CH₂)_(m)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CONR⁷SO₂NR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—CONR⁷SO₂NR¹³R¹³,-Het-(CH₂)_(m)—(CHOR⁸)_(m)—CONR⁷SO₂NR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷SO₂NR¹³R¹³,-Het-(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷SO₂NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONR⁷SO₂NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONR⁷SO₂NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷SO₂NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷SO₂NR¹³R¹³,—(CH₂)—SO₂NR¹³R¹³, -Het-(CH₂)_(m)—SO₂NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—SO₂NR¹³R¹³, -Het-(CH₂)_(n)—SO₂NR¹³R¹³,—(CH₁₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—SO₂NR¹³R¹³,-Het-(CH₂)_(m)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—SO₂NR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—SO₂NR¹³R¹³,-Het-(CH₂)_(m)—(CHOR⁸)_(m1)SO₂NR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—SO₂NR¹³R¹³,-Het-(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—SO₂NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)SO₂NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)SO₂NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—SO₂NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—SO₂NR¹³R¹³,—(CH₂)_(n)—CONR¹³R¹³, -Het-(CH₂)_(m)—CONR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—CONR¹³R¹³, -Het-(CH₂)_(m)—(Z)_(g)—CONR¹³R¹³,—(CH₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CONR¹³R¹³,-Het-(CH₂)_(m)—(CHOR⁸)_(m)—CONR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CONR¹³R¹³,-Het-(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CONR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—CONR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)-(Z)_(g)—CONR¹³R¹³,—(CH₂)_(n)—CONR⁷COR¹³, -Het-(CH₂)_(m)—CONR⁷COR¹³,—(CH₂)_(n)—(Z)_(g)—CONR⁷COR¹³, -Het-(CH₂)_(m)—(Z)_(g)—CONR⁷COR¹³,—(CH₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CONR⁷COR¹³,-Het-(CH₂)_(m)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CONR⁷COR¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—CONR⁷COR¹³,-Het-(CH₂)_(m)—(CHOR⁸)_(m)—CONR⁷COR¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷COR¹³,-Het-(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷COR¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONR⁷COR¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONR⁷COR¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷COR¹³,—(CH₂)_(n)—CONR⁷CO₂R¹³, —(CH₂)_(n)—(Z)_(g)—CONR⁷CO₂R¹³,-Het-(CH₂)_(m)—(Z)_(g)—CONR⁷CO₂R¹³,—(CH₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(m)—CONR⁷CO₂R¹³,-Het-(CH₂)_(m)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—CONR⁷CO₂R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—CONR⁷CO₂R¹³,-Het-(CH₂)_(m)—(CHOR⁸)_(m)—CONR⁷CO₂R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷CO₂R¹³,-Het-(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷CO₂R¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONR⁷CO₂R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)CONR⁷CO₂R¹³,—(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷CO₂R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—CONR⁷CO₂R¹³,—(CH₂)_(n)—NH—C(═NR¹³)—NR¹³R¹³, -Het-(CH₂)_(m)—NH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—NH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(m)—(Z)_(g)—NH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—NH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(m)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—NH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—NH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(m)—(CHOR⁸)_(m)—NH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—NH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—NH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)NH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)NH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—NH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—NH—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—C(═NR¹³)—NR¹³R¹³, Het-(CH₂)_(m)—C(═NH)—NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—C(═NH)—NR¹³R¹³, Het-(CH₂)_(m)—(Z)_(g)—C(═NH)—NR¹³R¹³,—(CH₂)_(n)—NR¹⁰—(CH₂)_(n)—(CHOR⁸)_(m)—C(═NR¹³)—NR¹³R¹³,Het-(CH₂)_(m)—NR¹⁰—(CH₂)_(m)(CHOR⁸)_(n)—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(m)—(CHOR⁸)_(m)—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—C(═NR¹³)—NR¹³R¹³,—Het-(CH₂)_(n)—(CHOR⁸)_(m)—(Z)_(g)—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)—C(═NHC(═NR¹³)—NR¹³R¹³,Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CHOR⁸)_(m)—(Z)_(g)—C(═NR¹³)—NR¹³R¹³,—(CH₂)_(n)—NR¹²R¹², —O—(CH₂)_(m)—NR¹²R¹², —O—(CH₂)_(n)—NR¹²R¹²,—O—(CH₂)_(m)(Z)_(g)R¹², —(CH₂)_(n)NR¹¹R¹¹, —O—(CH₂)_(m)NR¹¹R¹¹,—(CH₂)_(n)—N^(⊕)—(R¹¹)₃, —O—(CH₂)_(m)—N^(⊕)—(R¹¹)₃,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)—NR¹⁰R¹⁰,—O—(CH₂)_(m)—(Z)_(g)—(CH₂)_(m)—NR¹⁰R¹⁰, —(CH₂CH₂O)_(m)—CH₂CH₂NR¹²R¹²,—O—(CH₂CH₂O)_(m)—CH₂CH₂NR¹²R¹², —(CH₂)_(n)—(C═O)NR¹²R¹²,—O—(CH₂)_(m)—(C═O)NR¹²R¹², —O—(CH₂)_(m)—(CHOR⁸)_(m)CH₂NR¹⁰—(Z)_(g)—R¹⁰,—(CH₂)_(n)—(CHOR⁸)_(m)—CH₂—NR¹⁰—(Z)_(g)—R¹⁰,—(CH₂)_(n)NR¹⁰—O(CH₂)_(m)(CHOR⁸)_(n)CH₂NR¹⁰—(Z)_(g)—R¹⁰,—O(CH₂)_(m)—NR¹⁰—(CH₂)_(m)—(CHOR⁸)_(n)CH₂NR¹⁰—(Z)_(g)—R¹⁰,-(Het)-(CH₂)_(m)—OR⁸, -(Het)-(CH₂)_(m)—NR⁷R¹⁰,-(Het)-(CH₂)_(m)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, -(Het)-(CH₂CH₂O)_(m)—R⁸,-(Het)-(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰, -(Het)-(CH₂)_(m)—C(═O)NR⁷R¹⁰,-(Het)-(CH₂)_(m)—(Z)_(g)—R⁷,-(Het)-(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,-(Het)-(CH₂)_(m)—CO₂R⁷, -(Het)-(CH₂)_(m)—NR¹²R¹²,-(Het)-(CH₂)_(n)—NR¹²R¹², -(Het)-(CH₂)_(m)—(Z)_(g)R¹²,-(Het)-(CH₂)_(m)NR¹¹R¹¹, -(Het)-(CH₂)_(m)—N^(⊕)—(R¹¹)₃,-(Het)-(CH₂)_(m)—(Z)_(g)—(CH₂)_(m)—NR¹⁰R¹⁰,-(Het)-(CH₂CH₂O)_(m)—CH₂CH₂NR¹²R¹², -(Het)-(CH₂)_(m)—(C═O)NR¹²R¹²,-(Het)-(CH₂)_(m)—(CHOR⁸)_(m)CH₂NR¹⁰—(Z)_(g)—R¹⁰,-(Het)-(CH₂)_(m)—NR¹⁰—(CH₂)_(m)—(CHOR⁸)_(n)CH₂NR¹⁰—(Z)_(g)—R¹⁰,—(CH₂)_(n)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—O—(CH₂)_(m)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—(CH₂)_(n)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—O—(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, Link-(CH₂)_(n)—CAP,Link-(CH₂)_(n)(CHOR⁸)(CHOR⁸)_(n)—CAP, Link-(CH₂CH₂O)_(m)—CH₂—CAP,Link-(CH₂CH₂O)_(m)—CH₂CH₂—CAP, Link-(CH₂)_(n)—(Z)_(g)—CAP,Link-(CH₂)_(n)(Z)_(g)—(CH₂)_(m)—CAP,Link-(CH₂)_(n)—NR¹³—CH₂(CHOR⁸)(CHOR⁸)_(n)—CAP,Link-(CH₂)_(n)—(CHOR⁸)_(m)CH₂—NR¹³—(Z)_(g)—CAP,Link-(CH₂)_(n)NR¹³—(CH₂)_(m)(CHOR⁸)_(n)CH₂NR¹³—(Z)_(g)—CAP,-Link-(CH₂)_(m)-(4-(CH₂)_(m)—CAP, Link-NH—C(═O)—NH—(CH₂)_(m)—CAP,Link-(CH₂)_(m)—C(═O)NR¹³—(CH₂)_(m)—C(═O)NR¹⁰R¹⁰,Link-(CH₂)_(m)—C(═O)NR¹³—(CH₂)_(m)—CAP, Link-(CH₂)_(m)—C(═O)NR¹¹R¹¹,Link-(CH₂)_(m)—C(═O)NR¹²R¹²,Link-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)—(Z)_(g)—CAP,Link-(Z)_(g)—(CH₂)_(m)-Het-(CH₂)_(m)—CAP, Link —(CH₂)_(n)—CR¹¹R¹¹—CAP,Link —(CH₂)_(n)(CHOR⁸)(CHOR⁸)_(n)—CR¹¹R¹¹—CAP, Link—(CH₂CH₂O)_(m)—CH₂—R¹¹R¹¹—CAP, Link —(CH₂CH₂O)_(m)—CH₂CH₂—CR¹¹R¹¹—CAP,Link —(CH₂)_(n)—(Z)_(g)—CR¹¹R¹¹—CAP, Link—(CH₂)^(n)(Z)_(g)—(CH₂)_(m)—CR¹¹R¹¹—CAP, Link—(CH₂)_(n)NR¹³—CH₂(CHOR⁸)(CHOR⁸)_(n)—CR¹¹R¹¹—CAP, Link—(CH₂)_(n)—(CHOR⁸)_(m)CH₂—NR¹³—(Z)_(g)—CR¹¹R¹¹—CAP, Link—(CH₂)_(n)NR¹³—(CH₂)_(m)(CHOR⁸)_(n)CH₂NR¹³—(Z)_(g)—CR¹¹R¹¹—CAP, Link—(CH₂)_(m)—(Z)_(g)—(CH₂)_(m)—CR¹¹R¹¹—CAP, LinkNH—C(═O)—NH—(CH₂)_(m)—CR¹¹R¹¹—CAP, Link—(CH₂)_(m)—C(═O)NR¹³—(CH₂)_(m)—CR¹¹R¹¹—CAP, Link—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)—(Z)_(g)—CR¹¹R¹¹—CAP, or Link—(Z)_(g)—(CH₂)_(m)-Het-(CH₂)_(m)—CR¹¹R¹¹—CAP.

In a preferred embodiment, R⁵ is —OH, —O—(CH₂)_(m)(Z)_(g)R¹²,-Het-(CH₂)_(m)—NH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)NH—C(═NR¹³)—NR¹³R¹³,-Link-(CH₂)_(m)—(Z)_(g)—(CH₂)_(m)—CAP, -Het-(CH₂)_(m)—CONR¹³R¹³,—(CH₂)_(n)—NR¹²R¹², —O—(CH₂)_(m)NR¹¹R¹¹, —O—(CH₂)_(m)—N^(⊕)—(R¹¹)₃,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)—NR¹⁰R¹⁰,-Het-(CH₂)_(m)—(Z)_(g)—NH—C(═NR¹³)—NR¹³R¹³,—O—(CH₂)_(m)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —O—(CH₂)_(m)—C(═O)NR⁷R¹⁰,—O—(CH₂)_(m)—(Z)_(g)—R⁷, or—O—(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸.

In another preferred embodiment R⁵ is one of the following:—(CH₂)_(m)—OR⁸, —(CH₂)₄—OH, —O—(CH₂)_(m)—OR⁸, —O—(CH₂)₄—OH,—(CH₂)_(n)—NR⁷R¹⁰, —NHSO₂CH₃, —CH₂NH(C═O)—(OCH₃)₃, —NH(C═O)CH₃, —CH₂NH₂,—NH—CO₂C₂H₅, —CH₂NH(C═O)CH₃, —CH₂NHCO₂CH₃, —CH₂NHSO₂CH₃,—(CH₂)₄—NH(C═O)O(CH₃)₃, —(CH₂)₄—NH₂, —(CH₂)₃—NH(C═O)O(CH₃)₃,—(CH₂)₃—NH₂, —O—(CH₂)_(m)—NR⁷R¹⁰, —OCH₂CH₂NHCO₂(CH₃)₃,—OCH₂CH₂NHCO₂C₂H₅, —O—(CH₂)₃—NH—CO₂—(CH₃)₃, —O(CH₂)₃—NH₂,—OCH₂CH₂NHSO₂CH₃, —(CH₂)_(n)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—O—(CH₂)_(m)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —OCH₂CHOHCH₂O-glucuronide,—OCH₂CH₂CHOHCH₂OH, —OCH₂—(α-CHOH)₂CH₂OH, —OCH₂—(CHOH)₂CH₂OH,—(CH₂CH₂O)_(m)—R⁸, —O—(CH₂CH₂O)_(m)—R⁸, —(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰,—O—(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰, —(CH₂)_(n)—C(═O)NR⁷R¹⁰, —C(═O)NH₂,—O—(CH₂)_(m)—C(═O)NR⁷R¹⁰, —O—CH₂—(C═O)NHCH₂CHOH,—O—CH₂—(C═O)NHCH₂CHOHCH₂OH, —O—CH₂(C═O)NHCH₂(CHOH)₂CH₂OH,—O—CH₂C(C═O)NHSO₂CH₃, —O—CH₂(C═O)NHCO₂CH₃, —O—CH₂—C(C═O)NH—C(C═O)NH₂,—O—CH₂—(C═O)NH—(C═O)CH₃, —(CH₂)_(n)—(Z)_(g)—R⁷, —(CH₂)_(n)—(C═N)—NH₂,—(C═NH)NH₂, —(CH₂)_(n)—NH—C(═NH)—NH₂, —(CH₂)₃—NH—C(═NH)—NH₂,—CH₂NH—C(═NH)—NH₂, —(CH₂)_(n)—CONHCH₂(CHOH)_(n)—CH₂OH,—NH—C(═O)—CH₂—(CHOH)_(n)CH₂OH, —NH—(C═O)—NH—CH₂(CHOH)₂CHOH,—NHC(C═O)NHCH₂CH₂OH, —O—(CH₂)_(m)—(Z)_(g)—R⁷,—O—(CH₂)_(m)—NH—C(═NH)—N(R⁷)₂, —O(CH₂)₃—NH—C(═NH)—NH₂,—O—(CH₂)_(m)—CHNH₂—CO₂NR⁷R¹⁰, —OCH₂—CHNH₂—CO₂NH₂,—O—(CH₂)_(m)—CHNH₂—CO₂NR⁷R¹⁰ (anomeric center is the (R) enantiomer),—O—(CH₂)_(m)—CHNH₂—CO₂NR⁷R¹⁰ (anomeric center is the (5) enantiomer),—OCH₂CHOH—CH₂NHCO₂(CH₃)₃, —(CH₂)_(n)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—NHCH₂(CHOH)₂CH₂OH, —O—(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—O—(CH₂)_(m)—CO₂R⁷, —OCH₂CH₂CO₂(CH₃)₃, —OCH₂CO₂H, —OCH₂CO₂C₂H₅,—O—(CH₂)_(m)-Boc, —(CH₂)_(m)-Boc, —O—(CH₂)_(m)—NH—C(═NH)—N(R⁷)₂,—(CH₂)_(n)—NH—C(═NH)—N(R⁷)₂, —(CH₂)_(m)—NH—C(═O)—OR⁷,—O—(CH₂)_(m)—NH—C(═O)—OR⁷, —(CH₂)_(n)—NH—C(═O)—R¹¹,—O—(CH₂)_(m)—NH—C(═O)—R¹¹, —O—(CH₂)_(m)—C(═O)N(R⁷)₂,—(CH₂)_(m)—CHOH—CH₂—NHBoc, —O—(CH₂)_(m)—CHOH—CH₂—NHBoc,—(CH₂)_(m)—NHC(O)OR⁷, —O—(CH₂)_(m)—NHC(O)OR⁷,—O—(CH₂)_(m)—C(═NH)—N(R⁷)₂, or —(CH₂)_(n)—C(═NH)—N(R⁷)₂.

In another embodiment, R⁵ is selected from the group consisting of—O—(CH₂)₃—OH, —NH₂, —O—CH₂—(CHOH)₂—CH₂OH —O—CH₂—CHOH—CH₂OH,—O—CH₂CH₂—O-tetrahydropyran-2-yl, —O—CH₂CHOH—CH₂—O-glucuronide,—O—CH₂CH₂OH, —O—(CH₂CH₂O)₄—CH₃, —O—CH₂CH₂OCH₃,—O—CH₂—(CHOC(═O)CH₃)—CH₂—OC(═O)CH₃, —O—(CH₂CH₂O)₂—CH₃,—OCH₂—CHOH—CHOH—CH₂OH, —CH₂OH, —CO₂CH₃,

In another embodiment, R⁵ is selected from the group consisting of—O—(CH₂)₃—OH, —NH₂, —O—CH₂—(CHOH)₂—CH₂OH, —O—CH₂—CHOH—CH₂OH,—O—CH₂CH₂—O-tetrahydropyran-2-yl, —O—CH₂CHOH—CH₂—O-glucuronide,—O—CH₂CH₂OH, —O—(CH₂CH₂O)₄—CH₃, —O—CH₂CH₂OCH₃,—O—CH₂—(CHOC(═O)CH₃)—CH₂—OC(═O)CH₃, —O—(CH₂CH₂O)₂—CH₃,—OCH₂—CHOH—CHOH—CH₂OH, —CH₂OH, —CO₂CH₃, —SO₃H, —O-glucuronide,

In a preferred embodiment, each —(CH₂)_(n)—(Z)_(g)—R⁷ falls within thescope of the structures described above and is, independently,

—(CH₂)_(n)—(C═N)—NH₂,

—(CH₂)_(n)—NH—C(═NH)NH₂,

—(CH₂)_(n)—CONHCH₂(CHOH)_(n)—CH₂OH, or

—NH—C(═O)—CH₂—(CHOH)_(n)CH₂OH.

In another a preferred embodiment, each —O—(CH₂)_(m)—(Z)_(g)—R⁷ fallswithin the scope of the structures described above and is,independently,

—O—(CH₂)_(m)—NH—C(═NH)—N(R⁷)₂, or

—O—(CH₂)_(m)—CHNH₂—CO₂NR⁷R¹⁰.

In another preferred embodiment, R⁵ may be one of the following:—O—CH₂CHOHCH₂O-glucuronide, —OCH₂CHOHCH₃, —OCH₂CH₂NH₂,—OCH₂CH₂NHCO(CH₃)₃, —CH₂CH₂OH, —OCH₂CH₂OH, —O—(CH₂)_(m)-Boc,—(CH₂)_(m)-Boc, —OCH₂CH₂OH, —OCH₂CO₂H, —O—(CH₂)_(m)—NH—C(═NH)—N(R⁷)₂,—(CH₂)_(n)—NH—C(═NH)—N(R⁷)₂, —NHCH₂(CHOH)₂—CH₂OH, —OCH₂CO₂Et, —NHSO₂CH₃,—(CH₂)_(m)—NH—C(═O)—OR⁷, —O—(CH₂)_(m)—NH—C(═O)—OR⁷,—(CH₂)_(n)—NH—C(═O)—R¹¹, —O—(CH₂)_(m)—NH—C(═O)—R¹¹, —O—CH₂C(═O)NH₂,—CH₂NH₂, —NHCO₂Et, —OCH₂CH₂CH₂CH₂OH, —CH₂NHSO₂CH₃, —OCH₂CH₂CHOHCH₂OH,—OCH₂CH₂NHCO₂Et, —NH—C(═NH₂)—NH₂, —OCH₂-(α-CHOH)₂—CH₂OH,—OCH₂CHOHCH₂NH₂, —(CH₂)_(m)—CHOH—CH₂—NHBoc, —O—(CH₂)_(m)—CHOH—CH₂—NHBoc,—(CH₂)_(m)—NHC(O)OR⁷, —O—(CH₂)_(m)—NHC(O)OR⁷, —OCH₂CH₂CH₂NH₂,—OCH₂CH₂NHCH₂(CHOH)₂CH₂OH, —OCH₂CH₂NH(CH₂[(CHOH)₂CH₂OH)]₂,—(CH₂)₄—NHBoc, —(CH₂)₄—NH₂, —(CH₂)₄—OH, —OCH₂CH₂NHSO₂CH₃,—O—(CH₂)_(m)—C(═NH)—N(R⁷)₂, —(CH₂)_(n)—C(═NH)—N(R⁷)₂, —(CH₂)₃—NH Boc,—(CH₂)₃NH₂, —O—(CH₂)_(m)—NH—NH—C(═NH)—N(R⁷)₂,—(CH₂)_(n)—NH—NH—C(═NH)—N(R⁷)₂, or —O—CH₂—CHOH—CH₂—NH—C(═NH)—N(R⁷)₂.

In another preferred embodiment, R⁵ is —OH, —O—(CH₂)_(m)(Z)_(g)R¹²,-Het-(CH₂)_(m)—NH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)NH—C(═NR¹³)—NR¹³R¹³,-Link-(CH₂)_(m)—(Z)_(g)—(CH₂)_(m)—CAP, Link-(CH₂)_(n)—CR¹¹R¹¹—CAP,-Het-(CH₂)_(m)—CONR¹³R¹³, —(CH₂)_(m)—NR¹²R¹², —O—(CH₂)_(m)NR¹¹R¹¹,—O—(CH₂)_(m)—N^(⊕)—(R¹¹)₃, —(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)—NR¹⁰R¹⁰,-Het-(CH₂)_(m)—(Z)_(g)—NH—C(═NR¹³)—NR¹³R¹³,—O—(CH₂)_(m)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —O—(CH₂)_(m)—C(═O)NR⁷R¹⁰,—O—(CH₂)_(m)—(Z)_(g)—R⁷, or—O—(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸.

In a particularly preferred embodiment, R⁵ is —O—CH₂—(CHOH)—CH₂OH, —OH,—O—(CH₂)₃NH₂, —O—(CH₂)₃NH(C═NH)NH₂, —O—(CH₂)₂NH(C═NH)NH₂, —O—CH₂(CO)NH₂,—O—(CH₂)₂—N^(⊕)—(CH₃)₃,

Selected substituents within the compounds of the invention are presentto a recursive degree. In this context, “recursive substituent” meansthat a substituent may recite another instance of itself. Because of therecursive nature of such substituents, theoretically, a large number ofcompounds may be present in any given embodiment. For example, R⁹contains a R¹³ substituent. R¹³ can contain an R¹⁰ substituent and R¹⁰can contain a R⁹ substituent. One of ordinary skill in the art ofmedicinal chemistry understands that the total number of suchsubstituents is reasonably limited by the desired properties of thecompound intended. Such properties include, by way of example and notlimitation, physical properties such as molecular weight, solubility orlog P, application properties such as activity against the intendedtarget, and practical properties such as ease of synthesis.

By way of example and not limitation, R⁹, R¹³ and R¹⁰ are recursivesubstituents in certain embodiments. Typically, each of these mayindependently occur 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7,6, 5, 4, 3, 2, 1, or 0, times in a given embodiment. More typically,each of these may independently occur 12 or fewer times in a givenembodiment. More typically yet, R⁹ will occur 0 to 8 times in a givenembodiment, R¹³ will occur 0 to 6 times in a given embodiment and R¹⁰will occur 0 to 6 times in a given embodiment. Even more typically yet,R⁹ will occur 0 to 6 times in a given embodiment, R¹³ will occur 0 to 4times in a given embodiment and R¹⁰ will occur 0 to 4 times in a givenembodiment.

Recursive substituents are an intended aspect of the invention. One ofordinary skill in the art of medicinal chemistry understands theversatility of such substituents. To the degree that recursivesubstituents are present in an embodiment of the invention, the totalnumber will be determined as set forth above.

Each -Het- is, independently, —N(R⁷)—, —N(R¹⁰)—, —S—, —SO—, —SO₂—; —O—,—SO₂NH—, —NHSO₂—, —NR⁷CO—, —CONR⁷—, —N(R¹³)—, —SO₂NR¹³—, —NR¹³CO—, or—CONR¹³—. In a preferred embodiment, -Het- is —O—, —N(R⁷)—, or —N(R¹⁰)—.Most preferably, -Het- is —O—.

Each -Link- is, independently, —O—, —(CH₂)_(n)—, —O(CH₂)_(m)—,—NR¹³—C(═O)—NR¹³—, —NR¹³—C(═O)—(CH₂)_(m)—, —C(═O)NR¹³—(CH₂)_(m)—,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(n) ⁻, —S—, —SO—, —SO₂—, —SO₂NR⁷—, —SO₂NR¹⁰—,or -Het-. In a preferred embodiment, -Link- is —O—, —(CH₂)_(n)—,—NR¹³—C(═O)—(CH₂)_(m)—, or —C(═O)NR¹³—(CH₂)_(m) ⁻.

Each —CAP is, independently, thiazolidinedione, oxazolidinedione,-heteroaryl-C(═O)NR¹³R¹³, heteroaryl-W, —CN, —O—C(═S)NR¹³R¹³,—(Z)_(g)R¹³, —CR¹⁰((Z)_(g)R¹³)((Z)_(g)R¹³), —C(═O)OAr, —C(═O)NR¹³Ar,imidazoline, tetrazole, tetrazole amide, —SO₂NHR¹³,—SO₂NH—C(R¹³R¹³)—(Z)_(g)—R¹³, a cyclic sugar or oligosaccharide, acyclic amino sugar, oligosaccharide,—CR¹⁰(—(CH₂)_(m)—R⁹)(—(CH₂)_(m)—R⁹), —N(—(CH₂)_(m)—R⁹)(—(CH₂)_(m)—R⁹),—NR¹³(—(CH₂)_(m)—CO₂R¹³),

In a preferred embodiment, CAP is

Each Ar is, independently, phenyl, substituted phenyl, wherein thesubstituents of the substituted phenyl are 1-3 substituentsindependently selected from the group consisting of OH, OCH₃, NR¹³R¹³,Cl, F, and CH₃, or heteroaryl.

Examples of heteroaryl include pyridinyl, pyrazinyl, furanyl, thienyl,tetrazolyl, thiazolidinedionyl, imidazoyl, pyrrolyl, quinolinyl,indolyl, adeninyl, pyrazolyl, thiazolyl, isoxazolyl, benzimidazolyl,purinyl, isoquinolinyl, pyridazinyl, pyrimidinyl, 1,2,3-triazinyl,1,2,4-triazinyl, 1,3,5-triazinyl, cinnolinyl, phthalazinyl,quinazolinyl, quinoxalinyl, and pterdinyl groups.

Each W is, independently, thiazolidinedione, oxazolidinedione,heteroaryl-C(═O)N R¹³R¹³, —CN, —O—C(═S)NR¹³R¹³, —(Z)_(g)R¹³,—CR¹⁰((Z)_(g)R¹³)((Z)_(g)R¹³), —C(═O)OAr, —C(═O)N R¹³Ar, imidazoline,tetrazole, tetrazole amide, —SO₂NHR¹³, —SO₂NH—C(R¹³R¹³)—(Z)_(g)—R¹³, acyclic sugar or oligosaccharide, a cyclic amino sugar, oligosaccharide,

There is at least one R⁵ on A¹ and A² and the remaining substituents areR⁶. Each R⁶ is, independently, R⁵, —R⁷, —OR¹¹, —N(R⁷)₂, —(CH₂)_(m)—OR⁸,—O—(CH₂)_(m)—OR⁸, —(CH₂)_(n)—NR⁷R¹⁰, —O—(CH₂)_(m)—NR⁷R¹⁰,—(CH₂)_(n)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—O—(CH₂)_(m)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —(CH₂CH₂O)_(m)—R⁸,—O—(CH₂CH₂O)_(m)—R⁸, —(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰,—O—(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰, —(CH₂)_(n)—C(═O)NR⁷R¹⁰,—O—(CH₂)_(m)—C(═O)NR⁷R¹⁰, —(CH₂)_(n)—(Z)_(g)—R⁷,—O—(CH₂)_(m)—(Z)_(g)—R⁷, —(CH₂)_(n)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—O—(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —(CH₂)_(n)—CO₂R⁷,—O—(CH₂)_(m)—CO₂R⁷, —OSO₃H, —O—glucuronide, —O-glucose,

When two R⁶ are —OR¹¹ and are located adjacent to each other on thearomatic carbocycle or aromatic heterocycle, the two OR¹¹ may form amethylenedioxy group; i.e., a group of the formula —O—CH₂—O—.

In addition, one or more of the R⁶ groups can be one of the R⁵ groupswhich fall within the broad definition of R⁶ set forth above.

R⁶ may be hydrogen. Therefore, provided that the aromatic carbocycle oraromatic heterocycle is substituted with R⁵, the remaining R⁶ may behydrogen. Preferably, at most, 3 of the R⁶ groups are other thanhydrogen. More preferably, provided that the aromatic carbocycle oraromatic heterocycle is substituted with R⁵, then R⁶ is H.

Each g is, independently, an integer from 1 to 6. Therefore, each g maybe 1, 2, 3, 4, 5, or 6.

Each m is an integer from 1 to 7. Therefore, each m may be 1, 2, 3, 4,5, 6, or 7.

Each n is an integer from 0 to 7. Therefore, each n may be 0, 1, 2, 3,4, 5, 6, or 7.

Each Z is, independently, —(CHOH)—, —C(═O)—, —(CHNR⁷R¹⁰)—, —(C═NR¹⁰)—,—NR¹⁰—, —(CH₂)_(n)—, —(CHNR¹³R¹³)—, —(C═NR¹³)—, or —NR¹³—. As designatedby (Z)_(g) in certain embodiments, Z may occur one, two, three, four,five or six times and each occurrence of Z is, independently, —(CHOH)—,—C(═O)—, —(CHNR⁷R¹⁰)—, —(C═NR¹⁰—, —NR¹⁰—, —(CH₂)_(n)—, —(CHNR¹³R¹³)—,—(C═NR¹³)—, or —NR¹³—. Therefore, by way of example and not by way oflimitation, (Z)_(g) can be —(CHOH)—(CHNR⁷R¹⁰)—,—(CHOH)—(CHNR⁷R¹⁰—C(═O)—, —(CHOH)—(CHNR⁷R¹⁰)—C(═O)—(CH₂)_(n)—,—(CHOH)—(CHNR⁷R¹⁰)—C(═O)—(CH₂)_(n)—(CHNR¹³R¹³)—,—(CHOH)—(CHNR⁷R¹⁰)—C(═O)—(CH₂)_(n)—(CHNR¹³R¹³)—C(═O)—, and the like.

In any variable containing —CHOR⁸— or —CH₂OR⁸ groups, when any —CHOR⁸—or —CH₂OR⁸ groups are located 1,2- or 1,3- with respect to each other,the R⁸ groups may, optionally, be taken together to form a cyclic mono-or di-substituted 1,3-dioxane or 1,3-dioxolane.

More specific examples of suitable compounds represented by formula (I)are shown in formulas II and III below wherein A¹ and A² are defined asabove:

In a preferred aspect of formula II, A¹ is selected from indenyl,napthalenyl, 1,2-dihydronapthalenyl, 1,2,3,4-tetrahydronapthalenyl,anthracenyl, fluorenyl, phenanthrenyl, azulenyl,cyclohepta-1,3,5-trienyl or 5H-dibenzo[a,d]cycloheptenyl.

In another preferred aspect of formula II, A¹ is

wherein each Q is, independently, C—H, C—R⁵, or C—R⁶, with the provisothat at least one Q is C—R⁵. Preferably, six Q are C—H. Preferably, eachR⁶ is H. Preferably, R⁵ is —OH, —O—(CH₂)_(m)(Z)_(g)R¹²,-Het-(CH₂)_(m)—NH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)NH—C(═NR¹³)—NR¹³R¹³,-Link-(CH₂)_(m)—(Z)_(g)—(CH₂)_(m)—CAP, Link-(CH₂)_(n)—CR¹¹R¹¹—CAP,-Het-(CH₂)_(m)—CONR¹³R¹³, —(CH₂)_(n)—NR¹²R¹², —O—(CH₂)_(m)NR¹¹R¹¹,—O—(CH₂)_(m)—N^(⊕)—(R¹¹)₃, —(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)—NR¹⁰R¹⁰,-Het-(CH₂)_(m)—(Z)_(g)—NH—C(═NR¹³)—NR¹³R¹³,—O—(CH₂)_(m)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —O—(CH₂)_(m)—C(═O)NR⁷R¹⁰,—O—(CH₂)_(m)—(Z)_(g)—R⁷, or—O—(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸. More preferably, six Qare C—H and R⁵ is —OH, —O—(CH₂)_(m)(Z)_(g)R¹²,-Het-(CH₂)_(m)—NH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)NH—C(═NR¹³)—NR¹³R¹³,-Link-(CH₂)_(m)—(Z)_(g)—(CH₂)_(m)—CAP, Link-(CH₂)_(n)—CR¹¹R¹¹—CAP,-Het-(CH₂)_(m)—CONR¹³R¹³, —(CH₂)_(n)—NR¹²R¹², —O—(CH₂)_(m)NR¹¹R¹¹,—O—(CH₂)_(m)—N^(⊕)—(R¹¹)₃, —(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)—NR¹⁰R¹⁰,-Het-(CH₂)_(m)—(Z)_(g)—NH—C(═NR¹³)—NR¹³R¹³,—O—(CH₂)_(m)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —O—(CH₂)_(m)—C(═O)NR⁷R¹⁰,—O—(CH₂)_(m)—(Z)_(g)—R⁷, or—O—(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸. More preferably, R⁵ is—O—CH₂—(CHOH)—CH₂OH, —OH, —O—(CH₂)₃NH₂, —O—(CH₂)₃NH(C═NH)NH₂,—O—(CH₂)₂NH(C═NH)NH₂, —O—CH₂(CO)NH₂, —O—(CH₂)₂—N′—(CH₃)₃,

Most preferably, R⁵—O—CH₂—(CHOH)—CH₂OH, —OH, —O—(CH₂)₃NH₂,—O—(CH₂)₃NH(C═NH)NH₂, —O—(CH₂)₂NH(C═NH)NH₂, —O—CH₂(CO)NH₂,—O—(CH₂)₂—N^(⊕)—(CH₃)₃,

and six Q are C—H.

In another preferred aspect of formula II, A¹ is

Preferably, R⁵ is —OH, —O—(CH₂)_(m)(Z)_(g)R¹²,-Het-(CH₂)_(m)—NH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)NH—C(═NR¹³)—NR¹³R¹³,-Link-(CH₂)_(m)—(Z)_(g)—(CH₂)_(m)—CAP, Link-(CH₂)_(n)—CR¹¹R¹¹—CAP,-Het-(CH₂)_(m)—CONR¹³R¹³, —(CH₂)_(n)—NR¹²R¹², —O—(CH₂)_(m)NR¹¹R¹¹,—O—(CH₂)_(m)—N^(⊕)—(R¹¹)₃, —(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)—NR¹⁰R¹⁰,-Het-(CH₂)_(m)—(Z)_(g)—NH—C(═NR¹³)—NR¹³R¹³,—O—(CH₂)_(m)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —O—(CH₂)_(m)—C(═O)NR⁷R¹⁰,—O—(CH₂)_(m)—(Z)_(g)—R⁷, or—O—(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸. Most preferably, R⁵ is—O—CH₂—(CHOH)—CH₂OH, —OH, —O—(CH₂)₃NH₂, —O—(CH₂)₃NH(C═NH)NH₂,—O—(CH₂)₂NH(C═NH)NH₂, —O—CH₂(CO)NH₂, —O—(CH₂)₂—N^(e-)(CH₃)₃,

In a preferred aspect of formula III, A² is selected from indolizinyl,indolyl, isoindolyl, indolinyl, benzo[b]furanyl,2,3-dihydrobenzo[b]furanyl, benzo[b]thiophenyl,2,3-dihydrobenzo[b]thiophenyl, indazolyl, benzimidazolyl, benzthiazolyl,purinyl, quinolinyl, 1,2,3,4-tetrahydroquinolinyl,3,4-dihydro-2H-chromenyl, 3,4-dihydro-2H-thiochromenyl, isoquinolinyl,cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl,1,8-naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl,phenothiazinyl, phenoxazinyl, dibenzofuranyl, dibenzothiophenyl,1H-azepinyl, 5H-dibenz[b,f]azepinyl, or10,11-dihydro-5H-dibenz[b,f]azepinyl.

In another preferred aspect of formula III, A² is

wherein each Q is, independently, C—H, C—R⁵, C—R⁶, or a nitrogen atom,with the proviso that at least one Q is nitrogen and one Q is C—R⁵, andat most three Q in a ring are nitrogen atoms. In a preferred embodiment,only one Q in each ring is nitrogen. In another preferred embodiment,only a single Q is nitrogen. In a particularly preferred embodiment, asingle Q is nitrogen, one Q is C—R⁵, and the remaining Q are C—H. Inanother preferred embodiment, each R⁶ is H. Preferably, R⁵ is —OH,—O—(CH₂)_(m)(Z)_(g)R¹², -Het-(CH₂)_(m)—NH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)NH—C(═NR¹³)—NR¹³R¹³,-Link-(CH₂)_(m)—(Z)_(g)—(CH₂)_(m)—CAP, Link-(CH₂)_(n)—CR¹¹R¹¹—CAP,-Het-(CH₂)_(m)—CONR¹³R¹³, —(CH₂)_(n)—NR¹²R¹², —O—(CH₂)_(m)NR¹¹R¹¹,—O—(CH₂)_(m)—N^(⊕)—(R¹¹)₃, —(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)—NR¹⁰R¹⁰,-Het-(CH₂)_(m)—(Z)_(g)—NH—C(═NR¹³)—NR¹³R¹³,—O—(CH₂)_(m)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —O—(CH₂)_(m)—C(═O)NR⁷R¹⁰,—O—(CH₂)_(m)—(Z)_(g)—R⁷, or—O—(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸. More preferably, one Qis nitrogen, five Q are C—H and R⁵ is —OH, —O—(CH₂)_(m)(Z)_(g)R¹²,-Het-(CH₂)_(m)—NH—C(═NR¹³)—NR¹³R¹³,-Het-(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)NH—C(═NR¹³)—NR¹³R¹³,-Link-(CH₂)_(m)—(Z)_(g)—(CH₂)_(m)—CAP, Link-(CH₂)_(n)—CR¹¹R¹¹—CAP,-Het-(CH₂)_(m)—CONR¹³R¹³, —(CH₂)_(n)—NR¹²R¹², —O—(CH₂)_(m)NR¹¹R¹¹,—O—(CH₂)_(m)—N^(⊕)—(R¹¹)₃, —(CH₂)_(n)—(Z)_(g)—(CH₂)_(m)—NR¹⁰R¹⁰,-Het-(CH₂)_(m)—(Z)_(g)—NH—C(═NR¹³)—NR¹³R¹³, —O—(CH₂)_(m)(CHOR⁸)(CHOR⁸),—CH₂OR⁸, —O—(CH₂)_(m)—C(═O)NR⁷R¹⁰, —O—(CH₂)_(m)—(Z)_(g)—R⁷, or—O—(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸. More preferably, R⁵ is—O—CH₂—(CHOH)—CH₂OH, —OH, —O—(CH₂)₃NH₂, —O—(CH₂)₃NH(C═NH)NH₂,—O—(CH₂)₂NH(C═NH)NH₂, —O—CH₂(CO)NH₂, —O—(CH₂)₂—N^(⊕)—(CH₃)₃,

Most preferably, R⁵ is —O—CH₂—(CHOH)—CH₂OH, —OH, —O—(CH₂)₃NH₂,—O—(CH₂)₃NH(C═NH)NH₂, —O—(CH₂)₂NH(C═NH)NH₂, —O—CH₂(CO)NH₂,—O—(CH₂)₂—N^(⊕)—(CH₃)₃,

a single Q is nitrogen and five Q are C—H.

In a particularly preferred embodiment, the compounds of formula I,formula II, or formula III are:

In another preferred embodiment, the compounds of the present inventionare represented by the following formulas:

The compounds described herein may be prepared and used as the freebase. Alternatively, the compounds may be prepared and used as apharmaceutically acceptable salt. Pharmaceutically acceptable salts aresalts that retain or enhance the desired biological activity of theparent compound and do not impart undesired toxicological effects.Examples of such salts are (a) acid addition salts formed with inorganicacids, for example, hydrochloric acid, hydrobromic acid, sulfuric acid,phosphoric acid, nitric acid and the like; (b) salts formed with organicacids such as, for example, acetic acid, oxalic acid, tartaric acid,succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid,malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid,alginic acid, polyglutamic acid, naphthalenesulfonic acid,methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonicacid, polygalacturonic acid, malonic acid, sulfosalicylic acid, glycolicacid, 2-hydroxy-3-naphthoate, pamoate, salicylic acid, stearic acid,phthalic acid, mandelic acid, lactic acid and the like; and (c) saltsformed from elemental anions for example, chlorine, bromine, and iodine.

It is to be noted that all enantiomers, diastereomers, and racemicmixtures, tautomers, polymorphs, pseudopolymorphs and pharmaceuticallyacceptable salts of compounds within the scope of formula (I), formulaII, or formula III are embraced by the present invention. All mixturesof such enantiomers and diastereomers are within the scope of thepresent invention.

A compound of formula I-III and its pharmaceutically acceptable saltsmay exist as different polymorphs or pseudopolymorphs. As used herein,crystalline polymorphism means the ability of a crystalline compound toexist in different crystal structures. The crystalline polymorphism mayresult from differences in crystal packing (packing polymorphism) ordifferences in packing between different conformers of the same molecule(conformational polymorphism). As used herein, crystallinepseudopolymorphism means the ability of a hydrate or solvate of acompound to exist in different crystal structures. The pseudopolymorphsof the instant invention may exist due to differences in crystal packing(packing pseudopolymorphism) or due to differences in packing betweendifferent conformers of the same molecule (conformationalpseudopolymorphism). The instant invention comprises all polymorphs andpseudopolymorphs of the compounds of formula I-III and theirpharmaceutically acceptable salts.

A compound of formula I-III and its pharmaceutically acceptable saltsmay also exist as an amorphous solid. As used herein, an amorphous solidis a solid in which there is no long-range order of the positions of theatoms in the solid. This definition applies as well when the crystalsize is two nanometers or less. Additives, including solvents, may beused to create the amorphous forms of the instant invention. The instantinvention comprises all amorphous forms of the compounds of formulaI-III and their pharmaceutically acceptable salts.

The compounds of formula I-III may exist in different tautomeric forms.One skilled in the art will recognize that amidines, amides, guanidines,ureas, thioureas, heterocycles and the like can exist in tautomericforms. By way of example and not by way of limitation, compounds offormula I-III can exist in various tautomeric forms as shown below:

All possible tautomeric forms of the amidines, amides, guanidines,ureas, thioureas, heterocycles and the like of all of the embodiments offormula I-III are within the scope of the instant invention.

“Enantiomers” refer to two stereoisomers of a compound which arenon-superimposable mirror images of one another.

Stereochemical definitions and conventions used herein generally followS. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984)McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S.,Stereochemistry of Organic Compounds (1994) John Wiley & Sons, Inc., NewYork. Many organic compounds exist in optically active forms, i.e., theyhave the ability to rotate the plane of plane-polarized light. Indescribing an optically active compound, the prefixes D and L or R and Sare used to denote the absolute configuration of the molecule about itschiral center(s). The prefixes d and l, D and L, or (+) and (−) areemployed to designate the sign of rotation of plane-polarized light bythe compound, with S, (−), or 1 meaning that the compound islevorotatory while a compound prefixed with R, (+), or d isdextrorotatory. For a given chemical structure, these stereoisomers areidentical except that they are mirror images of one another. A specificstereoisomer may also be referred to as an enantiomer, and a mixture ofsuch isomers is often called an enantiomeric mixture. A 50:50 mixture ofenantiomers is referred to as a racemic mixture or a racemate, which mayoccur where there has been no stereoselection or stereospecificity in achemical reaction or process. The terms “racemic mixture” and “racemate”refer to an equimolar mixture of two enantiomeric species, devoid ofoptical activity.

A single stereoisomer, e.g. an enantiomer, substantially free of itsstereoisomer may be obtained by resolution of the racemic mixture usinga method such as formation of diastereomers using optically activeresolving agents (“Stereochemistry of Carbon Compounds,” (1962) by E. L.Eliel, McGraw Hill; Lochmuller, C. H., (1975) J. Chromatogr., 113:(3)283-302). Racemic mixtures of chiral compounds of the invention can beseparated and isolated by any suitable method, including: (1) formationof ionic, diastereomeric salts with chiral compounds and separation byfractional crystallization or other methods, (2) formation ofdiastereomeric compounds with chiral derivatizing reagents, separationof the diastereomers, and conversion to the pure stereoisomers, and (3)separation of the substantially pure or enriched stereoisomers directlyunder chiral conditions.

“Diastereomer” refers to a stereoisomer with two or more centers ofchirality and whose molecules are not mirror images of one another.Diastereomers have different physical properties, e.g. melting points,boiling points, spectral properties, and reactivities. Mixtures ofdiastereomers may separate under high resolution analytical proceduressuch as electrophoresis and chromatography.

Without being limited to any particular theory, it is believed that thecompounds of formula (I), formula II, or formula III function in vivo assodium channel blockers. By blocking epithelial sodium channels presentin mucosal surfaces the compounds of formula (I), formula II, or formulaIII reduce the absorption of water by the mucosal surfaces. This effectincreases the volume of protective liquids on mucosal surfaces,rebalances the system, and thus treats disease.

The present invention also provides methods of treatment that takeadvantage of the properties of the compounds described herein asdiscussed above. Thus, subjects that may be treated by the methods ofthe present invention include, but are not limited to, patientsafflicted with cystic fibrosis, primary ciliary dyskinesia, chronicbronchitis, bronchiectasis chronic obstructive airway disease,artificially ventilated patients, patients with acute pneumonia, etc.The present invention may be used to obtain a sputum sample from apatient by administering the active compounds to at least one lung of apatient, and then inducing or collecting a sputum sample from thatpatient. Typically, the invention will be administered to respiratorymucosal surfaces via aerosol (liquid or dry powders) or lavage.

Subjects that may be treated by the method of the present invention alsoinclude patients being administered supplemental oxygen nasally (aregimen that tends to dry the airway surfaces); patients afflicted withan allergic disease or response (e.g., an allergic response to pollen,dust, animal hair or particles, insects or insect particles, etc.) thataffects nasal airway surfaces; patients afflicted with a bacterialinfection e.g., staphylococcus infections such as Staphylococcus aureusinfections, Hemophilus influenza infections, Streptococcus pneumoniaeinfections, Pseudomonas aeuriginosa infections, etc.) of the nasalairway surfaces; patients afflicted with an inflammatory disease thataffects nasal airway surfaces; or patients afflicted with sinusitis(wherein the active agent or agents are administered to promote drainageof congested mucous secretions in the sinuses by administering an amounteffective to promote drainage of congested fluid in the sinuses), orcombined, Rhinosinusitis. The invention may be administered torhino-sinal surfaces by topical delivery, including aerosols and drops.

The present invention may be used to hydrate mucosal surfaces other thanairway surfaces. Such other mucosal surfaces include gastrointestinalsurfaces, oral surfaces, genito-urethral surfaces, ocular surfaces orsurfaces of the eye, the inner ear and the middle ear. For example, theactive compounds of the present invention may be administered by anysuitable means, including locally/topically, orally, or rectally, in aneffective amount.

The compounds of the present invention are also useful for treating avariety of functions relating to the cardiovascular system. Thus, thecompounds of the present invention are useful for use asantihypertensive agents. The compounds may also be used to reduce bloodpressure and to treat edema. In addition, the compounds of the presentinvention are also useful for promoting diuresis, natriuresis, andsaluresis. The compounds may be used alone or in combination with betablockers, ACE inhibitors, HMGCoA reductase inhibitors, calcium channelblockers and other cardiovascular agents to treat hypertension,congestive heart failure and reduce cardiovascular mortality.

The present invention is concerned primarily with the treatment of humansubjects, but may also be employed for the treatment of other mammaliansubjects, such as dogs and cats, for veterinary purposes.

As discussed above, the compounds used to prepare the compositions ofthe present invention may be in the form of a pharmaceuticallyacceptable free base. Because the free base of the compound is generallyless soluble in aqueous solutions than the salt, free base compositionsare employed to provide more sustained release of active agent to thelungs. An active agent present in the lungs in particulate form whichhas not dissolved into solution is not available to induce aphysiological response, but serves as a depot of bioavailable drug whichgradually dissolves into solution.

Another aspect of the present invention is a pharmaceutical composition,comprising a compound of formula (I), formula II, or formula III in apharmaceutically acceptable carrier (e.g., an aqueous carrier solution).In general, the compound of formula (I), formula II, or formula III isincluded in the composition in an amount effective to inhibit thereabsorption of water by mucosal surfaces.

Without being limited to any particular theory, it is believed thatsodium channel blockers of the present invention block epithelial sodiumchannels present in mucosal surfaces the sodium channel blocker,described herein reduce the absorption of salt and water by the mucosalsurfaces. This effect increases the volume of protective liquids onmucosal surfaces, rebalances the system, and thus treats disease. Thiseffect is enhanced when used in combination with osmolytes.

The compounds of formula (I), formula II, or formula III may also beused in conjunction with osmolytes thus lowering the dose of thecompound needed to hydrate mucosal surfaces. This important propertymeans that the compound will have a lower tendency to cause undesiredside-effects by blocking sodium channels located at untargeted locationsin the body of the recipient, e.g., in the kidneys when used incombination with an osmolyte.

Active osmolytes of the present invention are molecules or compoundsthat are osmotically active (i.e., are “osmolytes”). “Osmoticallyactive” compounds of the present invention are membrane-impermeable(i.e., essentially non-absorbable) on the airway or pulmonary epithelialsurface. The terms “airway surface” and “pulmonary surface,” as usedherein, include pulmonary airway surfaces such as the bronchi andbronchioles, alveolar surfaces, and nasal and sinus surfaces. Activecompounds of the present invention may be ionic osmolytes (i.e., salts),or may be non-ionic osmolytes (i.e., sugars, sugar alcohols, and organicosmolytes). It is specifically intended that both racemic forms of theactive compounds that are racemic in nature are included in the group ofactive compounds that are useful in the present invention. It is to benoted that all racemates, enantiomers, diastereomers, tautomers,polymorphs and pseudopolymorphs and racemic mixtures of the osmoticallyactive compounds are embraced by the present invention.

Active osmolytes useful in the present invention that are ionicosmolytes include any salt of a pharmaceutically acceptable anion and apharmaceutically acceptable cation. Preferably, either (or both) of theanion and cation are non-absorbable (i.e., osmotically active and notsubject to rapid active transport) in relation to the airway surfaces towhich they are administered. Such compounds include but are not limitedto anions and cations that are contained in FDA approved commerciallymarketed salts, see, e.g., Remington: The Science and Practice ofPharmacy, Vol. II, pg. 1457 (19^(th) Ed. 1995), incorporated herein byreference, and can be used in any combination including theirconventional combinations.

Pharmaceutically acceptable osmotically active anions that can be usedto carry out the present invention include, but are not limited to,acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide,calcium edetate, camsylate (camphorsulfonate), carbonate, chloride,citrate, dihydrochloride, edetate, edisylate (1,2-ethanedisulfonate),estolate (lauryl sulfate), esylate (1,2-ethanedisulfonate), fumarate,gluceptate, gluconate, glutamate, glycollylarsanilate(p-glycollamidophenylarsonate), hexylresorcinate, hydrabamine(N,N′-Di(dehydroabietypethylenediamine), hydrobromide, hydrochloride,hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate,maleate, mandelate, mesylate, methylbromide, methylnitrate,methylsulfate, mucate, napsylate, nitrate, nitrte, pamoate (embonate),pantothenate, phosphate or diphosphate, polygalacturonate, salicylate,stearate, subacetate, succinate, sulfate, tannate, tartrate, teoclate(8-chlorotheophyllinate), triethiodide, bicarbonate, etc. Particularlypreferred anions include chloride, sulfate, nitrate, gluconate, iodide,bicarbonate, bromide, and phosphate.

Pharmaceutically acceptable cations that can be used to carry out thepresent invention include, but are not limited to, organic cations suchas benzathine (N,N′-dibenzylethylenediamine), chloroprocaine, choline,diethanolamine, ethylenediamine, meglumine (N-methyl D-glucamine),procaine, D-lysine, L-lysine, D-arginine, L-arginine, triethylammonium,N-methyl D-glycerol, and the like. Particularly preferred organiccations are 3-carbon, 4-carbon, 5-carbon and 6-carbon organic cations.Metallic cations useful in the practice of the present invention includebut are not limited to aluminum, calcium, lithium, magnesium, potassium,sodium, zinc, iron, ammonium, and the like. Particularly preferredcations include sodium, potassium, choline, lithium, meglumine,D-lysine, ammonium, magnesium, and calcium.

Specific examples of osmotically active salts that may be used with thesodium channel blockers described herein to carry out the presentinvention include, but are not limited to, sodium chloride, potassiumchloride, choline chloride, choline iodide, lithium chloride, megluminechloride, L-lysine chloride, D-lysine chloride, ammonium chloride,potassium sulfate, potassium nitrate, potassium gluconate, potassiumiodide, ferric chloride, ferrous chloride, potassium bromide, etc.Either a single salt or a combination of different osmotically activesalts may be used to carry out the present invention. Combinations ofdifferent salts are preferred. When different salts are used, one of theanion or cation may be the same among the differing salts.

Osmotically active compounds of the present invention also includenon-ionic osmolytes such as sugars, sugar-alcohols, and organicosmolytes. Sugars and sugar-alcohols useful in the practice of thepresent invention include but are not limited to 3-carbon sugars (e.g.,glycerol, dihydroxyacetone); 4-carbon sugars (e.g., both the D and Lforms of erythrose, threose, and erythrulose); 5-carbon sugars (e.g.,both the D and L forms of ribose, arabinose, xylose, lyxose, psicose,fructose, sorbose, and tagatose); and 6-carbon sugars (e.g., both the Dand L forms of altose, allose, glucose, mannose, gulose, idose,galactose, and talose, and the D and L forms of allo-heptulose,allo-hepulose, gluco-heptulose, manno-heptulose, gulo-heptulose,ido-heptulose, galacto-heptulose, talo-heptulose). Additional sugarsuseful in the practice of the present invention include raffinose,raffinose series oligosaccharides, and stachyose. Both the D and L formsof the reduced form of each sugar/sugar alcohol useful in the presentinvention are also active compounds within the scope of the invention.For example, glucose, when reduced, becomes sorbitol; within the scopeof the invention, sorbitol and other reduced forms of sugar/sugaralcohols (e.g., mannitol, dulcitol, arabitol) are accordingly activecompounds of the present invention.

Osmotically active compounds of the present invention additionallyinclude the family of non-ionic osmolytes termed “organic osmolytes.”The term “organic osmolytes” is generally used to refer to moleculesused to control intracellular osmolality in the kidney. See e.g., J. S.Handler et al., Comp. Biochem. Physiol, 117, 301-306 (1997); M. Burg,Am. J. Physiol. 268, F983-F996 (1995), each incorporated herein byreference. Although the inventor does not wish to be bound to anyparticular theory of the invention, it appears that these organicosmolytes are useful in controlling extracellular volume on theairway/pulmonary surface. Organic osmolytes useful as active compoundsin the present invention include but are not limited to three majorclasses of compounds: polyols (polyhydric alcohols), methylamines, andamino acids. The polyol organic osmolytes considered useful in thepractice of this invention include, but are not limited to, inositol,myo-inositol, and sorbitol. The methylamine organic osmolytes useful inthe practice of the invention include, but are not limited to, choline,betaine, carnitine (L-, D- and DL forms), phosphorylcholine,lyso-phosphorylcholine, glycerophosphorylcholine, creatine, and creatinephosphate. The amino acid organic osmolytes of the invention include,but are not limited to, the D- and L-forms of glycine, alanine,glutamine, glutamate, aspartate, proline and taurine. Additionalosmolytes useful in the practice of the invention include tihulose andsarcosine. Mammalian organic osmolytes are preferred, with human organicosmolytes being most preferred. However, certain organic osmolytes areof bacterial, yeast, and marine animal origin, and these compounds arealso useful active compounds within the scope of the present invention.

Under certain circumstances, an osmolyte precursor may be administeredto the subject; accordingly, these compounds are also useful in thepractice of the invention. The term “osmolyte precursor” as used hereinrefers to a compound which is converted into an osmolyte by a metabolicstep, either catabolic or anabolic. The osmolyte precursors of thisinvention include, but are not limited to, glucose, glucose polymers,glycerol, choline, phosphatidylcholine, lyso-phosphatidylcholine andinorganic phosphates, which are precursors of polyols and methylamines.Precursors of amino acid osmolytes within the scope of this inventioninclude proteins, peptides, and polyamino acids, which are hydrolyzed toyield osmolyte amino acids, and metabolic precursors which can beconverted into osmolyte amino acids by a metabolic step such astransamination. For example, a precursor of the amino acid glutamine ispoly-L-glutamine, and a precursor of glutamate is poly-L-glutamic acid.

Also intended within the scope of this invention are chemically modifiedosmolytes or osmolyte precursors. Such chemical modifications involvelinking to the osmolyte (or precursor) an additional chemical groupwhich alters or enhances the effect of the osmolyte or osmolyteprecursor (e.g., inhibits degradation of the osmolyte molecule). Suchchemical modifications have been utilized with drugs or prodrugs and areknown in the art. (See, for example, U.S. Pat. Nos. 4,479,932 and4,540,564; Shek, E. et al., J. Med. Chem. 19:113-117 (1976); Bodor, N.et al., J. Pharm. Sci. 67:1045-1050 (1978); Bodor, N. et al., J. Med.Chem. 26:313-318 (1983); Bodor, N. et al., J. Pharm. Sci. 75:29-35(1986), each incorporated herein by reference.

In general, osmotically active compounds of the present invention (bothionic and non-ionic) that do not promote, or in fact deter or retardbacterial growth are preferred.

The compounds of formula (I), formula II, or formula III describedherein and osmotically active compounds disclosed herein may beadministered in any order and/or concurrently to mucosal surfaces suchas the eye, the nose, and airway surfaces including the nasal passages,sinuses and lungs of a subject by any suitable means known in the art,such as by nose drops, mists, aerosols, continuous overnight nasalcannulation, etc. In one embodiment of the invention, the compounds offormula (I), formula II, or formula III and osmotically active compoundsof the present invention are administered concurrently bytransbronchoscopic lavage. In a preferred embodiment of the invention,the compounds of formula (I), formula II, or formula III and osmoticallyactive compounds of the present invention are deposited on lung airwaysurfaces by administering by inhalation an respirable aerosol respirableparticles comprised of the compounds of formula (I), formula II, orformula III and the osmotically active compounds, in which the compoundsof formula (I), formula II, or formula III can precede or follow theindependent delivery of an osmotically active compound within asufficiently short time for their effects to be additive. The respirableparticles may be liquid or solid. Numerous inhalers for administeringaerosol particles to the lungs of a subject are known. In anotherpreferred embodiment of the invention, the compounds of formula (I),formula II, or formula III and osmotically active compounds can be givenconcurrently as defined herein.

The compounds of formula (I), formula II, or formula III and osmoticallyactive compounds of the present invention are administered sequentially(in any order) or concurrently to the subject in need thereof. As usedherein, the term “concurrently” means sufficiently close in time toproduce a combined effect (that is, concurrently may be simultaneously,or it may be two or more events occurring within a short time periodbefore or after each other). Concurrently also embraces the delivery ofthe compounds of formula (I), formula II, or formula III and osmolytesas a mixture or solution of the two components as well as when deliveredfrom two different nebulizers. An example of that would be the deliveryof compound 1 in one nebulizer and hypertonic saline in a secondnebulizer connected by a T-piece. When administered with other activeagents, the active compounds of the present invention may function as avehicle or carrier for the other active agent, or may simply beadministered concurrently with the other active agent. The activecompound of the present invention may be used as a dry or liquid vehiclefor administering other active ingredients to airway surfaces. Suchother active agents may be administered for treating the disease ordisorder for which they are intended, in their conventional manner anddosages, in combination with the active compounds of the presentinvention, which may be thought of as serving as a vehicle or carrierfor the other active agent. Any such other active ingredient may beemployed, particularly where hydration of the airway surfaces (i.e., theactivity of the osmotically active compounds of the present invention)facilitates the activity of the other active ingredient (e.g., byfacilitating or enhancing uptake of the active ingredient, bycontributing to the mechanism of action of the other active ingredient,or by any other mechanisms). In a preferred embodiment of the invention,when the active compound of the present invention is administeredconcurrently with another active agent, the active compound of thepresent invention has an additive effect in relation to the other activeagent; that is, the desired effect of the other active agent is enhancedby the concurrent administration of the active compounds of the presentinvention.

The compounds of formula (I), formula II, or formula III of the presentinvention are also useful for treating airborne infections. Examples ofairborne infections include, for example, RSV. The compounds of formula(I), formula II, or formula III of the present invention are also usefulfor treating an anthrax infection. The present invention relates to theuse of the compounds of formula (I), formula II, or formula III of thepresent invention for prophylactic, post-exposure prophylactic,preventive or therapeutic treatment against diseases or conditionscaused by pathogens. In a preferred embodiment, the present inventionrelates to the use of the compounds of formula (I), formula II, orformula III for prophylactic, post-exposure prophylactic, preventive ortherapeutic treatment against diseases or conditions caused by pathogenswhich may be used in bioterrorism.

In recent years, a variety of research programs and biodefense measureshave been put into place to deal with concerns about the use ofbiological agents in acts of terrorism. These measures are intended toaddress concerns regarding bioterrorism or the use of microorganisms orbiological toxins to kill people, spread fear, and disrupt society. Forexample, the National Institute of Allergy and Infectious Diseases(NIAID) has developed a Strategic Plan for Biodefense Research whichoutlines plans for addressing research needs in the broad area ofbioterrorism and emerging and reemerging infectious diseases. Accordingto the plan, the deliberate exposure of the civilian population of theUnited States to Bacillus anthracis spores revealed a gap in thenation's overall preparedness against bioterrorism. Moreover, the reportdetails that these attacks uncovered an unmet need for tests to rapidlydiagnose, vaccines and immunotherapies to prevent, and drugs andbiologics to cure disease caused by agents of bioterrorism.

Much of the focus of the various research efforts has been directed tostudying the biology of the pathogens identified as potentiallydangerous as bioterrorism agents, studying the host response againstsuch agents, developing vaccines against infectious diseases, evaluatingthe therapeutics currently available and under investigation againstsuch agents, and developing diagnostics to identify signs and symptomsof threatening agents. Such efforts are laudable but, given the largenumber of pathogens which have been identified as potentially availablefor bioterrorism, these efforts have not yet been able to providesatisfactory responses for all possible bioterrorism threats.Additionally, many of the pathogens identified as potentially dangerousas agents of bioterrorism do not provide adequate economic incentivesfor the development of therapeutic or preventive measures by industry.Moreover, even if preventive measures such as vaccines were availablefor each pathogen which may be used in bioterrorism, the cost ofadministering all such vaccines to the general population isprohibitive.

Until convenient and effective treatments are available against everybioterrorism threat, there exists a strong need for preventative,prophylactic or therapeutic treatments which can prevent or reduce therisk of infection from pathogenic agents.

The present invention provides such methods of prophylactic treatment.In one aspect, a prophylactic treatment method is provided comprisingadministering a prophylactically effective amount of the compounds offormula (I), formula II, or formula III to an individual in need ofprophylactic treatment against infection from one or more airbornepathogens. A particular example of an airborne pathogen is anthrax.

In another aspect, a prophylactic treatment method is provided forreducing the risk of infection from an airborne pathogen which can causea disease in a human, said method comprising administering an effectiveamount of the compounds of formula (I), formula II, or formula III tothe lungs of the human who may be at risk of infection from the airbornepathogen but is asymptomatic for the disease, wherein the effectiveamount of a sodium channel blocker and osmolye are sufficient to reducethe risk of infection in the human. A particular example of an airbornepathogen is anthrax.

In another aspect, a post-exposure prophylactic treatment or therapeutictreatment method is provided for treating infection from an airbornepathogen comprising administering an effective amount of the compoundsof formula (I), formula II, or formula III to the lungs of an individualin need of such treatment against infection from an airborne pathogen.The pathogens which may be protected against by the prophylactic postexposure, rescue and therapeutic treatment methods of the inventioninclude any pathogens which may enter the body through the mouth, noseor nasal airways, thus proceeding into the lungs. Typically, thepathogens will be airborne pathogens, either naturally occurring or byaerosolization. The pathogens may be naturally occurring or may havebeen introduced into the environment intentionally after aerosolizationor other method of introducing the pathogens into the environment. Manypathogens which are not naturally transmitted in the air have been ormay be aerosolized for use in bioterrorism. The pathogens for which thetreatment of the invention may be useful includes, but is not limitedto, category A, B and C priority pathogens as set forth by the NIAID.These categories correspond generally to the lists compiled by theCenters for Disease Control and Prevention (CDC). As set up by the CDC,Category A agents are those that can be easily disseminated ortransmitted person-to-person, cause high mortality, with potential formajor public health impact. Category B agents are next in priority andinclude those that are moderately easy to disseminate and cause moderatemorbidity and low mortality. Category C consists of emerging pathogensthat could be engineered for mass dissemination in the future because oftheir availability, ease of production and dissemination and potentialfor high morbidity and mortality. Particular examples of these pathogensare anthrax and plague. Additional pathogens which may be protectedagainst or the infection risk therefrom reduced include influenzaviruses, rhinoviruses, adenoviruses and respiratory syncytial viruses,and the like. A further pathogen which may be protected against is thecoronavirus which is believed to cause severe acute respiratory syndrome(SARS).

The compounds of the present invention may also be used in conjunctionwith a P2Y2 receptor agonist or a pharmaceutically acceptable saltthereof (also sometimes referred to as an “active agent” herein). Thecomposition may further comprise a P2Y2 receptor agonist or apharmaceutically acceptable salt thereof (also sometimes referred to asan “active agent” herein). The P2Y2 receptor agonist is typicallyincluded in an amount effective to stimulate chloride and watersecretion by airway surfaces, particularly nasal airway surfaces.Suitable P2Y2 receptor agonists are described in columns 9-10 of U.S.Pat. No. 6,264,975, U.S. Pat. No. 5,656,256, and U.S. Pat. No.5,292,498, each of which is incorporated herein by reference.

Bronchodiloators can also be used in combination with compounds of thepresent invention. These bronchodilators include, but are not limitedto, β-adrenergic agonists including but not limited to epinephrine,isoproterenol, fenoterol, albutereol, terbutalin, pirbuterol,bitolterol, metaproterenol, isoetharine, salmeterol xinofoate, as wellas anticholinergic agents including but not limited to ipratropiumbromide, as well as compounds such as theophylline and aminophylline.These compounds may be administered in accordance with known techniques,either prior to or concurrently with the active compounds describedherein.

Another aspect of the present invention is a pharmaceutical formulation,comprising an active compound as described above in a pharmaceuticallyacceptable carrier (e.g., an aqueous carrier solution). In general, theactive compound is included in the composition in an amount effective totreat mucosal surfaces, such as inhibiting the reabsorption of water bymucosal surfaces, including airway and other surfaces.

The active compounds disclosed herein may be administered to mucosalsurfaces by any suitable means, including topically, orally, rectally,vaginally, ocularly and dermally, etc. For example, for the treatment ofconstipation, the active compounds may be administered orally orrectally to the gastrointestinal mucosal surface. The active compoundmay be combined with a pharmaceutically acceptable carrier in anysuitable form, such as sterile physiological or dilute saline or topicalsolution, as a droplet, tablet or the like for oral administration, as asuppository for rectal or genito-urethral administration, etc.Excipients may be included in the formulation to enhance the solubilityof the active compounds, as desired.

The active compounds disclosed herein may be administered to the airwaysurfaces of a patient by any suitable means, including as a spray, mist,or droplets of the active compounds in a pharmaceutically acceptablecarrier such as physiological or dilute saline solutions or distilledwater. For example, the active compounds may be prepared as formulationsand administered as described in U.S. Pat. No. 5,789,391 to Jacobus, thedisclosure of which is incorporated by reference herein in its entirety.

Solid or liquid particulate active agents prepared for practicing thepresent invention could, as noted above, include particles of respirableor non-respirable size; that is, for respirable particles, particles ofa size sufficiently small to pass through the mouth and larynx uponinhalation and into the bronchi and alveoli of the lungs, and fornon-respirable particles, particles sufficiently large to be retained inthe nasal airway passages rather than pass through the larynx and intothe bronchi and alveoli of the lungs. In general, particles ranging fromabout 1 to 5 microns in size (more particularly, less than about 4.7microns in size) are respirable. Particles of non-respirable size aregreater than about 5 microns in size, up to the size of visibledroplets. Thus, for nasal administration, a particle size in the rangeof 10-500 μm may be used to ensure retention in the nasal cavity.

In the manufacture of a formulation according to the invention, activeagents or the physiologically acceptable salts or free bases thereof aretypically admixed with, inter alia, an acceptable carrier. Of course,the carrier must be compatible with any other ingredients in theformulation and must not be deleterious to the patient. The carrier mustbe solid or liquid, or both, and is preferably formulated with thecompound as a unit-dose formulation, for example, a capsule, that maycontain 0.5% to 99% by weight of the active compound. One or more activecompounds may be incorporated in the formulations of the invention,which formulations may be prepared by any of the well-known techniquesof pharmacy consisting essentially of admixing the components.

Compositions containing respirable or non-respirable dry particles ofmicronized active agent may be prepared by grinding the dry active agentwith a mortar and pestle, and then passing the micronized compositionthrough a 400 mesh screen to break up or separate out largeagglomerates.

The particulate active agent composition may optionally contain adispersant which serves to facilitate the formulation of an aerosol. Asuitable dispersant is lactose, which may be blended with the activeagent in any suitable ratio (e.g., a 1 to 1 ratio by weight).

Active compounds disclosed herein may be administered to airway surfacesincluding the nasal passages, sinuses and lungs of a subject by asuitable means know in the art, such as by nose drops, mists, etc. Inone embodiment of the invention, the active compounds of the presentinvention and administered by transbronchoscopic lavage. In a preferredembodiment of the invention, the active compounds of the presentinvention are deposited on lung airway surfaces by administering anaerosol suspension of respirable particles comprised of the activecompound, which the subject inhales. The respirable particles may beliquid or solid. Numerous inhalers for administering aerosol particlesto the lungs of a subject are known.

Inhalers such as those developed by Inhale Therapeutic Systems, PaloAlto, Calif., USA, may be employed, including but not limited to thosedisclosed in U.S. Pat. Nos. 5,740,794; 5,654,007; 5,458,135; 5,775,320;and 5,785,049, each of which is incorporated herein by reference. TheApplicant specifically intends that the disclosures of all patentreferences cited herein be incorporated by reference herein in theirentirety. Inhalers such as those developed by Dura Pharmaceuticals,Inc., San Diego, Calif., USA, may also be employed, including but notlimited to those disclosed in U.S. Pat. Nos. 5,622,166; 5,577,497;5,645,051; and 5,492,112, each of which is incorporated herein byreference. Additionally, inhalers such as those developed by AradigmCorp., Hayward, Calif., USA, may be employed, including but not limitedto those disclosed in U.S. Pat. Nos. 5,826,570; 5,813,397; 5,819,726;and 5,655,516, each of which is incorporated herein by reference. Theseapparatuses are particularly suitable as dry particle inhalers.

Aerosols of liquid particles comprising the active compound may beproduced by any suitable means, such as with a pressure-driven aerosolnebulizer (L C Star)or an ultrasonic nebulizer (Pari eFlow). See, e.g.,U.S. Pat. No. 4,501,729, which is incorporated herein by reference.Nebulizers are commercially available devices which transform solutionsor suspensions of the active ingredient into a therapeutic aerosol misteither by means of acceleration of compressed gas, typically air oroxygen, through a narrow venturi orifice or by means of ultrasonicagitation. Suitable formulations for use in nebulizers consist of theactive ingredient in a liquid carrier, the active ingredient comprisingup to 40% w/w of the formulation, but preferably less than 20% w/w. Thecarrier is typically water (and most preferably sterile, pyrogen-freewater) or dilute aqueous alcoholic solution. Perfluorocarbon carriersmay also be used. Optional additives include preservatives if theformulation is not made sterile, for example, methyl hydroxybenzoate,antioxidants, flavoring agents, volatile oils, buffering agents andsurfactants.

Aerosols of solid particles comprising the active compound may likewisebe produced with any solid particulate medicament aerosol generator.Aerosol generators for administering solid particulate medicaments to asubject produce particles which are respirable, as explained above, andgenerate a volume of aerosol containing predetermined metered dose ofmedicament at a rate suitable for human administration. One illustrativetype of solid particulate aerosol generator is an insufflator. Suitableformulations for administration by insufflation include finelycomminuted powders which may be delivered by means of an insufflator ortaken into the nasal cavity in the manner of a snuff. In theinsufflator, the powder (e.g., a metered dose thereof effective to carryout the treatments described herein) is contained in capsules orcartridges, typically made of gelatin or plastic, which are eitherpierced or opened in situ and the powder delivered by air drawn throughthe device upon inhalation or by means of a manually-operated pump. Thepowder employed in the insufflator consists either solely of the activeingredient or of powder blend comprising the active ingredient, asuitable powder diluent, such as lactose, and an optional surfactant.The active ingredient typically comprises of 0.1 to 100% w/w of theformulation. A second type of illustrative aerosol generator comprises ametered dose inhaler. Metered dose inhalers are pressurized aerosoldispensers, typically containing a suspension or solution formulation ofactive ingredient in a liquified propellant. During use, these devicesdischarge the formulation through a valve adapted to deliver a meteredvolume, typically from 10 to 150 p. 1, to produce a fine particle spraycontaining the active ingredient. Suitable propellants include certainchlorofluorocarbon compounds, for example, dichlorodifluoromethane,trichlorofluoromethane, dichlorotetrafluoroethane and mixtures thereof.The formulation may additionally contain one of more co-solvents, forexample, ethanol, surfactants, such as oleic acid or sorbitan trioleate,antioxidants and suitable flavoring agents.

The aerosol, whether formed from solid or liquid particles, may beproduced by the aerosol generator at a rate of from about 10 to 150liters per minute, more preferable from 30 to 150 liters per minute, andmost preferably about 60 liters per minute. Aerosols containing greateramounts of medicament may be administered more rapidly.

The dosage of the active compounds disclosed herein will vary dependingon the condition being treated and the state of the subject, butgenerally may be from about 0.01, 0.03, 0.05, 0.1 to 1, 5, 10 or 20 mgof the pharmaceutic agent, deposited on the airway surfaces. The dailydose may be divided among one or multiple unit dose administrations. Thegoal is to achieve a concentration of the pharmaceutic agents on lungairway surfaces of between 10⁻⁹-10⁴ M.

In another embodiment, they are administered by administering an aerosolsuspension of respirable or non-respirable particles (preferablynon-respirable particles) comprised of active compound, which thesubject inhales through the nose. The respirable or non-respirableparticles may be liquid or solid. The quantity of active agent includedmay be an amount of sufficient to achieve dissolved concentrations ofactive agent on the airway surfaces of the subject of from about 10⁻⁹,10⁻⁸, or 10⁻⁷ to about 10⁻³, 10⁻², 10⁻¹ moles/liter, and more preferablyfrom about 10⁻⁹ to about 10⁻⁴ moles/liter.

The dosage of active compound will vary depending on the condition beingtreated and the state of the subject, but generally may be an amountsufficient to achieve dissolved concentrations of active compound on thenasal airway surfaces of the subject from about 10⁻⁹, 10⁻⁸, 10⁻⁷ toabout 10⁻³, 10⁻², or 10⁻¹ moles/liter, and more preferably from about10⁻⁷ to about 10⁻⁴ moles/liter. Depending upon the solubility of theparticular formulation of active compound administered, the daily dosemay be divided among one or several unit dose administrations. The dailydose by weight may range from about 0.01, 0.03, 0.1, 0.5 or 1.0 to 10 or20 milligrams of active agent particles for a human subject, dependingupon the age and condition of the subject. A currently preferred unitdose is about 0.5 milligrams of active agent given at a regimen of 2-10administrations per day. The dosage may be provided as a prepackagedunit by any suitable means (e.g., encapsulating a gelatin capsule).

In one embodiment of the invention, the particulate active agentcomposition may contain both a free base of active agent and apharmaceutically acceptable salt to provide both early release andsustained release of active agent for dissolution into the mucussecretions of the nose. Such a composition serves to provide both earlyrelief to the patient, and sustained relief over time. Sustained relief,by decreasing the number of daily administrations required, is expectedto increase patient compliance with the course of active agenttreatments.

Pharmaceutical formulations suitable for airway administration includeformulations of solutions, emulsions, suspensions and extracts. Seegenerally, J. Nairn, Solutions, Emulsions, Suspensions and Extracts, inRemington: The Science and Practice of Pharmacy, chap. 86 (19^(th) ed.1995), incorporated herein by reference. Pharmaceutical formulationssuitable for nasal administration may be prepared as described in U.S.Pat. Nos. 4,389,393 to Schor; 5,707,644 to Illum; 4,294,829 to Suzuki;and 4,835,142 to Suzuki, the disclosures of which are incorporated byreference herein in their entirety.

Mists or aerosols of liquid particles comprising the active compound maybe produced by any suitable means, such as by a simple nasal spray withthe active agent in an aqueous pharmaceutically acceptable carrier, suchas a sterile saline solution or sterile water. Administration may bewith a pressure-driven aerosol nebulizer or an ultrasonic nebulizer. Seee.g. U.S. Pat. Nos. 4,501,729 and 5,656,256, both of which areincorporated herein by reference. Suitable formulations for use in anasal droplet or spray bottle or in nebulizers consist of the activeingredient in a liquid carrier, the active ingredient comprising up to40% w/w of the formulation, but preferably less than 20% w/w. Typicallythe carrier is water (and most preferably sterile, pyrogen-free water)or dilute aqueous alcoholic solution, preferably made in a 0.12% to 0.8%solution of sodium chloride. Optional additives include preservatives ifthe formulation is not made sterile, for example, methylhydroxybenzoate, antioxidants, flavoring agents, volatile oils,buffering agents, osmotically active agents (e.g. mannitol, xylitol,erythritol) and surfactants.

Compositions containing respirable or non-respirable dry particles ofmicronized active agent may be prepared by grinding the dry active agentwith a mortar and pestle, and then passing the micronized compositionthrough a 400 mesh screen to break up or separate out largeagglomerates.

The particulate composition may optionally contain a dispersant whichserves to facilitate the formation of an aerosol. A suitable dispersantis lactose, which may be blended with the active agent in any suitableratio (e.g., a 1 to 1 ratio by weight).

The compounds of formula I-III may be synthesized according toprocedures known in the art. A representative synthetic procedure isshown in the scheme below:

These procedures are described in, for example, E. J. Cragoe, “TheSynthesis of Amiloride and Its Analogs” (Chapter 3) in Amiloride and ItsAnalogs, pp. 25-36, incorporated herein by reference. Other methods ofpreparing the compounds are described in, for example, U.S. Pat. No.3,313,813, incorporated herein by reference. See in particular MethodsA, B, C, and D described in U.S. Pat. No. 3,313,813. Additional methodsof preparing intermediates used in the preparation of compounds of theinstant invention are disclosed in U.S. Pat. No. 7,064,129, U.S. Pat.No. 6,858,615, U.S. Pat. No. 6,903,105, WO 2004/073629, WO 2007/146869,and WO 2007/018640, each of which is expressly incorporated byreference.

Several assays may be used to characterize the compounds of the presentinvention. Representative assays are discussed below.

In Vitro Measure of Sodium Channel Blocking Activity and Reversibility

One assay used to assess mechanism of action and/or potency of thecompounds of the present invention involves the determination of lumenaldrug inhibition of airway epithelial sodium currents measured undershort circuit current (I_(SC)) using airway epithelial monolayersmounted in Using chambers. Cells obtained from freshly excised human,dog, sheep or rodent airways are seeded onto porous 0.4 micron Snapwell™Inserts (CoStar), cultured at air-liquid interface (ALI) conditions inhormonally defined media, and assayed for sodium transport activity(I_(SC)) while bathed in Krebs Bicarbonate Ringer (KBR) in Usingchambers. All test drug additions are to the lumenal bath with half-logdose addition protocols (from 1×10⁻¹¹ M to 3×10⁻⁵ M), and the cumulativechange in I_(sc) (inhibition) recorded. All drugs are prepared indimethyl sulfoxide as stock solutions at a concentration of 1×10⁻² M andstored at −20° C. Eight preparations are typically run in parallel; twopreparations per run incorporate amiloride and/or benzamil as positivecontrols. After the maximal concentration (5×10⁻⁵ M) is administered,the lumenal bath is exchanged three times with fresh drug-free KBRsolution, and the resultant I_(SC) measured after each wash forapproximately 5 minutes in duration. Reversibility is defined as thepercent return to the baseline value for sodium current after the thirdwash. All data from the voltage clamps are collected via a computerinterface and analyzed off-line.

Dose-effect relationships for all compounds are considered and analyzedby the Prism 3.0 program. IC₅₀ values, maximal effective concentrations,and reversibility are calculated and compared to amiloride and benzamilas positive controls. The potency of the sodium channel blockingactivity of representative compounds relative to amiloride in freshlyexcised cell from human airways is shown in Table 1.

TABLE 1 Potency of sodium channel blocking activity of compoundscompared to amiloride. Compound Potency of Sodium Channel NumberBlockade Relative to Amiloride 26 30 34 63 72 164 76 347

The potency of the sodium channel blocking activity of representativecompounds in freshly excised cell from dog airways is shown in Table 2.

TABLE 2 Compound Number IC₅₀ nM Amiloride 781 79 23.5 34 18.8 26 25.4 726.3 75 4.3 91 6.1 94 9.6 107 8.1 105 23.5 116 2.7 118 3.2

Pharmacological Assays of Absorption (1) Apical Disappearance Assay

Bronchial cells (dog, human, sheep, or rodent cells) are seeded at adensity of 0.25×10⁶/cm² on a porous Transwell-Col collagen-coatedmembrane with a growth area of 1.13 cm² grown at an air-liquid interfacein hormonally defined media that promotes a polarized epithelium. From12 to 20 days after development of an air-liquid interface (ALI) thecultures are expected to be >90% ciliated, and mucins will accumulate onthe cells. To ensure the integrity of primary airway epithelial cellpreparations, the transepithelial resistance (R_(t)) and transepithelialpotential differences (PD), which are indicators of the integrity ofpolarized nature of the culture, are measured. Human cell systems arepreferred for studies of rates of absorption from apical surfaces. Thedisappearance assay is conducted under conditions that mimic the “thin”films in vivo (˜25 μl) and is initiated by adding experimental sodiumchannel blockers or positive controls (amiloride, benzamil, phenamil) tothe apical surface at an initial concentration of 10 μM. A series ofsamples (5 μl volume per sample) is collected at various time points,including 0, 5, 20, 40, 90 and 240 minutes. Concentrations aredetermined by measuring intrinsic fluorescence of each sodium channelblocker using a Fluorocount Microplate Fluorometer or HPLC. Quantitativeanalysis employs a standard curve generated from authentic referencestandard materials of known concentration and purity. Data analysis ofthe rate of disappearance is performed using nonlinear regression, onephase exponential decay (Prism V 3.0).

2. Confocal Microscopy Assay of Amiloride Congener Uptake

Virtually all amiloride-like molecules fluoresce in the ultravioletrange. This property of these molecules may be used to directly measurecellular update using x-z confocal microscopy. Equimolar concentrationsof experimental compounds and positive controls including amiloride andcompounds that demonstrate rapid uptake into the cellular compartment(benzamil and phenamil) are placed on the apical surface of airwaycultures on the stage of the confocal microscope. Serial x-z images areobtained with time and the magnitude of fluorescence accumulating in thecellular compartment is quantitated and plotted as a change influorescence versus time.

3. In vitro Assays of Compound Metabolism

Airway epithelial cells have the capacity to metabolize drugs during theprocess of transepithelial absorption. Further, although less likely, itis possible that drugs can be metabolized on airway epithelial surfacesby specific ectoenzyme activities. Perhaps more likely as anecto-surface event, compounds may be metabolized by the infectedsecretions that occupy the airway lumens of patients with lung disease,e.g. cystic fibrosis. Thus, a series of assays is performed tocharacterize the compound metabolism that results from the interactionof test compounds with human airway epithelia and/or human airwayepithelial lumenal products.

In the first series of assays, the interaction of test compounds in KBRas an “ASL” stimulant are applied to the apical surface of human airwayepithelial cells grown in the T-Col insert system. For most compounds,metabolism (generation of new species) is tested for using highperformance liquid chromatography (HPLC) to resolve chemical species andthe endogenous fluorescence properties of these compounds to estimatethe relative quantities of test compound and novel metabolites. For atypical assay, a test solution (25 μl KBR, containing 10 μM testcompound) is placed on the epithelial lumenal surface. Sequential 5 to10 μl samples are obtained from the lumenal and serosal compartments forHPLC analysis of (1) the mass of test compound permeating from thelumenal to serosal bath and (2) the potential formation of metabolitesfrom the parent compound. In instances where the fluorescence propertiesof the test molecule are not adequate for such characterizations,radiolabeled compounds are used for these assays. From the HPLC data,the rate of disappearance and/or formation of novel metabolite compoundson the lumenal surface and the appearance of test compound and/or novelmetabolite in the basolateral solution is quantitated. The data relatingthe chromatographic mobility of potential novel metabolites withreference to the parent compound are also quantitated.

To analyze the potential metabolism of test compounds by CF sputum, a“representative” mixture of expectorated CF sputum obtained from 10 CFpatients (under IRB approval) has been collected. The sputum has been besolubilized in a 1:5 mixture of KBR solution with vigorous vortexing,following which the mixture was split into a “neat” sputum aliquot andan aliquot subjected to ultracentrifugation so that a “supernatant”aliquot was obtained (neat=cellular; supernatant=liquid phase). Typicalstudies of compound metabolism by CF sputum involve the addition ofknown masses of test compound to “neat” CF sputum and aliquots of CFsputum “supernatant” incubated at 37° C., followed by sequentialsampling of aliquots from each sputum type for characterization ofcompound stability/metabolism by HPLC analysis as described above. Asabove, analysis of compound disappearance, rates of formation of novelmetabolites, and HPLC mobilities of novel metabolites are thenperformed.

4. Pharmacological Effects and Mechanism of Action of the Drug inAnimals

The effect of compounds for enhancing mucociliary clearance (MCC) can bemeasured using an in vivo model described by Sabater et al., Journal ofApplied Physiology, 1999, pp. 2191-2196, incorporated herein byreference.

Methods Animal Preparation:

Adult ewes (ranging in weight from 25 to 35 kg) were restrained in anupright position in a specialized body harness adapted to a modifiedshopping cart. The animals' heads were immobilized and local anesthesiaof the nasal passage was induced with 2% lidocaine. The animals werethen nasally intubated with a 7.5 mm internal diameter endrotrachealtube (ETT). The cuff of the ETT was placed just below the vocal cordsand its position was verified with a flexible bronchoscope. Afterintubation the animals were allowed to equilibrate for approximately 20minutes prior to initiating measurements of mucociliary clearance.

Administration of Radio-Aerosol:

Aerosols of ^(99m)Tc-Human serum albumin (3.1 mg/ml; containingapproximately 20 mCi) were generated using a Raindrop Nebulizer whichproduces a droplet with a median aerodynamic diameter of 3.6 μm. Thenebulizer was connected to a dosimetry system consisting of a solenoidvalve and a source of compressed air (20 psi). The output of thenebulizer was directed into a plastic T connector; one end of which wasconnected to the endrotracheal tube, the other was connected to a pistonrespirator. The system was activated for one second at the onset of therespirator's inspiratory cycle. The respirator was set at a tidal volumeof 500 mL, an inspiratory to expiratory ratio of 1:1, and at a rate of20 breaths per minute to maximize the central airway deposition. Thesheep breathed the radio-labeled aerosol for 5 minutes. A gamma camerawas used to measure the clearance of ^(99m)Tc-Human serum albumin fromthe airways. The camera was positioned above the animal's back with thesheep in a natural upright position supported in a cart so that thefield of image was perpendicular to the animal's spinal cord. Externalradio-labeled markers were placed on the sheep to ensure properalignment under the gamma camera. All images were stored in a computerintegrated with the gamma camera. A region of interest was traced overthe image corresponding to the right lung of the sheep and the countswere recorded. The counts were corrected for decay and expressed aspercentage of radioactivity present in the initial baseline image. Theleft lung was excluded from the analysis because its outlines aresuperimposed over the stomach and counts can be swallowed and enter thestomach as radio-labeled mucus.

Treatment Protocol (Assessment of Activity at t-Zero):

A baseline deposition image was obtained immediately after radio-aerosoladministration. At time zero, after acquisition of the baseline image,vehicle control (distilled water), positive control (amiloride), orexperimental compounds were aerosolized from a 4 ml volume using a PariLC JetPlus nebulizer to free-breathing animals. The nebulizer was drivenby compressed air with a flow of 8 liters per minute. The time todeliver the solution was 10 to 12 minutes. Animals were extubatedimmediately following delivery of the total dose in order to preventfalse elevations in counts caused by aspiration of excess radio-tracerfrom the ETT. Serial images of the lung were obtained at 15-minuteintervals during the first 2 hours after dosing and hourly for the next6 hours after dosing for a total observation period of 8 hours. Awashout period of at least 7 days separated dosing sessions withdifferent experimental agents.

Treatment Protocol (Assessment of Activity at t-4 Hours):

The following variation of the standard protocol was used to assess thedurability of response following a single exposure to vehicle control(distilled water), positive control compounds (amiloride or benzamil),or investigational agents. At time zero, vehicle control (distilledwater), positive control (amiloride), or investigational compounds wereaerosolized from a 4 ml volume using a Pari LC JetPlus nebulizer tofree-breathing animals. The nebulizer was driven by compressed air witha flow of 8 liters per minute. The time to deliver the solution was 10to 12 minutes. Animals were restrained in an upright position in aspecialized body harness for 4 hours. At the end of the 4-hour periodanimals received a single dose of aerosolized ^(99m)Tc-Human serumalbumin (3.1 mg/ml; containing approximately 20 mCi) from a RaindropNebulizer. Animals were extubated immediately following delivery of thetotal dose of radio-tracer. A baseline deposition image was obtainedimmediately after radio-aerosol administration. Serial images of thelung were obtained at 15-minute intervals during the first 2 hours afteradministration of the radio-tracer (representing hours 4 through 6 afterdrug administration) and hourly for the next 2 hours after dosing for atotal observation period of 4 hours. A washout period of at least 7 daysseparated dosing sessions with different experimental agents.

Statistics: Data were analyzed using SYSTAT for Windows, version 5. Datawere analyzed using a two-way repeated ANOVA (to assess overalleffects), followed by a paired t-test to identify differences betweenspecific pairs. Significance was accepted when P was less than or equalto 0.05. Slope values (calculated from data collected during the initial45 minutes after dosing in the t-zero assessment) for mean MCC curveswere calculated using linear least square regression to assessdifferences in the initial rates during the rapid clearance phase.

EXAMPLES

Having generally described this invention, a further understanding canbe obtained by reference to certain specific examples which are providedherein for purposes of illustration only and are not intended to belimiting unless otherwise specified.

Preparation of Sodium Channel Blockers

Materials and methods. All reagents and solvents were purchased fromAldrich Chemical Corp. and used without further purification. Proton andcarbon NMR spectra were obtained on a Bruker AC 300 spectrometer at 300MHz and 75 MHz, respectively. Proton spectra were referenced totetramethylsilane as an internal standard and the carbon spectra werereferenced to CDCl₃, CD₃OD, acetone-d₆ or DMSO-d₆ (purchased fromAldrich or Cambridge Isotope Laboratories, unless otherwise specified).Melting points were obtained on a MeI-Temp II apparatus and areuncorrected. ESI Mass spectra were obtained on a Shimadzu LCMS-2010 EVMass Spectrometer. HLPC analyses were obtained using a Waters XTerra RPC18 Analytical Column detected at 220 nm (unless otherwise specified) ona Shimadzu Prominence HPLC system. With a flow rate of 1.0 mL perminute, the following time program was utilized:

Percent A Percent B Time (H₂O with 0.05% TFA) (CH₃CN with 0.05% TFA) 0:00 90 10 20:00 10 90 30:00 10 90 35:00 90 10

The following definitions for abbreviations will apply unless otherwiseindicated.

Abbreviation Definition THF tetrahydrofuran Cbz Benzyloxycarbonyl i.e.—(CO)O-benzyl AUC Area under the curve or peak EtOAc Ethyl acetate R_(f)Retardation factor HPLC High performance liquid chromatography MTBEMethyl tertiary butyl ether t_(R) Retention time GC-MS Gaschromatography-mass spectrometry wt % Percent by weight h hours minminutes MHz megahertz MeOH methanol TFA Trifluoroacetic acid UVUltraviolet

Preparation of 4-Bromonaphthol (13)

To a solution of naphthol (12, 5.0 g, 35 mmol) in CH₃CN (125 mL) at 0°C. was added N-bromosuccinimide (7.9 g, 45 mmole) in several portions.The reaction mixture was warmed to room temperature, stirred for 1 h,and concentrated. The residue was dissolved in EtOAc (500 mL) and thesolution was washed with water (300 mL) and brine (300 mL). The organiclayer was dried over MgSO₄, filtered, and concentrated. The residue waspurified by column chromatography (silica gel, 4:1 hexanes/EtOAc) toafford 4-bromonaphthol (13, 5.0 g, 64%) as a white solid: ¹H NMR (300MHz, CDCl₃) δ 8.22-8.16 (m, 2H), 7.62-7.26 (m, 3H), 6.71 (d, J=8.0 Hz,1H), 5.46 (s, 1H).

Preparation of (4-Bromonaphthalen-1-yloxy)(tert-butyl)dimethylsilane(14)

To a solution of imidazole (2.3 g, 34 mmole) and 4-bromonaphthol (13,5.0 g, 22 mmole) in DMF (10 mL) at 0° C. was added t-butyldimethylsilylchloride (3.7 g, 24.6 mmole) in several portions. The mixture was warmedto room temperature and stirred for 2 h. The reaction mixture waspartitioned between Et₂O (500 mL) and water (300 mL) and the aqueouslayer was back-extracted with Et₂O (300 mL). The combined organic layerswere washed with water (300 mL) and brine (300 mL), dried over MgSO₄,filtered, and concentrated. The residue was purified by columnchromatography (silica gel, hexanes) to afford(4-bromonaphthalen-1-yloxy)(tert-butyl)dimethylsilane (14, 6.4 g, 85%)as a white solid: ¹H NMR (300 MHz, CDCl₃) δ 8.21-8.14 (m, 2H), 7.61-7.49(m, 3H), 6.74 (d, J=8.2 Hz, 1H), 1.10 (s, 9H), 0.28 (s, 6H).

Preparation of tert-Butyl (4-Bromonaphthalen-1-yloxy)dimethylsilane (15)

n-Butyllithium (1.6 M in hexanes, 6.8 mL) was added dropwise to asolution of (4-bromonaphthalen-1-yloxy)(tert-butyl)dimethylsilane (14,3.0 g, 9.0 mmole) in anhydrous THF (30 mL) at −78° C. and the mixturewas stirred for 1 h. Iodine (3.4 g, 14 mmole) in THF (20 mL) was addeddropwise at the same temperature and the reaction mixture was stirredfor 2 h. The reaction mixture was diluted with Et₂O (500 mL), washedwith 1:1 saturated Na₂S₂O₃/NaHCO₃ (2×300 mL) and 1:1 H₂O/brine (300 mL),dried over MgSO₄, filtered, and concentrated. The residue was purifiedby column chromatography (silica gel, hexanes) to afford tert-butyl(4-bromonaphthalen-1-yloxy)dimethylsilane (15, 1.8 g, 52%) as a whitesolid: ¹H NMR (300 MHz, CDCl₃) δ 8.15 (d, J=8.4 Hz, 1H), 8.02 (d, J=8.6Hz, 1H), 7.89 (d, J=8.1 Hz, 1H), 7.59-7.47 (m, 2H), 6.64 (d, J=8.1 Hz,1H), 1.09 (s, 9H), 0.28 (s, 6H).

Preparation of 3-Butyn-1-amine (17)

To a solution of 4-pentynoic acid (16, 15 g, 150 mmole), benzyl alcohol(17 mL, 170 mmole), and 4-methyl morpholine (17 mL, 150 mmole) inanhydrous toluene (80 mL) was added dropwise diphenyl phosphoryl azide(33 mL, 150 mmole) at room temperature. The reaction mixture was stirredfor 15 min. The reaction temperature was carefully raised to 60-70° C.,during which vigorous efflorescence was observed. The reaction mixturewas stirred at the same temperature for 2 h and then at 110° C. for 18h. The reaction mixture was cooled to room temperature and concentratedto a thick brown slurry. The residue was dissolved in CH₂Cl₂ (300 mL)and the solution was stirred for an additional 30 min. The mixture waswashed with water (2×300 mL) and the combined aqueous layers wereback-extracted with CH₂Cl₂ (2×300 mL). The combined organic layers weredried over MgSO₄, filtered, and concentrated. The residue was purifiedby column chromatography (silica gel, 4:1 hexanes/EtOAc) to afford amine17 (16 g, 52%) as a light yellow oil: ¹H NMR (300 MHz, CDCl₃) δ7.37-7.33 (m, 5H), 5.11 (br s, 3H), 3.36 (q, J=6.4 Hz, 2H), 2.41 (td,J=6.4, 2.4 Hz, 2H), 1.99 (t, J=2.6 Hz, 1H).

Preparation of Benzyl4-[4-(tert-Butyldimethylsilyloxy)naphthalen-1-yl]-3-butynylcarbamate(18)

A solution of tert-butyl (4-bromonaphthalen-1-yloxy)dimethylsilane (15,3.1 g, 8.2 mmole), amine 17 (3.3 g, 16 mmole), and triethyl amine (4.5mL, 33 mmole) in CH₃CN (70 mL) pre-cooled to −78° C. was degassed withargon. Tri-tert-butyl phosphine (10% in hexanes, 3.3 g, 1.6 mmole),Pd(PPh₃)₄ (940 mg, 0.82 mmole), and CuI (78 mg, 0.41 mmole) were addedrapidly in one portion at the same temperature. The mixture was warmedto −30° C. and shaken until a homogeneous solution was formed, thencooled to −78° C., and degassed with argon. The mixture was warmed toroom temperature and stirred for 18 h. Water (10 mL) was added to thereaction mixture and the mixture was concentrated. The residue wasdiluted with EtOAc (500 mL) and the organic layer was washed with water(300 mL) and brine (300 mL), dried over Na₂SO₄, filtered, andconcentrated. The residue was purified by column chromatography (silicagel, 4:1 hexanes/EtOAc) to afford carbamate 18 (2.0 g, 52%) as a lightyellow oil: ¹H NMR (300 MHz, CDCl₃) δ 8.24-8.16 (m, 2H), 7.53-7.45 (m,3H), 7.38-7.30 (m, 5H), 6.77 (d, J=7.9 Hz, 1H), 5.14 (br s, 3H),3.56-3.49 (m, 2H), 2.76 (t, J=6.5 Hz, 2H), 1.09 (s, 9H), 0.29 (s, 6H).

Preparation of Benzyl4-[4-(tert-Butyldimethylsilyloxy)naphthalen-1-yl]butylcarbamate (19)

A solution of carbamate 18 (2.0 g, 4.3 mmole) and 10% Pd/C (300 mg) inMeOH (60 mL) was subjected to hydrogenation conditions (50 psi) for 8 hat room temperature. The reaction mixture was filtered through a plug ofdiatomaceous earth and the plug was washed with MeOH (2×20 mL). Thefiltrate was then concentrated in vacuo to afford crude amine (1.4 g)which was dissolved in 1:1 CH₂Cl₂/NaHCO₃ (saturated solution) (30 mL).Benzyl chloroformate (0.62 mL) was added dropwise at room temperatureand the reaction mixture was stirred for 1 h. The mixture wasconcentrated, the residue was dissolved in EtOAc (500 mL), and thesolution was washed with water (300 mL) and brine (300 mL). The organiclayer was dried over Na₂SO₄, filtered, and concentrated. The residue waspurified by column chromatography (silica gel, 4:1 hexanes/EtOAc) toafford butylcarbamate 19 (1.5 g, 77%) as a light yellow oil: ¹H NMR (300MHz, DMSO-d₆) δ 8.24 (m, 1H), 7.91 (d, J=7.4 Hz, 1H), 7.51-7.42 (m, 2H),7.34-7.28 (m, 5H), 7.12 (d, J=7.6 Hz, 1H), 6.77 (d, J=7.6 Hz, 1H), 5.08(br s, 2H), 4.75 (br s, 1H), 3.22 (q, J=6.4 Hz, 2H), 2.99 (q, J=7.4 Hz,2H), 1.76-1.71 (m, 2H), 1.67-1.56 (m, 2H), 1.09 (s, 9H), 0.27 (s, 6H).

Preparation of Benzyl 4-(4-Hydroxynaphthalen-1-yl)butylcarbamate (20)

Tetrabutylammonium fluoride (1 M in THF, 1.0 mL) was added to a solutionof benzyl4-[4-(tert-butyldimethylsilyloxy)naphthalen-1-yl]butylcarbamate (19, 380mg, 0.80 mmol) in anhydrous THF (15 ml) at room temperature. Thereaction mixture was stirred for 2 h and concentrated to dryness. Theresidue was purified by column chromatography (silica gel, 3:1hexanes/EtOAc) to afford butylcarbamate 20 (287 mg, 99%) as white solid:¹H NMR (300 MHz, CDCl₃) δ 8.23-8.21 (m, 1H), 7.84-7.81 (m, 1H),7.42-7.34 (m, 2H), 7.25-7.15 (m, 5H), 6.96 (d, J=7.5 Hz, 1H), 6.62 (d,J=7.5 Hz, 1H), 5.00 (br s, 2H), 4.65 (br s, 1H), 3.13 (q, J=6.6 Hz, 2H),2.87 (t, J=7.5 Hz, 2H), 1.64-1.47 (m, 4H).

Preparation of Benzyl4-[4-(2,3-Dihydroxypropoxy)naphthalen-1-yl]butylcarbamate (22)

A solution of benzyl 4-(4-hydroxynaphthalen-1-yl)butylcarbamate (20, 287mg, 0.82 mmole), oxiran-2-ylmethanol (21, 0.07 mL, 1.00 mmole) andtriethylamine (0.01 mL, 0.05 mmole) in absolute EtOH (9.28 mL) wassubjected to microwave irradiation at 130° C. for 30 min. The reactionmixture was concentrated in vacuo and the residue was purified by columnchromatography (silical gel, 95:5 CH₂Cl₂/MeOH) to afford butylcarbamate22 (293 mg, 83%) as a light yellow thick oil: ¹H NMR (300 MHz, CDCl₃) δ8.24 (d, J=7.7 Hz, 1H), 7.94 (d, J=8.1 Hz, 1H), 7.52-7.45 (m, 2H),7.37-7.28 (m, 5H), 7.18 (d, J=7.7 Hz, 1H), 6.75 (d, J=8.0 Hz, 1H), 5.09(br s, 2H), 4.71 (br s, 1H), 4.29-4.20 (m, 3H), 3.98-3.81 (m, 2H), 3.23(q, J=6.5 Hz, 2H), 3.00 (t, J=7.5 Hz, 2H), 2.65 (d, J=4.5 Hz, 1H), 2.06(t, J=5.8 Hz, 1H), 1.83-1.53 (m, 4H).

Preparation of 3-[4-(4-Aminobutyl)naphthalen-1-yloxy]propane-1,2-diol(23)

A solution of benzyl4-[4-(2,3-dihydroxypropoxy)naphthalen-1-yl]butylcarbamate (22, 340 mg,0.80 mmole) and 10% Pd/C (50 mg) in MeOH (50 mL) was subjected tohydrogenation conditions (1 atm) for 2 h at room temperature. Thereaction mixture was filtered through a plug of diatomaceous earth andthe plug was washed with MeOH. The filtrate was then concentrated invacuo to afford diol 23 (226 mg, 97%) as a yellow solid: MS m/z 290[C₁₇H₂₃NO₃+H]⁺. Diol 23 was used in the next step without furtherpurification.

Preparation of2,4-Diamino-5-chloro-N-{N-[4-(4-(2,3-dihydroxypropoxy)naphthalen-1-yl)butyl]carbamimidoyl}benzamide(24)

To a solution of 3-[4-(4-aminobutyl)naphthalen-1-yloxy]propane-1,2-diol(23, 226 mg, 0.78 mmole) and methyl3,5-diamino-6-chloropyrazine-2-carbonylcarbamimidothioate (10, 455 mg,1.17 mmole) in EtOH (10 mL) was added diisopropylethylamine (0.82 mL,4.69 mmole) at room temperature. The reaction mixture was heated at 70°C. in a sealed tube for 7 h, then cooled to room temperature, andconcentrated in vacuo. The residue was purified by column chromatography(silica gel, 80:18:2 CHCl₃/CH₃OH/NH₄OH) to afford benzamide 24 (140 mg,36%) as a yellow solid: ¹H NMR (300 MHz, CD₃OD) δ 8.31 (d, J=8.2 Hz,1H), 7.98 (d, J=8.2 Hz, 1H), 7.53-7.40 (m, 2H), 7.23 (d, J=7.9 Hz, 1H),6.83 (d, J=7.8 Hz, 1H), 4.22-4.10 (m, 3H), 3.84-3.72 (m, 2H), 3.31-3.25(m, 2H), 3.08-3.03 (m, 2H), 1.89-1.70 (m, 4H).

Preparation of3,5-Diamino-6-chloro-N-(N-{4-[6-(2,3-dihydropropoxy)naphthalen-2-yl]butyl}carbamimidoyl)pyrazine-2-carboxamideMethanesulfonic Acid Salt (25)

To a solution of3,5-diamino-6-chloro-N-(N-{4-[6-(2,3-dihydropropoxy)naphthalen-2-yl]butyl}carbamimidoyl)pyrazine-2-carboxamide(24, 119 mg, 0.24 mmole) in EtOH (5 mL) was added methanesulfonic acid(22.7 mg, 0.24 mmole) at room temperature. The reaction mixture wasstirred for 15 min. The solution was concentrated and the residue wasazeotroped with MeOH. The residue was dissolved in H₂O (4 mL) andlyophilized to afford methanesulfonic acid salt 25 (130 mg, 92%) as ayellow solid: mp 129-132° C.; ¹H NMR (300 MHz, DMSO-d₆) δ 10.45 (br s,1H), 9.12 (br s, 1H), 8.86 (br s, 1H), 8.70 (br s, 1H), 8.27 (dd, J=8.0,1.3 Hz, 1H), 8.02 (d, J=8.2 Hz, 1H), 7.59-7.49 (m, 2H), 7.47 (br s, 2H),7.26 (d, J=7.8, 1H), 6.87 (d, J=7.9 Hz, 1H), 5.06 (d, J=4.7 Hz, 1H),4.71 (t, J=5.4, 1H), 4.16-3.93 (m, 3H), 3.55 (td, J=5.6, 1.5 Hz, 2H),3.16 (d, J=5.3 Hz, 2H), 3.00 (t, J=7.0 Hz, 2H), 2.29 (s, 3H), 1.76-1.57(m, 4H); ESI-MS m/z 524 [C₂₃H₂₈ClN₇O₄+H]⁺.

Preparation of2,4-Diamino-5-chloro-N-(N-{4-[4-(2,3-dihydroxypropoxy)naphthalen-1-yl]butyl}carbamimidoyl)benzamideL-(+)-Lactic Acid Salt (26)

To a solution of2,4-diamino-5-chloro-N-(N-{4-[4-(2,3-dihydroxypropoxy)naphthalen-1-yl]butyl}carbamimidoyl)benzamide(24, 28 mg, 0.06 mmole) in EtOH (10 mL) was added L-(+)-lactic acid(5.20 mg, 0.06 mmole) at room temperature and the reaction mixture wasstirred for 15 min. The solution was concentrated and the residue wasazeotroped with MeOH. The residue was dissolved in H₂O (3 mL) andlyophilized to afford lactic acid salt 26 (28 mg, 84%) as a yellowsolid: mp 115-118° C.; ¹H NMR (300 MHz, CD₃OD) δ 8.32 (d, J=8.4 Hz, 1H),8.01 (d, J=8.4 Hz, 1H), 7.53-7.40 (m, 2H), 7.24 (d, J=7.8 Hz, 1H), 6.83(d, J=7.8 Hz, 1H), 4.21-4.10 (m, 3H), 4.01-3.94 (m, 1H), 3.82-3.73 (m,2H), 3.35-3.33 (m, 2H), 3.08 (t, J=7.0, Hz, 1H), 1.89-1.77 (m, 4H), 1.31(d, J=7.0 Hz, 3H); ESI-MS m/z 524 [C₂₃H₂₈ClN₇O₄+H]⁺.

Preparation of (6-Bromonaphthalen-2-yloxy)(tert-butyl)dimethylsilane(28)

A solution of 6-bromonaphthalen-2-ol (5.0 g, 22.4 mmol) and imidazole(2.3 g, 33.6 mmole) in N,N-dimethylformamide (DMF) (5.0 mL) was addedt-butyldimethylsilyl chloride (TBDMSCl) (3.7 g, 24.6 mmole) in oneportion at 0° C. The mixture was allowed to warm to room temperature andstirred for 3 h. The reaction mixture was partitioned between EtOAc (500mL) and water (300 mL). The aqueous layer was separated and extractedwith EtOAc (2×100 mL) and the combined organic extracts were washed withbrine (300 mL), dried over Na₂SO₄, filtered, and concentrated. Theresidue was purified by column chromatography (silica gel, hexanes) toafford (6-bromonaphthalen-2-yloxy)(tert-butyl)dimethylsilane (28, 7.4 g,98%) as a white solid: ¹H NMR (300 MHz, CDCl₃) δ 7.91 (d, J=1.8 Hz, 1H),7.64 (d, J=8.7 Hz, 1H), 7.56 (d, J=8.7 Hz, 1H), 7.48 (dd, J=8.7, 1.8 Hz,1H), 7.15 (d, J=2.4 Hz, 1H), 7.09 (dd, J=9.0, 2.4 Hz, 1H), 1.01 (s, 9H),0.24 (s, 6H).

Preparation of Benzyl4-[6-(tert-Butyldimethylsilyloxy)naphthalen-2-yl]but-3-ynylcarbamate(29)

A solution of (6-bromonaphthalen-2-yloxy)(tert-butyl)dimethylsilane (28,3.4 g, 10.0 mmol), benzyl but-3-ynylcarbamate (17, 2.0 g, 10 mmole), andtriethylamine (20 mL) in anhydrous THF (60 mL) pre-cooled to −78° C. wasdegassed with argon. The mixture was warmed to room temperature anddichlorobis(triphenylphosphine)palladium(II) (PdCl₂(PPh₃)₂ (702 mg, 1mmole) and CuI (381 mg, 2 mmole) were added rapidly in one portion underargon. The mixture was heated at 60° C. for 4 h, then at roomtemperature for 48 h. The reaction mixture was filtered through a plugof diatomaceous earth and the filtrate was partitioned between EtOAc(500 mL) and 1 N HCl (200 mL). The aqueous layer was separated andback-extracted with EtOAc (300 mL) The combined organic extracts werewashed with water (300 mL) and brine (300 mL), dried over Na₂SO₄,filtered, and concentrated. The residue was purified by columnchromatography (silical gel, 10:1 hexanes/EtOAc) to afford carbamate 29(1.24 g, 37%) as a brown thick oil: ¹H NMR (300 MHz, CDCl₃) δ 7.83 (s,1H), 7.65 (d, J=9.0 Hz, 1H), 7.60 (d, J=8.7 Hz, 1H), 7.39-7.29 (m, 6H),7.13 (d, J=2.1 Hz, 1H), 7.07 (dd, J=8.7, 2.4 Hz, 1H), 5.17 (br s, 1H),5.13 (s, 2H), 3.46 (q, J=6.3 Hz, 2H), 2.67 (t, J=6.3 Hz, 2H), 1.01 (s,9H), 0.25 (s, 6H).

Preparation of Benzyl 4-(6-Hydroxynaphthalen-2-yl)but-3-ynylcarbamate(30)

To a solution of benzyl4-[6-(tert-butyldimethylsilyloxy)naphthalen-2-yl]but-3-ynylcarbamate(29, 578 mg, 1.26 mmol) in anhydrous THF (60 mL) was added dropwisetetrabutylammonium fluoride (1 M in THF, 1.38 mL) and the mixture wasstirred for 2 h at room temperature. The resulting solution wasconcentrated in vacuo and the residue was purified by columnchromatography (silical gel, 95:5 CH₂Cl₂/MeOH) to afford carbamate 30(418 mg, 96%) as a pale yellow solid: ¹H NMR (300 MHz, CDCl₃) δ 7.82 (s,1H), 7.67 (d, J=9.6 Hz, 1H), 7.58 (d, J=8.4 Hz, 1H), 7.37-7.29 (m, 6H),7.11-7.08 (m, 2H), 5.30 (br s, 2H), 5.14 (s, 2H), 3.48 (q, J=6.3 Hz,2H), 2.68 (t, J=6.6 Hz, 2H).

Preparation of Benzyl4-[6-(2,3-Dihydroxypropoxy)naphthalen-2-yl]but-3-ynylcarbamate (31)

A solution of 4-(6-hydroxynaphthalen-2-yl)but-3-ynylcarbamate (30, 390mg, 1.1 mmole), oxiran-2-ylmethanol (21, 0.1 mL, 1.4 mmole), andtriethylamine (0.01 mL, 0.06 mmole) in absolute EtOH (8.8 mL) wassubjected to microwave irradiation at 130° C. for 30 min. The reactionmixture was concentrated in vacuo and the residue was purified by columnchromatography (silical gel, 95:5 CH₂Cl₂/MeOH) to afford carbamate 31(236 mg, 42%) as a white solid: ¹H NMR (300 MHz, CD₃OD) δ 7.80 (s, 1H),7.68 (dd, J=8.7, 3.9 Hz, 2H), 7.38-7.16 (m, 8H), 5.10 (s, 2H), 4.18 (dd,J=9.6, 4.2 Hz, 1H), 4.11-4.01 (m, 2H), 3.76-3.67 (m, 2H), 3.39-3.31 (m,4H), 2.63 (t, J=6.9 Hz, 2H).

Preparation of 3-[6-(4-Aminobutyl)naphthalen-2-yloxy]propane-1,2-diol(32)

A suspension of benzyl4-[6-(2,3-dihydroxypropoxy)naphthalen-2-yl]but-3-ynylcarbamate (31, 236mg, 0.5 mmole) and 10% Pd/C (96 mg) in MeOH (70 mL) was subjected tohydrogenation conditions (1 atm) for 1 h at room temperature. Thereaction mixture was filtered through a plug of diatomaceous earth andthe plug was washed with MeOH. The filtrate was then concentrated invacuo to afford diol 32 (123 mg, 78%) as a white solid: ¹H NMR (300 MHz,CD₃OD) δ 7.67 (d, J=8.4 Hz, 2H), 7.56 (s, 1H), 7.30 (dd, J=8.4, 1.5 Hz,1H), 7.20 (d, J=2.4 Hz, 1H), 7.14 (dd, J=8.7, 2.4 Hz, 1H), 4.18-3.99 (m,3H), 3.76-3.65 (m, 2H), 2.75 (dt, J=10.8, 7.2 Hz, 4H), 1.80-1.70 (m,2H), 1.62-1.52 (m, 2H).

Preparation of3,5-Diamino-6-chloro-N-(N-{4-[6-(2,3-dihydropropoxy)naphthalen-2-yl]butyl}carbamimidoyl)pyrazine-2-carboxamide(33)

To a solution of 3-[6-(4-aminobutyl)naphthalen-2-yloxy]propane-1,2-diol(32, 51 mg, 0.2 mmole) and methyl3,5-diamino-6-chloropyrazine-2-carbonylcarbamimidothioate (10, 103 mg,0.3 mmole) in EtOH (2 mL) was added diisopropylethylamine (0.2 mL, 1.1mmole) at room temperature. The reaction mixture was heated at 70° C. ina sealed tube for 7 h, then cooled to room temperature, and concentratedin vacuo. The residue was purified by column chromatography (silica gel,80:18:2 CHCl₃/CH₃OH/NH₄OH) to afford carboxamide 33 (34 mg, 68%) as ayellow solid: ¹H NMR (300 MHz, CD₃OD) δ 7.67 (d, J=8.7 Hz, 2H), 7.56 (s,1H), 7.30 (dd, J=8.4, 1.5 Hz, 1H), 7.19 (d, J=2.4 Hz, 1H), 7.13 (dd,J=9.0, 2.4 Hz, 1H), 4.22-3.99 (m, 3H), 3.76-3.65 (m, 2H), 3.25-3.23 (m,2H), 2.79 (t, J=7.2 Hz, 2H), 1.84-1.65 (m, 4H).

Preparation of3,5-Diamino-6-chloro-N-(N-{4-[6-(2,3-dihydropropoxy)naphthalen-2-yl]butyl}carbamimidoyl)pyrazine-2-carboxamideMethanesulfonic Acid Salt (34)

To a solution of3,5-diamino-6-chloro-N-(N-{4-[6-(2,3-dihydropropoxy)naphthalen-2-yl]butyl}carbamimidoyl)pyrazine-2-carboxamide(33, 190 mg, 0.4 mmole) in EtOH (10 mL) was added methanesulfonic acid(72.7 mg, 0.8 mmole) at room temperature and the reaction mixture wasstirred for 15 min. The solution was concentrated and the residue wasazeotroped with MeOH. The residue was dissolved in 8:2 MeOH/H₂O (10 mL)and lyophilized to afford methanesulfonic acid salt 34 (185 mg, 81%) asa yellow solid: mp 146-149° C.; ¹H NMR (300 MHz, DMSO-d₆) δ 10.4 (s,1H), 9.14 (br s, 1H), 8.87 (br s, 1H), 8.71 (br s, 1H), 7.74 (d, J=8.7Hz, 2H), 7.62 (s, 1H), 7.44 (br s, 2H), 7.34 (dd, J=8.4, 0.9 Hz, 1H),7.26 (d, J=2.1 Hz, 1H), 7.14 (dd, J=9.0, 2.4 Hz, 1H), 5.76 (s, 1H), 4.09(dd, J=9.9, 4.2 Hz, 1H), 3.98-3.81 (m, 2H), 3.48 (d, J=5.4 Hz, 2H), 3.32(q, J=5.7 Hz, 2H), 2.75 (t, J=7.2 Hz, 2H), 2.34 (s, 6H), 1.72-1.59 (m,4H); ESI-MS m/z 502 [C₂₃H₂₈ClN₇O₄+H]⁺.

Preparation of Benzyl 4-(4-Hydroxynaphthalen-1-yl)butylcarbamate (20)

Tetrabutylammoniumfluoride (1.0 M in THF, 1.1 mL) was added to asolution of benzyl4-[4-(tert-butyldimethylsilyloxy)naphthalen-1-yl]butylcarbamate (19, 500mg, 1.1 mmole) in THF (5 ml) at room temperature. The reaction mixturewas stirred for 2 h. The reaction mixture was concentrated to dryness.The residue was purified by column chromatography (silica gel, 3:1hexanes/EtOAc) to afford carbamate 20 (230 mg, 61%) as a white solid: ¹HNMR (300 MHz, CDCl₃) δ 8.25-8.21 (m, 1H), 7.91 (dd, J=6.6, 1.8 Hz, 1H),7.52-7.43 (m, 2H), 7.35-7.27 (m, 5H), 7.05 (d, J=7.5 Hz, 1H), 6.72 (d,J=7.5 Hz, 1H), 5.10 (s, 2H), 4.75 (br s, 1H), 3.23 (q, J=6.6 Hz, 2H),2.95 (t, J=7.2 Hz, 2H), 1.76-1.56 (m, 4H).

Preparation of tert-Butyl 3-Hydroxypropylcarbamate (67)

To a solution of 3-aminopropanol (66, 5.0 g, 67 mmole) in 1:1 dioxane/2N NaOH (100 mL) was added di-tert-butyl dicarbonate (17.0 g, 80 mmole)in dioxane (10 mL) at 0° C. The reaction mixture was warmed to roomtemperature and stirred for 1 h. The mixture was first acidified to pH 1with concentrated HCl and then neutralized to pH 7 with 2 N NaOH. Themixture was then extracted with EtOAc (3×200 mL). The combined organiclayers were dried over MgSO₄ and concentrated. The residue was purifiedby column chromatography (silica gel, 3:1 hexanes/EtOAc) to affordtert-butyl 3-hydroxypropylcarbamate (67, 11.0 g, 94%) as a light yellowoil: ¹H NMR (300 MHz, CDCl₃) δ 4.80 (br s, 1H), 3.66 (q, J=5.7 Hz, 2H),3.33 (q, J=6.3 Hz, 2H), 2.97 (br s, 1H), 1.71-1.63 (m, 2H), 1.45 (s,9H).

Preparation of Compound (68)

Diisopropylazodicarboxylate (120 mg, 0.59 mmole) was added dropwise to asolution of benzyl 4-(4-hydroxynaphthalen-1-yl)butylcarbamate (20, 206mg, 0.59 mmole), tert-butyl 3-hydroxypropylcarbamate (67, 104 mg, 0.59mmole), and triphenylphosphine (187 mg, 0.71 mmole) in anhydrous THF (5mL) at 0° C. The reaction mixture was warmed to room temperature andstirred for 5 h. The reaction mixture was concentrated and the residuewas purified by column chromatography (silica gel, 2:1 hexanes/EtOAc) toafford a mixture of ether 68 and hydrazine byproduct (630 mg) which wasused in the next step without further purification.

Preparation of tert-Butyl3-[4-(4-Aminobutyl)naphthalene-1-yloxy]propylcarbamate (69)

A suspension of mixture 68 (630 mg) and 10% Pd/C (300 mg) in MeOH (25mL) was subject to hydrogenation conditions (1 atm) for 1 h at roomtemperature. The reaction mixture was filtered through a plug ofdiatomaceous earth and the plug was washed with MeOH. The filtrate wasconcentrated in vacuo and the residue was purified by columnchromatography (silica gel, 80:18:2 CHCl₃/CH₃OH/NH₄OH) to affordcarbamate 69 (260 mg, 68% over two steps) as a white solid: ¹NMR (300MHz, CD₃OD) δ 8.28 (dd, J=8.4, 1.2 Hz, 1H), 7.98 (d, J=8.1 Hz, 1H),7.55-7.42 (m, 2H), 7.22 (d, J=7.8 Hz, 1H), 6.79 (d, J=8.1 Hz, 1H), 4.15(t, J=6.0 Hz, 2H), 3.32-3.30 (m, 2H), 3.05 (t, J=6.9 Hz, 2H), 2.90 (t,J=7.5 Hz, 2H), 2.11-2.03 (m, 2H), 1.79-1.68 (m, 4H), 1.42 (s, 9H).

Preparation of tert-Butyl3-{4-[4-(3-(3,5-Diamino-6-chloropyrazine-2-carbonyl)guanidine)butyl]naphthalen-1-yloxy}propylcarbamate(70)

To a solution of tert-butyl3-[4-(4-aminobutyl)naphthalene-1-yloxy]propylcarbamate (69, 350 mg, 0.94mmole) and methyl3,5-diamino-6-chloropyrazine-2-carbonylcarbamimidothioate (10, 600 mg,1.41 mmole) in EtOH (20 mL) was added diisopropylethylamine (1.6 mL, 5.2mmole) at room temperature. The reaction mixture was heated at 70° C. ina sealed tube for 7 h, cooled to room temperature and concentrated todryness. The residue was dissolved in CHCl₃ (300 mL) and washed withsaturated NaHCO₃ (2×200 mL). The organic layer was dried over MgSO₄,filtered, and concentrated. The residue was purified by columnchromatography (silica gel, 90:9:1 CHCl₃/CH₃OH/NH₄OH) to affordcarbamate 70 (350 mg, 64%) as a light yellow solid: ¹H NMR (300 MHz,CD₃OD) δ 8.27 (dd, J=8.1, 0.9 Hz, 1H), 7.99 (d, J=8.1 Hz, 1H), 7.50 (td,J=6.6, 1.2 Hz, 1H), 7.42 (td, J=6.6, 1.2 Hz, 1H), 7.23 (d, J=7.8 Hz,1H), 6.80 (d, J=7.8 Hz, 1H), 4.17 (t, J=6.0 Hz, 2H), 3.66-3.54 (m, 2H),3.16-3.05 (m, 4H), 2.12-2.03 (m, 2H), 1.84-1.76 (m, 4H), 1.41 (s, 9H).

Preparation of3,5-Diamino-N-(N-{4-[4-(3-aminopropoxy)naphthalen-1-yl]butyl}carbamimidoyl)-6-chloropyrazine-2-carboxamide(71)

To a solution of carbamate 70 (350 mg, 0.6 mmole) in CH₂Cl₂ (35 mL) wasadded dropwise trifluoroacetic acid (2.0 mL) at room temperature. Thereaction mixture was stirred for 3 h. The reaction mixture wasconcentrated in vacuo and azeotroped with MeOH (2×100 mL). The residuewas dissolved in water and the solution was neutralized with saturatedNaHCO₃ which resulted in the precipitation of carboxamide 71. Compound71 was collected by filtration and purified by column chromatography(silica gel, 80:18:2 CHCl₃/CH₃OH/NH₄OH) to afford amine 71 (185 mg, 64%)as an off-white solid: ¹H NMR (300 MHz, CD₃OD) δ 8.23 (dd, J=8.1, 0.6Hz, 1H), 7.99 (d, J=8.1 Hz, 1H), 7.50 (td, J=6.9, 1.5 Hz, 1H), 7.41 (td,J=6.9, 1.2 Hz, 1H), 7.22 (d, J=7.8 Hz, 1H), 6.81 (d, J=7.8 Hz, 1H), 4.20(t, J=6.3 Hz, 2H), 3.25 (t, J=6.3 Hz, 2H), 3.05 (t, J=6.9 Hz, 2H), 2.97(t, J=6.9 Hz, 2H), 2.14-2.05 (m, 2H), 1.89-1.69 (m, 4H).

Preparation of3,5-Diamino-N-(N-[4-{4-(3-aminopropoxy)naphthalen-1-yl]butyl}carbamimidoyl)-6-chloropyrazine-2-carboxamideMethanesulfonic Acid Salt (72)

To a solution of carboxamide 71 (120 mg, 0.247 mmole) in EtOH (10 mL)was added methanesulfonic acid (48 mg, 0.495 mmole) at room temperatureand the reaction mixture was stirred for 15 min. The solvent was removedin vacuo. The residue was dissolved in water (10 mL) and lyophilized toafford methanesulfonic acid salt 72 (160 mg, 95%) as a yellow solid: ¹HNMR (300 MHz, DMSO-d₆) δ 10.44 (s, 1H), 9.15 (br s, 1H), 8.86 (br s,1H), 8.72 (br s, 1H), 8.22 (dd, J=8.1, 0.9, Hz, 1H), 8.03 (d, J=8.1 Hz,1H), 7.80 (br s, 4H), 7.61-7.49 (m, 3H), 7.42 (br s, 2H), 7.28 (d, J=7.8Hz, 1H), 6.89 (d, J=7.8 Hz, 1H), 4.22 (t, J=5.7 Hz, 2H), 3.35-3.33 (m,2H), 3.17-2.99 (m, 4H), 2.32 (s, 6H), 2.20-2.10 (m, 2H), 1.68 (br s,4H); ESI-MS m/z 485 [C₂₃H₂₉ClN₈O₂+H]⁺.

Preparation of Compound (74)

To a solution of amine 71 (60 mg, 0.12 mmole) and Goodman's reagent 73(100 mg, 0.19 mmole) in MeOH (10 mL) was added diisopropylethylamine(0.2 mL, 1.0 mmole) at room temperature. The reaction mixture wasstirred for 6 h and then concentrated. The residue was dissolved inCHCl₃ (100 mL) and washed with saturated NaHCO₃ (2×100 mL). The organiclayer was dried over MgSO₄, filtered, and concentrated. The residue waspurified by column chromatography (silica gel, 90:9:1 CHCl₃/CH₃OH/NH₄OH)to afford 74 (82 mg, 92%) as a light yellow solid: ¹H NMR (300 MHz,CD₃OD) δ 8.26 (dd, J=8.1, 0.9 Hz, 1H), 7.96 (d, J=8.1 Hz, 1H), 7.48 (td,J=6.6, 1.2 Hz, 1H), 7.41 (td, J=6.9, 1.2 Hz, 1H), 7.19 (d, J=7.8 Hz,1H), 6.77 (d, J=7.8 Hz, 1H), 4.19 (t, J=5.7 Hz, 2H), 3.65 (t, J=6.6 Hz,2H), 3.25 (t, J=6.6 Hz, 2H), 3.01 (t, J=7.2 Hz, 2H), 2.22-2.14 (m, 2H),1.82-1.65 (m, 4H), 1.41 (s, 9H), 1.42 (s, 9H).

Preparation of Compound (75)

To a solution of compound 74 (130 mg, 0.18 mmole) in CH₂Cl₂ (20 mL) wasadded dropwise trifluoroacetic acid (2.5 mL) at room temperature. Thereaction mixture was stirred for 6 h and the solvent was removed invacuo. The residue was dissolved in water (10 mL) and the solution wasbasified to pH 10 with 2 N NaOH which resulted in the precipitation ofcrude 75. Compound 75 was collected by filtration and purified by columnchromatography (silica gel, 6:3:1 CHCl₃/CH₃OH/NH₄OH) to afford compound75 (48 mg, 51%) as a light yellow solid: ¹H NMR (300 MHz, CD₃OD) δ 8.27(dd, J=8.1, 0.9 Hz, 1H), 8.01 (d, J=8.1 Hz, 1H), 7.53 (td, J=6.9, 1.5Hz, 1H), 7.45 (td, J=6.9, 1.2 Hz, 1H), 7.26 (d, J=7.8 Hz, 1H), 6.85 (d,J=7.8 Hz, 1H), 4.24 (t, J=6.0 Hz, 2H), 3.51 (t, J=6.9 Hz, 2H), 3.35-3.33(m, 2H), 3.08 (t, J=6.9 Hz, 2H), 2.24-2.19 (m, 2H), 1.84-1.80 (m, 4H).

Preparation of Methanesulfonic Acid Salt (76)

To a solution of compound 75 (48 mg, 0.09 mmole) in EtOH (5 mL) wasadded CH₃SO₃H (17.5 mg, 0.18 mmole) at room temperature and the reactionmixture was stirred for 15 min. The solvent was removed in vacuo. Theresidue was dissolved in water (5 mL) and lyophilized to affordmethanesulfonic salt 76 (60 mg, 90%) as a yellow solid: mp 85-87° C.; ¹HNMR (300 MHz, DMSO-d₆) δ 10.44 (s, 1H), 9.15 (br s, 1H), 8.86 (br s,1H), 8.70 (br s, 1H), 8.24 (dd, J=8.1, 1.5 Hz, 1H), 8.03 (d, J=8.4 Hz,1H), 7.66-7.42 (m, 6H), 7.42 (br s 2H), 7.28 (d, J=6.9 Hz, 2H), 7.10 (s,1H), 6.90 (t, J=6.0 Hz, 2H), 4.18 (t, J=6.0 Hz, 2H), 3.43-3.33 (m, 4H),3.01 (t, J=6.9 Hz, 2H), 2.33 (s, 9H), 2.11-2.06 (m, 2H), 1.68 (br s,4H); ESI-MS m/z 528 [C₂₄H₃₁ClN₁₀O₂+H]⁺.

Preparation of4-[6-(tert-Butyldimethylsilyloxy)naphthalen-2-yl]butan-1-amine (77)

A suspension of crude 29 (900 mg) and 10% Pd/C (400 mg) in MeOH (50 mL)was subject to hydrogenation conditions (1 atm) for 6 h at roomtemperature. The reaction mixture was filtered through a plug ofdiatomaceous earth and the plug was washed with MeOH. The filtrate wasconcentrated in vacuo and the residue was purified by columnchromatography (silica gel, 80:18:2 CHCl₃/CH₃OH/NH₄OH) to afford amine77 (405 mg, 27% over two steps) as a white solid: ¹H NMR (300 MHz,CDCl₃) δ 7.62 (t, J=8.9, 2H), 7.52 (br s, 1H), 7.26 (dd, J=8.4, 1.7 Hz,1H), 7.15 (d, J=2.2 Hz, 1H), 7.04 (dd, J=8.8, 2.5 Hz, 1H), 3.03-2.37 (brs, 1H), 2.74 (t, J=7.5 Hz, 2H), 1.78-1.65 (m, 2H), 1.58-1.47 (m, 2H),1.01 (s, 9H), 0.23 (s, 6H).

Preparation of3,5-Diamino-N-(N-{4-[6-(tert-butyldimethylsilyloxy)naphthalen-2-yl]butyl}carbamimidoyl)-6-chloropyrazine-2-carboxamide(78)

To a solution of amine 77 (337 mg, 1.02 mmole) and methyl3,5-diamino-6-chloropyrazine-2-carbonylcarbamimidothioate (10, 596 mg,1.53 mmole) in EtOH (20 mL) was added diisopropylethylamine (1.06 mL,6.13 mmole) at room temperature. The reaction mixture was heated at 70°C. in a sealed tube for 6 h, then cooled to room temperature, andconcentrated to dryness. The residue was purified by columnchromatography (silica gel, 80:18:2 CHCl₃/CH₃OH/NH₄OH) to affordcarboxamide 78 (280 mg, 50%) as a light yellow solid: ¹H NMR (300 MHz,CD₃OD) δ 7.67 (d, J=9.2 Hz, 1H), 7.63 (d, J=8.6 Hz, 1H), 7.57 (br s,1H), 7.30 (d, J=8.1 Hz, 1H), 7.14 (br s, 1H), 7.03 (dd, J=9.2, 1.7 Hz,1H), 3.30 (m, 2H), 2.81 (t, J=7.0 Hz, 2H), 1.95-1.62 (m, 4H), 1.03 (s,9H), 0.24 (s, 6H).

Preparation of3,5-Diamino-6-chloro-N-{N-[4-(6-hydroxynaphthalen-2-yl)butyl]carbamimidoyl}pyrazine-2-carboxamide(79)

To a solution of carboxamide 78 (24 mg, 0.05 mmol) in absolute ethanol(5 mL) was added dropwise 1 N HCl (2 mL) at room temperature and themixture was stirred for 12 h. The reaction mixture was neutralized withsaturated NaHCO₃ and compound 79 precipitated out. Compound 79 wascollected by filtration and washed with water (2×10 mL) and hexanes(2×10 mL) to afford3,5-diamino-6-chloro-N-{N-[4-(6-hydroxynaphthalen-2-yl)butyl]carbamimidoyl}pyrazine-2-carboxamide(79, 10 mg, 53%), after air-drying, as a light yellow solid: ¹11NMR (300MHz, CD₃OD) δ 7.63-7.53 (m, 3H), 7.26 (dd, J=8.3, 1.5 Hz, 1H), 7.07-6.98(m, 2H), 3.36-3.30 (m, 2H), 2.80

Preparation of (6-Bromonaphthalen-2-yloxy)(tert-Butyl)dimethylsilane(81);

A solution of 6-bromonaphthalen-2-ol (12.0 g, 53.7 mmol) and imidazole(6.0 g, 79.5 mmol) in DMF (12.0 mL) was added t-butyldimethylsilylchloride (TBDMSC1) (9.0 g, 59.0 mmol) in one portion at 0° C. Themixture was allowed to warm to room temperature and stirred for 3 h. Thereaction mixture was partitioned between EtOAc (500 mL) and water (300mL) The aqueous layer was separated and extracted with EtOAc (2×100 mL)and the combined organic extracts were washed with brine (300 mL), driedover Na₂SO₄, filtered, and concentrated. The residue was purified bycolumn chromatography (silica gel, hexanes) to afford(6-bromonaphthalen-2-yloxy)(tert-butyl)dimethylsilane (81, 18.0 g, 98%)as a white solid: ¹H NMR (300 MHz, CDCl₃) δ 7.91 (d, J=1.8 Hz, 1H), 7.64(d, J=8.7 Hz, 1H), 7.56 (d, J=8.7 Hz, 1H), 7.48 (dd, J=8.7, 1.8 Hz, 1H),7.15 (d, J=2.4 Hz, 1H), 7.09 (dd, J=9.0, 2.4 Hz, 1H), 1.01 (s, 9H), 0.24(s, 6H).

Preparation of Benzyl4-[6-(tert-butyldimethylsilyloxy)naphthalen-2-yl]but-3-ynylcarbamate(83)

A solution of (6-bromonaphthalen-2-yloxy)(tert-butyl)dimethylsilane (81,16.1 g, 47.7 mmol), benzyl but-3-ynylcarbamate (82, 9.0 g, 47.7 mmol),and triethylamine (95 mL) in anhydrous THF (100 mL) was cooled to −78°C. and degassed with argon. The mixture was warmed to room temperatureand dichlorobis(triphenylphosphine)palladium(II) (3.3 g, 4.8 mmol) andCuI (1.8 g, 9.6 mmol) were added rapidly in one portion under argon. Themixture was heated at 50° C. for 12 h. The reaction mixture was filteredthrough a plug of diatomaceous earth and the filtrate was concentrated.The residue was purified by column chromatography (silical gel, 10:1hexanes/EtOAc) to afford carbamate 83 (8.5 g, 38%) as a thick brown oil:¹H NMR (300 MHz, CDCl₃) δ 7.83 (s, 1H), 7.65 (d, J=9.0 Hz, 1H), 7.60 (d,J=8.7 Hz, 1H), 7.39-7.29 (m, 6H), 7.13 (d, J=2.1 Hz, 1H), 7.07 (dd,J=8.7, 2.4 Hz, 1H), 5.17 (br s, 1H), 5.13 (s, 2H), 3.46 (q, J=6.3 Hz,2H), 2.67 (t, J=6.3 Hz, 2H), 1.01 (s, 9H), 0.25 (s, 6H).

Preparation of Benzyl 4-(6-hydroxynaphthalen-2-yl)but-3-ynylcarbamate(84)

To a solution of benzyl4-[6-(tert-butyldimethylsilyloxy)naphthalen-2-yl]but-3-ynylcarbamate(83, 2.5 g, 5.44 mmol) in anhydrous THF (25 mL) at 0° C. was addeddropwise tetrabutylammonium fluoride (1 M in THF, 6.0 mL) and themixture was stirred for 2 h at room temperature. The resulting solutionwas concentrated in vacuo and the residue was purified by columnchromatography (silica gel, 95:5 CH₂Cl₂/MeOH) to afford carbamate 84(2.0 g, 50%) as a pale yellow solid: ¹H NMR (300 MHz, CDCl₃) δ 7.82 (s,1H), 7.67 (d, J=9.6 Hz, 1H), 7.58 (d, J=8.4 Hz, 1H), 7.37-7.29 (m, 6H),7.11-7.08 (m, 2H), 5.30 (br s, 2H), 5.14 (s, 2H), 3.48 (q, J=6.3 Hz,2H), 2.68 (t, J=6.6 Hz, 2H).

Preparation of tert-Butyl 3-hydroxypropylcarbamate (66)

To a solution of 3-aminopropanol (55, 5.0 g, 67 mmol) in dioxane/2 NNaOH (1:1, 100 mL) was added a solution of di-tert-butyl dicarbonate(17.0 g, 80 mmol) in dioxane (10 mL) at 0° C. The reaction mixture waswarmed to room temperature and stirred for 1 h. The mixture was firstacidified to pH 1 with concentrated HCl and then neutralized to pH 7with 2 N NaOH. The mixture was then extracted with EtOAc (3×200 mL). Thecombined organic layers were dried over MgSO₄ and concentrated. Theresidue was purified by column chromatography (silica gel, 3:1hexanes/EtOAc) to afford tert-butyl 3-hydroxypropylcarbamate (86, 11.7g, 99%) as a light yellow oil: ¹H NMR (300 MHz, CDCl₃) δ 4.80 (br s,1H), 3.66 (q, J=5.7 Hz, 2H), 3.33 (q, J=6.3 Hz, 2H), 2.97 (br s, 1H),1.71-1.63 (m, 2H), 1.45 (s, 9H).

Preparation of Boc-protected carbamate (87)

Diisopropylazodicarboxylate (557 mg, 2.75 mmol) was added dropwise to asolution of 4-(6-hydroxynaphthalen-2-yl)but-3-ynylcarbamate (84, 638 mg,1.83 mmol), tert-butyl 3-hydroxypropylcarbamate (86, 355 mg, 2.01 mmol),and triphenylphosphine (980 mg, 3.70 mmol) in anhydrous THF (20 mL) at0° C. The reaction mixture was warmed to room temperature and stirredfor 12 h. The reaction mixture was concentrated and the residue waspurified by column chromatography (silica gel, 2:1 hexanes/EtOAc) toafford a mixture of ether 87 and the hydrazine by-product (4.0 g) whichwas used in the next step without further purification.

Preparation of tert-Butyl3-[6-(4-aminobutyl)naphthalen-2-yloxy]propylcarbamate (88)

A suspension of 87 (4.0 g) and 10% Pd/C (500 mg) in MeOH/EtOAc (4:1, 350mL) was subjected to hydrogenation conditions (1 atm) for 6 h at roomtemperature. The reaction mixture was filtered through a plug ofdiatomaceous earth and the plug was washed with MeOH. The filtrate wasconcentrated in vacuo and the residue was purified by columnchromatography (silica gel, 90:9:1 CHCl₃/CH₃OH/NH₄OH) to affordcarbamate 88 (437 mg, 64% over two steps) as a white solid: ¹H NMR (300MHz, CD₃OD) δ 7.70 (dd, J=9.0 Hz, 2H), 7.59 (s, 1H), 7.34-7.31 (m, 1H),7.21 (d, J=2.4 Hz, 1H), 7.12 (d, J=9.0, 2.4 Hz, 1H), 4.13 (t, J=6.0 Hz,2H), 3.30 (t, J=6.3 Hz, 2H), 2.91-2.80 (m, 4H), 2.03-1.99 (m, 2H),1.90-1.60 (m, 4H), 1.46 (s, 9H).

Preparation of tert-Butyl3-(6-{4-[3-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidino]butyl}naphthalen-2-yloxy)propylcarbamate(89)

To a solution of carbamate 88 (500 mg, 1.34 mmol) and methyl3,5-diamino-6-chloropyrazine-2-carbonylcarbamimidothioate (10, 790 mg,2.01 mmol) in EtOH (30 mL) was added DIPEA (1.75 mL, 9.39 mmol) at roomtemperature. The reaction mixture was heated at 70° C. in a sealed tubefor 2 h, then cooled to room temperature, and concentrated in vacuo. Theresidue was purified by column chromatography (silica gel, 90:9:1CHCl₃/CH₃OH/NH₄OH) to afford carbamate 89 (660 mg, 84%) as a yellowsolid: ¹H NMR (300 MHz, CD₃OD) δ 7.65 (d, J=7.5 Hz, 2H), 7.56 (s, 1H),7.31 (dd, J=8.4, 1.5 Hz, 1H), 7.16 (d, J=2.4 Hz, 1H), 7.08 (dd, J=8.7,2.4 Hz, 1H), 4.10 (t, J=6.3 Hz, 2H), 2.81 (t, J=6.6 Hz, 2H), 2.01-1.97(m, 2H), 1.83-1.60 (m, 4H), 1.43 (s, 9H).

Preparation of3,5-Diamino-N-(N-{4-[6-(3-aminopropoxy)naphthalen-2-yl]butyl}carbainimidoyl-6-chloropyrazine-2-carboxamide(90)

To a solution of compound 89 (725 mg, 1.24 mmol) in CH₂Cl₂ (45 mL) wasadded dropwise trifluoroacetic acid (6.0 mL) at room temperature. Thereaction mixture was stirred for 4 h and the solvent was removed invacuo. The residue was dissolved in water (10 mL) and the solution wasbasified to pH 7 with saturated NaHCO₃ which resulted in theprecipitation of crude 20. This was filtered and purified by columnchromatography (silica gel, 80:18:2 CHCl₃/CH₃OH/NH₄OH) to affordcompound 90 (289 mg, 48%) as a light yellow solid: ¹H NMR (300 MHz,CD₃OD) δ 7.65 (d, J=7.5 Hz, 2H), 7.56 (s, 1H), 7.31 (dd, J=8.4, 1.5 Hz,1H), 7.16 (d, J=2.4 Hz, 1H), 7.08 (dd, J=8.7, 2.4 Hz, 1H), 4.10 (t,J=6.3 Hz, 2H), 2.81 (t, J=6.6 Hz, 2H), 2.01-1.97 (m, 2H), 1.83-1.60 (m,4H).

Preparation of3,5-Diamino-N-(N-{4-[6-(3-aminopropoxy)naphthalen-2-yl]butyl}carbamimidoyl-6-chloropyrazine-2-carboxamideMethanesulphonate Salt (91)

To a solution of3,5-diamino-N-(N-{4-[6-(3-aminopropoxy)naphthalen-2-yl]butyl}carbamimidoyl-6-chloropyrazine-2-carboxamide(20, 30 mg, 0.062 mmol) in EtOH (5 mL) was added methanesulphonic acid(12.5 mg, 0.13 mmol) at room temperature and the reaction mixture wasstirred for 15 min. The solution was concentrated and the residue wasazeotroped with MeOH. The residue was dissolved in H₂O/MeOH (8:2, 10 mL)and lyophilized to afford methanesulphonate salt 91 (33 mg, 79%) as ayellow solid: ¹H NMR (300 MHz, DMSO-d₆) δ 10.4 (s, 1H), 9.13 (br s, 1H),8.85 (br s, 1H), 8.74 (br s, 1H), 7.76-7.71 (m, 5H), 7.62 (s, 1H),7.50-7.33 (m, 3H), 7.26 (s, 1H), 7.13 (dd, J=8.8, 2.2 Hz, 1H), 4.15 (t,J=6.0 Hz, 5H), 3.32-3.04 (m, 2H), 3.01-2.97 (m, 2H), 2.77-2.72 (m, 2H),2.38 (s, 1H), 2.10-2.01 (m, 2H), 1.74-1.59 (m, 4H); ESI-MS m/z 485[C₂₃H₂₉ClN₈O₂+H]⁺.

Preparation of Boc-urea 92

To a solution of amine 90 (300 mg, 0.62 mmol) and Goodman's reagent (392mg, 1.00 mmol) in MeOH (60 mL) was added DIPEA (0.45 mL, 2.5 mmol) atroom temperature. The reaction mixture was stirred for 7 h and thenconcentrated. The residue was dissolved in CHCl₃ (200 mL) and washedwith saturated NaHCO₃ (2×100 mL). The organic layer was dried overMgSO₄, filtered, and concentrated. The residue was purified by columnchromatography (silica gel, 90:9:1 CHCl₃/CH₃OH/NH₄OH) to afford Boc-urea92 (280 mg, 62%) as a light yellow solid: ¹H NMR (300 MHz, CD₃OD) δ 7.67(t, J=7.8 Hz, 2H), 7.57 (s, 1H), 7.31 (d, J=8.1 Hz, 1H), 7.19 (s, 2H),4.18 (t, J=5.4 Hz, 2H), 3.62 (t, J=6.0 Hz, 2H), 2.82 (t, J=6.3 Hz, 2H),2.12 (t, J=5.7 Hz, 2H), 1.85-1.70 (m, 4H), 1.54 (s, 9H), 1.45 (s, 9H).

Preparation of Urea 93

To a solution of Boc-urea 92 (280 mg, 0.39 mmol) in CH₂Cl₂ (30 mL) wasadded dropwise trifluoroacetic acid (6.0 mL) at room temperature. Thereaction mixture was stirred for 4 h and the solvent was removed invacuo. The residue was dissolved in water (10 mL) and the solution wasbasified to pH 10 with 2 N NaOH which resulted in the precipitation ofcrude 23. This was filtered and purified by column chromatography(silica gel, 6:3:1 CHCl₃/CH₃OH/NH₄OH) to afford urea 93 (99 mg, 49%) asa light yellow solid: ¹H NMR (300 MHz, CD₃OD) δ 7.66 (dd, J=4.5, 8.1 Hz,2H), 7.57 (s, 1H), 7.32 (d, J=8.1 Hz, 1H), 7.20 (s, 1H), 7.10 (dd,J=2.4, 8.7 Hz, 1H), 4.17 (t, J=5.7 Hz, 2H), 3.43 (t, J=6.6 Hz, 2H), 2.82(t, J=6.3 Hz, 2H), 2.16-2.08 (m, 2H), 1.84-1.70 (m, 4H).

Preparation of Methanesulphonate Salt 94

To a solution of compound 93 (99 mg, 0.19 mmol) in EtOH (6 mL) was addedCH₃SO₃H (36 mg, 0.40 mmol) at room temperature and the reaction mixturewas stirred for 15 min. The solvent was removed in vacuo. The residuewas dissolved in water (5 mL) and lyophilized to affordmethanesulphonate salt 94 (115 mg, 85%) as a yellow solid: ¹H NMR (300MHz, DMSO-d₆) δ 10.42 (s, 1H), 9.12 (br s, 1H), 8.85 (br s, 1H), 8.68(br s, 1H), 7.76-6.90 (m, 16H), 4.10 (t, J=5.4 Hz, 2H), 3.31 (d, J=5.4Hz, 4H), 2.74-2.71 (m, 2H), 2.30 (s, 6H), 2.07-1.96 (m, 2H), 1.71-1.59(m, 4H); ESI-MS m/z 527 [C₂₄H₃₁ClN₁₀O₂+H]⁺.

Preparation of Benzyl4-[6-(tert-butyldimethylsilyloxy)naphthalen-2-yl]butan-1-amine (95)

A suspension of 83 (8.0 g, 17.41 mmol) and 10% Pd/C (3.6 g) in MeOH (240mL) was subjected to hydrogenation conditions (1 atm) for 6 h at roomtemperature. The reaction mixture was filtered through a plug ofdiatomaceous earth and the plug was washed with MeOH. The filtrate wasconcentrated in vacuo and the residue was purified by columnchromatography (silica gel, 90:9:1 CHCl₃/CH₃OH/NH₄OH) to afford amine 95(3.2 g, 56%) as a yellow solid: ¹H NMR (300 MHz, CD₃OD) δ 7.64 (d, J=6.3Hz, 1H), 7.60 (s, 1H), 7.55 (s, 1H), 7.30 (d, J=1.5 Hz, 1H), 7.15 (s,1H), 7.03 (dd, J=8.9 Hz, 2.3 Hz, 1H), 2.76 (t, J=7.4 Hz, 2H), 2.70 (t,J=7.2 Hz, 2H), 1.79-1.69 (m, 2H), 1.59-1.49 (m, 2H), 1.04 (s, 9H), 0.25(s, 6H).

Preparation of Benzyl4-[6-(tert-butyldimethylsilyloxy)naphthalen-2-yl]carbamate (96)

To a solution of amine 95 (3.2 g, 9.7 mmol) in CH₂Cl₂/saturated aqueousNaHCO₃ (1:1, 135 mL), benzyl chloroformate (2.1 mL) was added dropwiseat room temperature and the reaction mixture was stirred for 2 h. Themixture was concentrated, the residue was dissolved in EtOAc (500 mL),and the solution was washed with water (300 mL) and brine (300 mL). Theorganic layer was dried over Na₂SO₄, filtered, and concentrated. Theresidue was purified by column chromatography (silica gel, 4:1hexanes/EtOAc) to afford carbamate 96 (4.0 g, 89%) as a light yellowsolid: ¹H NMR (300 MHz, CD₃OD) δ 7.64 (d, J=6.3 Hz, 1H), 7.60 (s, 1H),7.55 (s, 1H), 7.37-7.26 (m, 6H), 7.15 (s, 1H), 7.03 (dd, J=8.9 Hz, 2.3Hz, 1H), 5.10 (s, 1H), 2.77 (t, J=7.4 Hz, 2H), 2.70 (t, J=7.2 Hz, 2H),1.79-1.69 (m, 2H), 1.59-1.49 (m, 2H), 1.04 (s, 9H), 0.25 (s, 6H).

Preparation of Benzyl 4-[6-(hydroxynaphthalen-2-yl)]carbamate (97)

To a solution of carbamate 96 (4.0 g, 6.47 mmol) in THF (30 mL) wasadded dropwise tetrabutylammonium fluoride (1 M in THF, 7.2 mL, 7.2mmol) at room temperature. The reaction mixture was stirred for 2 h andthe solvent was removed in vacuo. The residue was purified by columnchromatography (silica gel, 7:3 hexanes/EtOAc) to afford compound 97(2.1 g, 70%) as a light yellow solid: ¹H NMR (300 MHz, CDCl₃) δ 7.63 (d,J=8.7 Hz, 1H), 7.56 (d, J=8.4 Hz, 1H), 7.48 (s, 1H), 7.37-7.26 (m, 5H),7.21 (dd, J=8.5 Hz, 1.3 Hz, 1H), 7.11 (d, J=2.1 Hz, 1H), 7.08 (d, J=2.4Hz, 1H), 7.05 (d, J=2.4 Hz, 1H), 5.10 (s, 2H), 4.75 (br, 1H), 3.23 (q,J=6.5 Hz, 2H), 2.72 (t, J=7.5 Hz, 2H), 1.75-1.65 (m, 2H), 1.60-1.47 (m,2H).

Preparation of Ether 98

Diisopropylazodicarboxylate (2.45 g, 12.0 mmol) was added dropwise to asolution of benzyl 4-(6-hydroxynaphthalen-2-yl)carbamate (97, 2.1 g, 6.0mmol), tert-butyl 3-hydroxypropylcarbamate (86, 2.1 g, 12.0 mmol), andtriphenylphosphine (4.8 g, 18.0 mmol) in anhydrous THF (63 mL) at 0° C.The reaction mixture was warmed to room temperature and stirred for 12h. The reaction mixture was concentrated and the residue was purified bycolumn chromatography (silica gel, 7:3 hexanes/EtOAc) to afford amixture of ether 98 and the hydrazine by-product (3.0 g) which was usedin the next step without further purification.

Preparation of Amine 29

To a solution of compound 98 (5.5 g, 11.0 mmol) in CH₂Cl₂ (350 mL) wasadded dropwise trifluoroacetic acid (84 mL) at room temperature. Thereaction mixture was stirred for 2 h and the solvent was removed invacuo. The residue was dissolved in CHCl₃ (300 mL) and washed withsaturated aqueous NaHCO₃, the organic layer was dried over MgSO₄,filtered, concentrated in vacuo, and purified by column chromatography(silica gel, 90:9:1 CHCl₃/CH₃OH/NH₄OH) to afford compound 99 (1.74 g,71% over two steps) as a light

yellow solid: ¹H NMR (300 MHz, CD₃OD) δ 7.65 (d, J=8.4 Hz, 2H), 7.53 (s,1H), 7.31-7.26 (m, 6H), 7.19 (s, 1H), 7.08 (dd, J=8.7 Hz, 2.4 Hz, 1H),5.05 (s, 2H), 4.17 (t, J=6.0 Hz, 2H), 3.15 (t, J=6.9 Hz, 2H), 2.96 (t,J=6.9 Hz, 2H), 2.73 (t, J=7.5 Hz, 2H), 2.09-2.00 (m, 2H), 1.80-1.65 (m,2H), 1.59-1.49 (m, 2H).

Preparation of Benzyl4-[6-(3-{(2S,3R)-2,3-dihydroxy-3-[(4R,5R)-5-hydroxy-2-methyl-1,3-dioxan-4-yl]propylamino}propoxy)naphthalene-2-yl]carbamate(101)

A solution of carbamate 99 (1.74 g, 4.28 mmol), triol 100 (922 mg, 4.28mmol), and sodium triacetoxyborohydride (1.43 g, 6.42 mmol) in CH₂Cl₂(18 mL) was stirred at room temperature for 8 h. The reaction mixturewas concentrated to dryness and the residue was purified by columnchromatography (silica gel, 86:12.5:1.5 CH₂Cl₂/CH₃OH/NH₄OH) to affordcarbamate 101 (508 mg, 20%) as an white gummy solid: ¹H NMR (300 MHz,CD₃OD) δ 7.65 (d, J=8.4 Hz, 2H), 7.53 (s, 1H), 7.31-7.26 (m, 6H), 7.19(s, 1H), 7.11 (dd, J=9.0 Hz, 2.4 Hz, 1H), 5.05 (s, 2H), 4.67 (q, J=4.9Hz, 1H), 4.18 (t, J=6.0 Hz, 2H), 4.07-3.94 (m, 2H), 3.82-3.74 (m, 2H),3.46 (dd, J=9.3 Hz, 2.1 Hz, 1H), 3.37 (d, J=10.5 Hz, 1H), 3.15 (t, J=6.9Hz, 2H), 3.08-2.72 (m, 6H), 2.13-2.04 (m, 2H), 1.75-1.66 (m, 2H),1.59-1.52 (m, 2H), 1.25 (d, J=5.1 Hz, 3H).

Preparation of Benzyl4-{6-[3-(bis{(2S,3R)-2,3-dihydroxy-3-[(4R,5R)-5-hydroxy-2-methyl-1,3-dioxan-4-yl]propyl}amino)propoxy]naphthalene-2-yl}carbamate(102)

A solution of carbamate 101 (368 mg, 0.62 mmol), triol 100 (675 mg, 3.10mmol), sodium cyanoborohydride (338 mg, 4.96 mmol), and HOAc (290 mg,4.96 mmol) in MeOH (15 mL) was stirred at room temperature for 7 d. Thereaction mixture was concentrated to dryness; the residue was washedwith saturated NaHCO₃, and extracted with EtOAc (3×200 mL). The organiclayers was dried over MgSO₄, filtered, concentrated, and purified bycolumn chromatography (silica gel, 80:18:2 CH₂Cl₂/CH₃OH/NH₄OH) to affordcarbamate 102 (318 mg, 65%) as an white gummy solid: ¹H NMR (300 MHz,CD₃OD) δ 7.67 (d, J=8.4 Hz, 2H), 7.54 (s, 1H), 7.31-7.27 (m, 6H), 7.21(s, 1H), 7.11 (dd, J=9.0 Hz, 2.4 Hz, 1H), 5.06 (s, 2H), 4.48 (q, J=5.0Hz, 2H), 4.17 (t, J=5.7 Hz, 2H), 3.98 (dd, J=10.5 Hz, 5.4 Hz, 2H),3.92-3.87 (m, 2H), 3.79-3.72 (m, 4H), 3.35 (d, J=2.1 Hz, 2H), 3.23 (t,J=10.5 Hz, 2H), 3.15 (t, J=6.9 Hz, 2H), 2.82-2.84 (m, 2H), 2.77-2.72 (m,4H), 2.67-2.60 (m, 2H), 2.03-1.99 (m, 2H), 1.76-1.66 (m, 2H), 1.59-1.52(m, 2H), 1.20 (d, J=5.1 Hz, 6H).

Preparation of(R,R,1R,1′R,2S,2′S)-3,3′-{3-[6-(4-Aminobutyl)naphthalene-2-yloxy]propylazanediyl}bis{1-[(4R,5R)-5-hydroxy-2-methyl-1,3-dioxan-4-yl]propane-1,2-diol}(103)

A suspension of carbamate 102 (318 mg) and 10% Pd/C (300 mg) in MeOH (15mL) was subjected to hydrogenation conditions (1 atm) for 2 h at roomtemperature. The reaction mixture was filtered through a plug ofdiatomaceous earth and the plug was washed with MeOH. The filtrate wasconcentrated in vacuo and the residue was purified by columnchromatography (silica gel, 80:18:2 CHCl₃/CH₃OH/NH₄OH) to afford amine103 (212 mg, 80%) as a white solid: ¹H NMR (300 MHz, CD₃OD) δ 7.68 (d,J=7.2 Hz, 2H), 7.56 (s, 1H), 7.30 (d, J=8.1 Hz, 1H), 7.21 (s, 1H), 7.11(d, J=8.7 Hz, 1H), 4.50-4.49 (m, 2H), 4.17-4.15 (m, 2H), 4.02-3.96 (m,2H), 3.88 (br s, 2H), 3.79-3.78 (m, 4H), 3.36-3.35 (m, 2H), 7.22 (d,J=10.5 Hz, 2H), 2.80-2.58 (m, 10H), 2.10-1.90 (m, 2H), 1.75-1.73 (m,2H), 1.65-1.45 (m, 2H), 1.22-1.20 (m, 6H).

Preparation of Carboxamide 104

To a solution of amine 103 (212 mg, 0.33 mmol) and methyl3,5-diamino-6-chloropyrazine-2-carbonylcarbamimidothioate (10, 202 mg,0.52 mmol) in EtOH (15 mL) was added DIPEA (0.40 mL, 2.28 mmol) at roomtemperature. The reaction mixture was heated at 70° C. in a sealed tubefor 2 h, then cooled to room temperature, and concentrated in vacuo. Theresidue was purified by column chromatography (silica gel, 80:18:2CHCl₃/CH₃OH/NH₄OH) to afford carboxamide 104 (120 mg, 43%) as a yellowsolid: ¹H NMR (300 MHz, CD₃OD) δ 7.69-7.65 (m, 2H), 7.57 (s, 1H), 7.30(d, J=8.1 Hz, 1H), 7.19 (s, 1H), 7.10 (dd, J=9.0 Hz, 2.4 Hz, 1H), 4.50(q, J=4.8 Hz, 2H), 4.16-4.15 (m, 2H), 4.02-3.96 (m, 2H), 3.90-3.86 (m,2H), 3.80-3.72 (m, 4H), 3.36-3.20 (m, 6H), 2.83-2.58 (m, 8H), 2.02-1.98(m, 2H), 1.82-1.79 (m, 2H), 1.71-1.69 (m, 2H), 1.21-1.16 (m, 6H).

Preparation of Carboxamide Lactate Salt 105

To a solution of carboxamide 104 (120 mg, 0.14 mmol) in EtOH (5 mL) wasadded lactic acid (27 mg, 0.30 mmol) at room temperature and thereaction mixture was stirred for 15 min. The solution was concentratedand the residue was azeotroped with MeOH. The residue was dissolved inH₂O/MeOH (8:2, 10 mL) and lyophilized to afford lactate salt 105 (147mg, >99%) as a yellow solid: ¹H NMR (300 MHz, DMSO-d₆) δ 7.74 (d, J=8.1Hz, 2H), 7.63 (s, 1H), 7.34 (d, J=8.4 Hz, 1H), 7.27 (s, 1H), 7.19 (s,1H), 7.12 (dd, J=9.0 Hz, 2.1 Hz, 1H), 5.14-5.06 (m, 1H), 4.90 (q, J=7.0Hz, 1H), 4.60 (q, J=5.0 Hz, 2H), 4.23-4.13 (m, 3H), 4.03-3.91 (m, 4H),3.78-3.77 (m, 2H), 3.70-3.62 (m, 5H), 3.38-3.19 (m, 13H), 2.78-2.58 (m,8H), 1.97-1.93 (m, 2H), 1.73-1.71 (m, 2H), 1.56-1.62 (m, 2H), 1.47 (d,J=6.9 Hz, 1H), 1.40 (d, J=7.0 Hz, 2H), 1.30 (d, J=6.9 Hz, 2H), 1.23 (d,J=6.9 Hz, 6H), 1.17 (d, J=5.1 Hz, 6H); ESI-MS m/z 887[C₃₉H₅₇ClN₈O₁₂+Na]⁺.

Alternate Synthesis ofN-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-N-{4-[4-(3-guanidino-propoxy)-naphthalen-1-yl]-butyl}-guanidine75 1. {3-[4-(4-Azido-but-1-enyl)-naphthalen-1-yloxy]-propyl}-carbamicacid tert-butyl ester

a. [3-(4-formyl-naphthalen-1-yloxy)-propyl]-carbamic acid tert-butylester

-   -   To a solution of 4-hydroxy-naphthalene-1-carbaldehyde (15.2 g,        58.1 mmol) in DMF (50 mL) at r.t. was added N-Boc        3-bromo-propylamine (15.2 g, 63.9 mmol), followed by potassium        carbonate (12 g, 87.2 mmol). The reaction mixture was stirred at        room temperature overnight. Water was added to the reaction        mixture and extracted by CH₂Cl₂. The combined organic layers        were washed with water, brine, dried over MgSO₄, filtered, and        concentrated. The residue was recrystallized from EtOAc/hexane        to afford [3-(4-formyl-naphthalen-1-yloxy)-propyl]-carbamic acid        tert-butyl ester (13.8 g, 72%) as a light yellow solid.

b. {3-[4-(4-Azido-but-1-enyl)-naphthalen-1-yloxy]-propyl}-carbamic acidtert-butyl ester

-   -   To a mixture of Wittig reagent        (3-azido-propyl)-triphenyl-phosphonium bromide (15.35 g, 36        mmol) in THF (150 mL) at −76° C., was added LIHMDS (0.5M in THF        solution, 66 mL, 66 mmol). The mixture was stirred at this        temperature for 1 h.        [3-(4-formyl-naphthalen-1-yloxy)-propyl]-carbamic acid        tert-butyl ester (10 g, 30 mmol) in 20 mL of THF solution was        added. The reaction mixture was stirred for 1 hour. Then warm up        to r.t. in 1 h. Water was added to quench the reaction, and        extracted with EtOAc. The organic layer was washed with water,        brine, dried over MgSO₄, filtered, and concentrated. The residue        was purified by column chromatography to afford        {3-[4-(4-azido-but-1-enyl)-naphthalen-1-yloxy]-propyl}-carbamic        acid tert-butyl ester, 11 g, 88% as a solid

c. Wittig reagent (3-azido-propyl)-triphenyl-phosphonium bromide

-   -   (3-Bromo-propyl)-triphenyl-phosphonium bromide was dissolved in        ethanol/water (1/1). To it sodium azide was added. The reaction        mixture was heated up to reflux overnight. Solvents were removed        by evaporation. The residue was extracted by dry ethanol.        Filtered and evaporated to give crude        (3-azido-propyl)-triphenyl-phosphonium bromide and was used        directly for the next step reaction without further        purification.

2.N-{4-[4-(3-Amino-propoxy)-naphthalen-1-yl]-butyl}-N-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-guanidine

-   -   {3-[4-(4-Azido-but-1-enyl)-naphthalen-1-yloxy]-propyl}-carbamic        acid tert-butyl ester 3.5 g was hydrogenated in ethanol with 5%        Pd/C (50% wet) for 2 h. Catalyst was removed, and the filtrate        was concentrated to give 2.94 g of        {3-[4-(4-Amino-butyl)-naphthalen-1-yloxy]-propyl}-carbamic acid        tert-butyl ester. One gram (2.66 mmol) of free amine was stirred        with        1-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea        (1.55 g, 3.99 mmol) in dry ethanol (25 mL).        Di-isopropyl-ethylamine (1.39 mL, 7.98 mmol) of was added and        the reaction mixture was warmed to 45° C. overnight. Ethanol was        added and the reaction filtered. After concentration of the        filtrate, the residue was purified by flash chromatography        (0-10% MeOH/CH₂Cl₂) to give 0.92 g of        [3-(4-{4-[N′-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-guanidino]-butyl}-naphthalen-1-yloxy)-propyl]-carbamic        acid tert-butyl ester.        [3-(4-{4-[N′-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-guanidino]-butyl}-naphthalen-1-yloxy)-propyl]-carbamic        acid tert-butyl ester (2.7 g was stirred with 4M HCl in        p-dioxane for 1 hour at room temperature. Solvents were removed        in vacuo.    -   A small amount of the product was purified by flash        chromatography to give 7 GS-426675        N-{4-[4-(3-Amino-propoxy)-naphthalen-1-yl]-butyl}-N′-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-guanidine        as an HCl salt.

3.N-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-N′-{4-[4-(3-guanidino-propoxy)-naphthalen-1-yl]-butyl}-guanidine75

-   -   N-{4-[4-(3-Amino-propoxy)-naphthalen-1-yl]-butyl}-N′-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-guanidine        HCl salt from reaction was stirred with Goodman's reagent        [(tert-butoxycarbonylamino-trifluoromethane        sulfonylimino-methyl)-carbamic acid tert-butyl ester] in        methanol. Diisopropylethylamine (1.18 mL) was added and the        reaction mixture was stirred at room temperature overnight.        Solvents were removed in vacuo and the residue was purified by        silica gel chromatography (0-10% MeOH(MeOH/NH₄OH=9/1)/CH₂Cl₂) to        give 2.7 g of 8, which was dissolve in 30 mL of methanol and        treated with 300 mL of 4M HCl in p-dioxane at room temperature        for 4 hour to give 9,        N-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-N′-{4-[4-(3-guanidino-propoxy)-naphthalen-1-yl]-butyl}-guanidine        as a crude product. About 200 mL of the solvents were removed by        reduced pressure, then cool to room temperature, and let the        product precipitated out. Filtration to collect the product, and        the product was further refluxed with dry EtOH, and cool down to        room temperature. Filtration to give 2.08 g of 75 as an HCl salt        (yellow solid).

Preparation of(1R,2S)-3-{3-[6-(4-Aminobutyl)naphthalene-2-yloxy]propylamino}-[1-[(4R,5R)-5-hydroxy-2-methyl-1,3-dioxan-4-yl]propane-1,2-diol}(105)

A suspension of 101 (76 mg) and 10% Pd/C (76 mg) in MeOH (5 mL) wassubjected to hydrogenation conditions (1 atm) for 2 h at roomtemperature. The reaction mixture was filtered through a plug ofdiatomaceous earth and the plug was washed with MeOH. The filtrate wasconcentrated in vacuo and the residue was purified by columnchromatography (silica gel, 80:18:2 CHCl₃/CH₃OH/NH₄OH) to afford amine105 (46 mg, 80%) as a white solid: ¹H NMR (300 MHz, CD₃OD) □ 7.65 (d,J=8.7 Hz, 2H), 7.53 (s, 1H), 7.28 (d, J=8.4 Hz, 1H), 7.18 (s, 1H), 7.10(dd, J=8.7 Hz, 1.8 Hz, 1H), 4.66 (q, J=4.8 Hz, 1H), 4.14 (t, J=6.0 Hz,2H), 4.06 (q, J=5.3 Hz, 1H), 3.98-3.92 (m, 1H), 3.83-3.74 (m, 2H), 3.45(dd, J=9.0 Hz, 1.5 Hz, 1H), 3.37 (d, J=10.5 Hz, 1H), 2.93-2.66 (m, 8H),2.08-2.00 (m, 2H), 1.77-1.67 (m, 2H), 1.58-1.49 (m, 2H), 1.25 (d, J=4.8Hz, 3H).

Preparation of Guanidine 106

To a solution of amine 105 (46 mg, 0.10 mmol) and methyl3,5-diamino-6-chloropyrazine-2-carbonylcarbamimidothioate (10, 70 mg,0.16 mmol) in EtOH (6 mL) was added DIPEA (0.13 mL, 0.7 mmol) at roomtemperature. The reaction mixture was heated at 70° C. in a sealed tubefor 2 h, then cooled to room temperature, and concentrated in vacuo. Theresidue was purified by column chromatography (silica gel, 80:18:2CHCl₃/CH₃OH/NH₄OH) to afford guanidine 106(16 mg, 24%) as a yellowsolid: ¹H NMR (300 MHz, CD₃OD) □ 7.66 (d, J=7.5 Hz, 2H), 7.55 (s, 1H),7.30 (d, J=8.1 Hz, 1H), 7.17 (s, 1H), 7.10 (d, J=8.7 Hz, 1H), 4.67-4.66(m, 1H), 4.16 (s, 2H), 4.08-3.97 (m, 2H), 3.82-3.77 (m, 2H), 3.64-3.58(m, 2H), 3.46 (d, J=9.0 Hz, 1H), 3.40 (d, J=3.3 Hz, 1H), 2.05-2.09 (m,2H), 1.82-1.70 (m, 4H), 1.25 (d, J=4.8 Hz, 3H).

Preparation of Guanidine Lactate Salt 107

To a solution of guanidine 106 (16 mg, 0.024 mmol) in EtOH (5 mL) wasadded lactic acid (4.5 mg, 0.048 mmol) at room temperature and thereaction mixture was stirred for 15 min. The solution was concentratedand the residue was azeotroped with MeOH. The residue was dissolved inH₂O/MeOH (8:2, 10 mL) and lyophilized to afford lactate salt 107 (20mg, >95%) as a yellow solid: ¹H NMR (300 MHz, CD₃OD) □ 7.78 (t, J=7.8Hz, 2H), 7.62 (s, 1H), 7.35 (d, J=8.4 Hz, 1H), 7.27 (s, 1H), 7.13 (dd,J=8.8 Hz, 2.3 Hz, 1H), 7.00 (br s, 1H), 5.10-5.05 (m, 1H), 4.85 (q,J=7.0 Hz, 1H), 4.63 (q, J=5.0 Hz, 1H), 4.21-4.12 (m, 3H), 3.99-3.87 (m,4H), 3.73 (d, J=5.1 Hz, 1H), 3.68-3.59 (m, 2H), 3.44-3.23 (m, 4H),3.06-3.00 (m, 4H), 2.90-2.83 (m, 1H), 2.75 (t, J=6.7 Hz, 2H), 2.11-2.07(m, 2H), 1.71-1.57 (m, 4H), 1.46 (d, J=6.9 Hz, 1H), 1.37 (d, J=7.2 Hz,3H), 1.28 (d, J=6.6 Hz, 3H), 1.24-1.13 (m, 10H), 0.86-0.82 (m, 1H);ESI-MS m/z 675 [C₃₁H₄₃ClN₈O₇+H]⁺.

Preparation ofN-{4-[4-(3-Amino-propoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-butyl}-N′-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-guanidine(116) andN-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-N′-{4-[4-(3-guanidino-propoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-butyl}-guanidine(118) 1. 4-hydroxy-5,6,7,8-tetrahydro-naphthalene-1-carbaldehyde (109)

5, 6, 7, 8-Tetrahydro-naphthalen-1-ol (108, 20 g, 135 mmol) was stirredin 100 mL of ethanol, and potassium hydroxide (7.57 g, 135 mmol) as anaqueous solution was added. The mixture was stirred for 15 minutes andwent clear. Solvents were removed and dried. PEG (MW 380-420, 53 mL) wasadded, followed by chloroform (32.3 mL, 405 mmol) and toluene (34 mL).An aqueous potassium hydroxide solution (50% by weight, 54.4 mL) wasintroduced dropwise with stirring over 15 minutes. The stirring wascontinued for another 30 minutes. 1M HCl was added to acidify thereaction mixture and it was extracted with EtOAc three times. Thecombined organic layers were washed with water and brine The combinedorganic layers were dried over MgSO₄, filtered, concentrated, andpurified by flash chromatography (0-40% EtOAc/hexane) to give4-hydroxy-5,6,7, 8-tetrahydro-naphthalene-1-carbaldehyde (109, 4.7 g).

2. [3-(4-Formyl-5,6,7,8-tetrahydro-naphthalen-1-yloxy)-propyl]-carbamicacid tert-butyl ester (111)

4-Hydroxy-5,6,7,8-tetrahydro-naphthalene-1-carbaldehyde (109, 4.6 g,29.1 mmol) (3-Bromopropyl)-carbamic acid tert-butyl ester (110, 4.6 g,32 mmol), and potassium carbonate (6.03 g, 43.7 mmol) were stirred in140 mL of dry DMF over night. The reaction mixture was poured into waterand extracted with dichloromethane. The organic layer was washed withwater and brine., dried with magnesium sulfate, filtered, concentratedand purified by flash chromatography (0-30% EtOAc/hexane) to give crudeproduct, which was recrystallized from EtOAc/Hexane to give 5.8 g of111,[3-(4-formyl-5,6,7,8-tetrahydro-naphthalen-1-yloxy)-propyl]-carbamicacid tert-butyl ester.

3.{3-[4-(4-Azido-but-1-enyl)-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-propyl}-carbamicacid tert-butyl ester (113)

(3-Azido-propyl)-triphenylphosphonium bromide (112, 11.5 g, 27 mmol) wasstirred with 100 mL of dry THF at −76° C. LiHMDS (0.5 M in toluene, 27mL) was added and the mixture was stirred for 30 minutes.[3-(4-Formyl-5,6,7,8-tetrahydro-naphthalen-1-yloxy)-propyl]-carbamicacid tert-butyl ester (111, 6 g, 18 mmol) in 12 mL dry THF solution wasintroduced. The reaction mixture was stirred at this temperature foranother 30 minutes, and slowly warmed to room temperature. The mixturewas poured into water and extracted twice with ethyl acetate. Thecombined organic layers were washed with water and brine, dried overmagnesium sulfate, filtered, concentrated, and purified by flashchromatography (0-25% EtOAc/Hexane) to give 3.5 g 113{3-[4-(4-azido-but-1-enyl)-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-propyl}-carbamicacid tert-butyl ester.

4.N-{4-[4-(3-Amino-propoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-butyl}-V-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-guanidine (116)

{3-[4-(4-Azido-but-1-enyl)-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-propyl}-carbamicacid tert-butyl ester 113, 3.5 g was hydrogenated in ethanol with 5%Pd/C (50% wet) for 2 h. Catalyst was removed, and the filtrate wasconcentrated to give 2.94 g of 114,{3-[4-(4-amino-butyl)-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-propyl}-carbamicacid tert-butyl ester.

One gram (2.66 mmol) of free amine 114 was stirred with1-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea (1.55g, 3.99 mmol) in dry ethanol (25 mL). Di-isopropyl-ethylamine (1.39 mL,7.98 mmol) of was added and the reaction mixture was warmed to 45° C.overnight. Ethanol was added and the reaction filtered. Afterconcentration of the filtrate, the residue was purified by flashchromatography (0-10% MeOH/CH₂Cl₂) to give 0.92 g of 115[3-(4-{4-[N′-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-guanidino]-butyl}-5,6,7,8-tetrahydro-naphthalen-1-yloxy)-propyl]-carbamicacid tert-butyl ester.

N-{4-[4-(3-Amino-propoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-butyl}-N′-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-guanidinewas stirred with 4M HCl in p-dioxane for 30 minutes at room temperature.Solvents were removed n vacuo, and the product was purified by aminecolumn (0-40% MeOH/CH₂Cl₂) to give 116N-{4-[4-(3-amino-propoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-butyl}-NT-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-guanidineas an HCl salt.

5.N-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-N′-{4-[4-(3-guanidino-propoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-butyl}-guanidineGS-429269 (11)

N-{4-[4-(3-Amino-propoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-butyl}-N′-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-guanidineHCl salt 116 (0.81 g, 1.37 mmol) was stirred with Goodman's reagent[(tert-butoxycarbonylamino-trifluoromethanesulfonylimino-methyl)-carbamic acid tert-butyl ester] in methanol.Diisopropylethylamine (1.18 mL) was added and the reaction mixture wasstirred at room temperature overnight. Solvents were removed in vacuoand the residue was purified by silica gel chromatography (0-10%MeOH/CH₂Cl₂) to give 820 mg of 117, which was treated with 4M HCl inp-dioxane at room temperature for 1 hour to give 118,N-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-N′-{4-[4-(3-guanidino-propoxy)-5,6,7,8-tetrahydro-naphthalen-1-yl]-butyl}-guanidineas a crude product. Purification by flash chromatography (0-40%(MeOH/NH₄OH; 3/1)/CH₂Cl₂) followed by further purification on an aminecolumn (0-30% MeOH/CH₂Cl₂) gave the free base, which was dissolved inethanol and a few drops of 1M HCl aq was added. The clear solution wasfiltered and lyophilized to give final product as a yellow solid.

All references cited herein are hereby incorporated in their entirety asif each reference was individually and specifically incorporated in itsentirety.

1-47. (canceled)
 48. A method of treating chronic bronchitis,bronchiectasis, cystic fibrosis, sinusitis, ventilator-inducedpneumonia, asthma, chronic obstructive pulmonary disease, emphysema,pneumonia or rhinosinusitis, comprising administering to a human in needthereof an effective amount of a compound represented by the formula(I):

and racemates, enantiomers, diastereomers, tautomers andpharmaceutically acceptable salts, thereof, wherein: X is hydrogen,halogen or lower alkyl; Y is hydrogen or —N(R²)₂; R¹ is hydrogen orlower alkyl; each R² is, independently, —R⁷, —(CH₂)_(m)—OR⁸,—(CH₂)_(m)—NR⁷R¹⁰, —(CH₂)_(n)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—(CH₂CH₂O)_(m)—R⁸, —(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰, —(CH₂)_(n)—C(═O)NR⁷R¹⁰,—(CH₂)_(n)—(Z)_(g)—R⁷, —(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—(CH₂)_(n)—CO₂R⁷, or

R³ and R⁴ are each, independently, hydrogen, lower alkyl, hydroxyl-loweralkyl, phenyl, (phenyl)-lower alkyl, (halophenyl)-lower alkyl,((lower-alkyl)phenyl)-lower-alkyl, ((lower-alkoxy)phenyl)-lower-alkyl,(naphthyl)-lower-alkyl, or (pyridyl)-lower-alkyl, or a group representedby formula A or formula B, with the proviso that at least one of R³ andR⁴ is a group represented by the formula A or formula B;—(C(R^(L))₂)_(o)-x-(C(R^(L))₂)_(p)A¹  formula A: A¹ is a C₇-C₁₅-memberedaromatic carbocycle substituted with at least one R⁵ and the remainingsubstituents are R⁶; each R^(L) is, independently, —R⁷, —(CH₂)_(n)—OR⁸,—O—(CH₂)_(m)—OR⁸, —(CH₂)_(n)—NR⁷R¹⁰, —O—(CH₂)_(m)—NR⁷R¹⁰,—(CH₂)_(n)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—O—(CH₂)_(m)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —(CH₂CH₂O)_(m)—R⁸,—O—(CH₂CH₂O)_(m)—R⁸, —(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰,—O—(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰, —(CH₂)_(n)—C(═O)NR⁷R¹⁰,—O—(CH₂)_(m)—C(═O)NR⁷R¹⁰, —(CH₂)_(n)—(Z)_(g)—R⁷,—O—(CH₂)_(m)—(Z)_(g)—R⁷, —(CH₂)_(n)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—O—(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —(CH₂)_(n)—CO₂R⁷,—O—(CH₂)_(m)—CO₂R⁷, —OSO₃H, —O-glucuronide, —O-glucose,

each o is, independently, an integer from 0 to 10; each p is,independently, an integer from 0 to 10; with the proviso that the sum ofo and p in each contiguous chain is from 1 to 10; each x is,independently, O, NR¹⁰, C(═O), CHOH, C(═N—R¹⁰, CHNR⁷R¹⁰, or a singlebond; each R⁵ is, independently, Link-(CH₂)_(n)—CAP,Link-(CH₂)_(n)—(Z)_(g)—CAP, Link-(CH₂)(Z)_(g)—(CH₂)_(m)—CAP,—(CH₂)_(n)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸ or—O—(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸; each R⁶ is,independently, R⁵, —R⁷, —OR¹¹, —N(R⁷)₂, —(CH₂)_(m)—OR⁸,—O—(CH₂)_(m)—OR⁸, —(CH₂)_(n)—NR⁷R¹⁰, —O—(CH₂)_(m)—NR⁷R¹⁰,—(CH₂)_(n)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—O—(CH₂)_(m)(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —(CH₂CH₂O)_(m)—R⁸,—O—(CH₂CH₂O)_(m)—R⁸, —(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰,—O—(CH₂CH₂O)_(m)—CH₂CH₂NR⁷R¹⁰, —(CH₂)_(n)—C(═O)NR⁷R¹⁰,—O—(CH₂)_(m)—C(═O)NR⁷R¹⁰, —(CH₂)_(n)—(Z)_(g)—R⁷,—O—(CH₂)_(m)—(Z)_(g)—R⁷, —(CH₂)_(n)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸,—O—(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸, —(CH₂)_(n)—CO₂R⁷,—O—(CH₂)_(m)—CO₂R⁷, —OSO₃H, —O-glucuronide, —O-glucose,

wherein when two R⁶ are —OR¹¹ and are located adjacent to each other onthe aromatic carbocycle or aromatic heterocycle, the two OR¹¹ may form amethylenedioxy group; each R⁷ is, independently, hydrogen, lower alkyl,phenyl or substituted phenyl; each R⁸ is, independently, hydrogen, loweralkyl, —C(═O)—R¹¹, glucuronide, 2-tetrahydropyranyl, or

each R⁹ is, independently, —CO₂R⁷, —CON(R⁷)₂, —SO₂CH₃, —C(═O)R⁷,—CO₂R¹³, —CON(R¹³)₂, —SO₂CH₂R¹³, or —C(═O)R¹³; each R¹⁰ is,independently, —H, —SO₂CH₃, —CO₂R⁷, —C(═O)NR⁷R⁹, —C(═O)R⁷, or—CH₂—(CHOH)_(n)—CH₂OH; each Z is, independently, —(CHOH)—, —C(═O)—,—(CHNR⁷R¹⁰)—, —(C═NR¹⁰)—, —NR¹⁰—, —(CH₂)_(n)—, —(CHNR¹³R¹³)—,—(C═NR¹³)—, or —NR¹³—; each R¹¹ is, independently, hydrogen, loweralkyl, phenyl lower alkyl or substituted phenyl lower alkyl; each R¹²is, independently, —SO₂CH₃, —CO₂R⁷, —C(═O)NR⁷R⁹, —C(═O)R⁷,—CH₂(CHOH)_(n)—CH₂OH, —CO₂R¹³, —C(═O)NR¹³R¹³, or —C(═O)R¹³; each R¹³ is,independently, R⁷, R¹⁹, —(CH₂)_(m)—NR⁷R¹⁰, —(CH₂)_(m)—NR⁷R⁷,—(CH₂)_(m)—NR¹¹R¹¹, —(CH₂)_(m)—(NR¹¹R¹¹R¹¹)⁺,—(CH₂)_(m)—(CHOR⁸)_(m)—(CH₂)_(m)NR¹¹R¹¹, —(CH₂)_(m)—(CHOR⁸)_(m) 13(CH₂)_(m)NR⁷R¹⁰, —(CH₂)_(m)—NR¹⁰R¹⁰,—(CH₂)_(m)—(CHOR⁸)_(m)—(CH₂)_(m)—(NR¹¹R¹¹R¹¹)⁺,—(CH₂)_(m)—(CHOR⁸)_(m)(CH₂)_(m)NR⁷R⁷,

with the proviso that in the moiety —NR¹³R¹³, the two R¹³ along with thenitrogen to which they are attached may, optionally, form a ringselected from:

each V is, independently, —(CH₂)_(m)—NR⁷R¹⁰, —(CH₂)_(m)—NR⁷R⁷,—(CH₂)_(m) 13 (NR¹¹R¹¹R¹¹)⁺, —(CH₂)_(n)—(CHOR⁸)_(m)—(CH₂)_(m)NR⁷R¹⁰,—(CH₂)_(n)—NR¹⁰R¹⁰ —(CH₂)_(n)—(CHOR⁸)_(m)—(CH₂)_(m)NR⁷R⁷,—(CH₂)_(n)—(CHOR⁸)_(m)—(CH₂)_(m)—(NR¹¹R¹¹R¹¹)⁺ with the proviso thatwhen V is attached directly to a nitrogen atom, then V can also be,independently, R⁷, R¹⁰, or (R¹¹)₂; each R¹⁴ is, independently, H, R¹²,—(CH₂)_(n)—SO₂CH₃, —(CH₂)_(n)—CO₂R¹³, —(CH₂)_(n)—C(═O)NR¹³R¹³,—(CH₂)_(n)—C(═O)R¹³, —(CH₂)_(n)—(CHOH)_(n)—CH₂OH, —NH—(CH₂)_(n)—SO₂CH₃,NH—(CH₂)_(n)—C(═O)R¹¹, NH—C(═O)—NH—C(═O)R¹¹, —C(═O)NR¹³R¹³, —OR¹¹,—NH—(CH₂)_(n)—R¹⁰, —Br, —Cl, —F, —I, SO₂NHR¹¹, —NHR¹³,—NH—C(═O)—NR¹³R¹³, —(CH₂)_(n)—NHR¹³, or —NH—(CH₂)_(n)—C(═O)—R¹³; each gis, independently, an integer from 1 to 6; each m is, independently, aninteger from 1 to 7; each n is, independently, an integer from 0 to 7;each -Het- is, independently, —N(R⁷)—, —N(R¹⁰)—, —S—, —SO—, —SO₂—, —O—,—SO₂NH—, —NHSO₂—, —NR⁷CO—, —CONR⁷—, —N(R¹³)—, —SO₂NR¹³—, —NR¹³CO—, or—CONR¹³—; each Link is, independently, —O—, —(CH₂)_(n)—, —O(CH₂)_(m)—,—NR¹³—C(═O)—NR¹³—, —NR¹³—C(═O)—(CH₂)_(m)—, —C(═O)NR¹³—(CH₂)_(m)—,—(CH₂)_(n)—(Z)_(g)—(CH₂)_(n)—, —S—, —SO—, —SO₂—, —SO₂NR⁷—, or —SO₂NR¹⁰—;each CAP is, independently, thiazolidinedione, oxazolidinedione,-heteroaryl-C(═O)N R¹³R¹³, heteroaryl-W, —CN, —O—C(═S)NR¹³R¹³,-(Z)_(g)R¹³, —CR¹⁰((Z)_(g)R¹³)((Z)_(g)R¹³), —C(═O)OAr, —C(═O)NR¹³Ar,imidazoline, tetrazole, tetrazole amide, —SO₂NHR¹³,—SO₂NH—C(R¹³R¹³)—(Z)_(g)—R¹³, a cyclic sugar or oligosaccharide, acyclic amino sugar, oligosaccharide,—CR¹⁰(—(CH₂)_(m)—R⁹)(—(CH₂)_(m)—R⁹), —N(—(CH₂)_(m)—R⁹)(—(CH₂)_(m)—R⁹),—NR¹³(—(CH₂)_(m)—CO₂R¹³),

wherein CAP is not hydrogen or lower alkyl; each Ar is, independently,phenyl, substituted phenyl, wherein the substituents of the substitutedphenyl are 1-3 substituents independently selected from the groupconsisting of OH, OCH₃, NR¹³R¹³, Cl, F, and CH₃, or heteroaryl; and eachW is, independently, thiazolidinedione, oxazolidinedione,heteroaryl-C(═O)N R¹³R¹³, —CN, —O—C(═S)NR¹³R¹³, —(Z)_(g)R¹³,—CR¹⁰((Z)_(g)R¹³)((Z)_(g)R¹³), —C(═O)OAr, —C(═O)N R¹³Ar, imidazoline,tetrazole, tetrazole amide, —SO₂NHR¹³, —SO₂NH—C(R¹³R¹³)—(Z)_(g)—R¹³, acyclic sugar or oligosaccharide, a cyclic amino sugar, oligosaccharide,

with the proviso that when any —CHOR⁸— or —CH₂OR⁸ groups are located1,2- or 1,3- with respect to each other, the R⁸ groups may, optionally,be taken together to form a cyclic mono- or di-substituted 1,3-dioxaneor 1,3-dioxolane.
 49. The method of claim 48, wherein the compound isrepresented by the formula:

and racemates, enantiomers, diastereomers, tautomers, andpharmaceutically acceptable salts, thereof.
 50. The method of claim 48,wherein A¹ is selected from indenyl, napthalenyl,1,2-dihydronapthalenyl, 1,2,3,4-tetrahydronapthalenyl, anthracenyl,fluorenyl, phenanthrenyl, azulenyl, cyclohepta-1,3,5-trienyl or5H-dibenzo[a,d]cycloheptenyl, substituted with at least one R⁵ and theremaining substituents are R⁶.
 51. The method of claim 48, wherein R³ ishydrogen and R⁴ is a group represented by formula A.
 52. The method ofclaim 48, wherein R³ is hydrogen and A¹ is a group represented by theformula:

wherein each Q is, independently, C—H, C—R⁵, C—R⁶, or a nitrogen atom,with the proviso that at least one Q is C—R⁵.
 53. The method of claim52, wherein one Q is C—R⁵ and the remaining Q are C—H.
 54. The method ofclaim 48, wherein R³ is hydrogen and A¹ is a group represented by theformula:


55. The method of claim 48, wherein R⁵ is Link-(CH₂)_(n)—CAP.
 56. Themethod of claim 48, wherein R⁵ is Link-(CH₂)_(n)—(Z)_(g)—CAP.
 57. Themethod of claim 48, wherein R⁵ is Link-(CH₂)(Z)_(g)—(CH₂)_(m)—CAP. 58.The method of claim 48, wherein R⁵ is—(CH₂)_(n)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸.
 59. The method of claim48, wherein R⁵ is —O—(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸. 60.The method of claim 48, wherein CAP is —(Z_(g))R¹³.
 61. The method ofclaim 48, wherein CAP is —CR¹⁰((Z)_(g)R¹³)((Z)_(g)R¹³).
 62. The methodof claim 48, wherein the compound of formula (I) is an acid additionsalt of an acid selected from the consisting of hydrochloric acid,hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, aceticacid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaricacid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoicacid, tannic acid, palmitic acid, alginic acid, polyglutamic acid,naphthalensulfonic acid, methanesulfonic acid, p-toluenesulfonic acid,naphthalenedisulfonic acid, polygalacturonic acid, malonic acid,sulfosalicylic acid, glycolic acid, 2-hydroxy-3-naphthoate, pamoate,salicylic acid, stearic acid, phthalic acid, mandelic acid, and lacticacid.
 63. The method of claim 48, wherein X, Y, R¹, R² and R³ are eachhydrogen; R⁴ is represented by formula A, A¹ is a naphthalenyl or1,2,3,4-tetrahydronaphthalenyl group, which is substituted by one R⁵group and the remaining substituents are hydrogen; each R^(L) group ishydrogen; x is a single bond; and the sum of 0 and p is from 2 to
 6. 64.The method of claim 63, wherein A¹ is a naphthalenyl group which issubstituted by one R⁵ group and the remaining substituents are hydrogen.65. The method of claim 63, wherein R⁵ is Link-(CH₂)_(n)—CAP.
 66. Themethod of claim 63, wherein R⁵ is Link-(CH₂)_(n)—(Z)_(g)—CAP.
 67. Themethod of claim 63, wherein R⁵ is Link-(CH₂)(Z)_(g)—(CH₂)_(in)—CAP. 68.The method of claim 63, wherein R⁵ is—(CH₂)_(n)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸.
 69. The method of claim63, wherein R⁵ is —O—(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸. 70.The method of claim 63, wherein CAP is —(Z_(g))R¹³.
 71. The method ofclaim 63, wherein CAP is —CR¹⁰((Z)_(g)R¹³)((Z)_(g)R¹³).
 72. The compoundof claim 48, wherein X, Y, R¹ R² and R³ are each hydrogen; each R^(L)group is hydrogen; x is a single bond; and the sum of 0 and p is from 2to
 6. 73. The method of claim 72, wherein R⁵ is Link-(CH₂)_(n)—CAP. 74.The method of claim 72, wherein R⁵ is Link-(CH₂)_(n)—(Z)_(g)—CAP. 75.The method of claim 72, wherein R⁵ is Link-(CH₂)(Z)_(g)—(CH₂)_(m)—CAP.76. The method of claim 72, wherein R⁵ is—(CH₂)_(n)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸.
 77. The method of claim72, wherein R⁵ is —O—(CH₂)_(m)—NR¹⁰—CH₂(CHOR⁸)(CHOR⁸)_(n)—CH₂OR⁸. 78.The method of claim 72, wherein CAP is —(Z_(g))R¹³.
 79. The method ofclaim 72, wherein CAP is —CR¹⁰((Z)_(g)R¹³)((Z)_(g)R¹³).
 80. The methodof claim 48, wherein the compound of formula (I) is represented by theformula, or a pharmaceutically acceptable salt thereof:


81. The method of claim 48, wherein the compound of formula (I) isrepresented by the formula:

Or or a pharmaceutically acceptable salt thereof.
 82. The method ofclaim 48, wherein the compound of formula (I) is represented by theformula:

or a pharmaceutically acceptable salt thereof.